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Mass spectrometry (MS)-based protein footprinting characterizes protein structure and protein-
ligand interactions by interrogating protein solvent-accessible surfaces by using chemical 
reagents as probes. The method is highly applicable to protein or protein-ligand complexes that 
are difficult to study by conventional means such as X-ray crystallography and nuclear magnetic 
resonance. In this dissertation, we describe the development and application of MS-based protein 
footprinting from three perspectives, including I) protein aggregation and amyloid formation 
(Chapter 2-3), II) protein-ligand interactions (Chapter 4-5), and III) in-cellulo structures and 
dynamic motion of membrane proteins (Chapter 6). Fast Photochemical Oxidation of Proteins 
(FPOP) is the main methodology implemented in the work presented in this dissertation. Chapter 
1 provides an overview of FPOP and discusses its fundamentals as well as its important 
applications in both academic research and biotechnology drug development. 
In Part I, Chapter 2 covers the early method development of FPOP for monitoring amyloid beta 
(Aβ) aggregation. In this work, we demonstrated the high sensitivity and spatial resolution of the 
xiii 
 
method in probing the solvent accessibility of Aβ at global, sub-regional, and some amino-acid 
residue levels as a function of its aggregation, and revealed Aβ species at various oligomeric 
states identified by their characteristic modification levels. In Chapter 3, we extended the 
application of the platform to assess the effect of a putative polyphenol inhibitor on amyloid 
formation and to provide insights into the mechanism of action of the inhibitor in remodeling Aβ 
aggregation pathways.  
In Part II, we evaluated different protein footprinting techniques, including FPOP, hydrogen-
deuterium exchange (HDX), and carboxyl group footprinting, for probing protein-ligand (drug 
candidates) interaction in the context of a therapeutic development. Chapter 4 focused on 
protein-protein interaction by investigating the epitope of IL-6 receptor for two adnectins that 
have similar apparent biophysical properties. In Chapter 5, we probed the hydrophobic binding 
cavity of bromodomain protein for a small molecule inhibitor. This study serves as an example 
of interrogating protein-small molecule interactions. The two studies in Part II demonstrate the 
unique capabilities and limitations of protein footprinting methods in protein structural 
characterization. 
In Part III, we pushed the boundary of MS-based protein footprinting by applying the method to 
footprint live cells and investigate the dynamic structures/motion of membrane-transport proteins 
in their native cellular environment. We employed protein engineering, suspension cell 
expression and isotopic-encoded carboxyl group footprinting to identify salt bridges in two 
proteins, GLUT1 and GLUT5, that control their alternating access motions for substrate 
translocation. With functional analysis and mutagenesis, live-cell footprinting provides new 
insights into the transport mechanism of proteins in the major facilitator superfamily. 
xiv 
 
The five studies in the dissertation demonstrate the powerful capability of MS-based protein 
footprinting in protein structural biology and biophysics research. The method also holds great 
potential in studying more complicated biological systems and solving demanding problems 
related to protein structure and properties. 
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Chapter 1: Introduction of Mass 
Spectrometry-Based Fast Photochemical 
Oxidation of Proteins (FPOP) for Higher 
Order Structure Characterization* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________ 
* This chapter is based on a recent accepted review: Li, K. S.; Shi, L.; Gross, M. L., Mass 
Spectrometry-Based Fast Photochemical Oxidation of Proteins (FPOP) for Higher Order 
Structure Characterization. Acc. Chem. Res. DOI: 10.1021/acs.accounts.7b00593  
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1.1  Abstract  
Assessment of protein structure and interaction is crucial for understanding protein 
structure/function relationships. Compared to high-resolution structural tools including X-ray 
crystallography, nuclear magnetic resonance (NMR) and cryo-EM, and traditional low-resolution 
methods such as circular dichroism, UV-Vis and florescence spectroscopy, mass spectrometry 
(MS)-based protein footprinting affords medium-to-high resolution (i.e., regional and residue-
specific insights) by taking advantage of proteomics methods focused on the primary structure. 
The methodology relies on “painting” the reactive and solvent-exposed amino acid residues with 
chemical tags and using the pattern of modifications as footprints from analysis by bottom-up 
MS-based proteomics to deduce protein higher order structures. The outcome can refer to 
proteins in solution or even in cells and is complementary to those of X-ray crystallography and 
NMR. It particularly useful in mapping protein-ligand interfaces and conformational changes 
resulted from ligand binding, mutation and aggregation.  
Fast photochemical oxidation of proteins (FPOP), in its original conception, is a type of 
hydroxyl-radical-based protein footprinting that utilizes a pulsed KrF laser (248 nm) to trigger 
hydrolysis of hydrogen peroxide to produce solution hydroxyl radicals, which subsequently 
modify the protein in-situ. The platform is expanding to adopt other reactive species including 
carbenes. The reactivity of the probe depends on the intrinsic reactivity of the radical with the 
residue side chain and the solvent accessibility of the residue as a function of the 
tertiary/quaternary structures. By introducing an appropriate scavenger to compete with hydroxyl 
radical self-quenching, the lifetime of the primary radicals is remarkably shortened to ~ μs. Thus, 
the sampling timescale of FPOP is much faster than hydrogen-deuterium exchange and other 
covalent labeling methods relying on non-radical reactions. 
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The short footprinting timescale of FPOP offers two major advantages for protein structure 
elucidation: 1) it allows the protein to be interrogated in its native or near-native state with 
minimum structural perturbation; 2) it exhibits high sensitivity toward alterations in protein 
higher order structures because its sampling time is short with respect to protein conformational 
changes and dynamic motion. In addition, the covalent and irreversible oxidation by the 
hydroxyl radical provides more flexibility in the downstream proteomics workflow and MS 
analysis, permitting high spatial resolution with residue-specific information.  
Since its invention in 2005 by Hambly and Gross, FPOP has developed from proof-of-concept to 
a valuable biophysical tool for interrogating protein structure. In this account, we summarize the 
principles and experimental design of FPOP that enable its fast labeling, and describe the current 
and unique capabilities of the technique in protein higher order structure elucidation. Application 
examples include characterization of amyloid beta self-assembly, protein-ligand interactions with 
a special emphasis on epitope mapping for protein therapeutics (e.g., antibody, Fab and adnectin), 
protein folding detailed to residue-specific folding kinetics, and protein flexibility/dynamics. 
Additionally, the utility of FPOP-based oxidative footprinting should grow with our continuing 
developments of novel reagents (e.g., sulfate radical anion, carbene diradical and trifluoromethyl 
radical). These reactive reagents are compatible with the current FPOP platform and offer 
different reactivity and selectivity towards various types of amino acid residues, providing 
complementary insights into protein higher order structures for soluble proteins and ultimately 
for membrane-bound proteins.  
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1.2  Introduction 
Mass spectrometry (MS)-based protein footprinting has become a compelling tool for proteins 
that are incompatible with or simply too demanding for traditional structural techniques of X-ray 
crystallography and NMR or not appropriate for cryo-EM. As a highly practical technique that 
can be applied routinely, MS affords regional and residue-specific information in assessing 
structure and dynamics of proteins. 
For perspective, we can view the commonly applied hydrogen-deuterium exchange (HDX) as a 
complementary and powerful means of protein footprinting. HDX interrogates protein higher 
order structures based on the stability, H-bonding, and structural protection of the protein 
backbone.1 The labile N-D bond after exchange, however, is prone to back exchange when the 
protein or its constituent peptides are placed in protic solvents for analysis, limiting the capacity 
of HDX in structural proteomics applications that require sophisticated sample handling (e.g., 
purification, proteolysis, buffer exchange) prior to MS analysis.  
In contrast, hydroxyl-radical (·OH) footprinting, first introduced by Chance2-3 who used 
synchrotron radiation to ionize water and produce ·OH, yields irreversible modifications on the 
protein. Its elaboration as Fast Photochemical Oxidation of Proteins (FPOP) gives a method 
complementary to HDX. Hydroxyl radicals label the protein irreversibly, allowing application of 
rigorous downstream proteomics workflows to report accurately on solvent accessibility of the 
protein (Figure 1.1A). It accomplishes the labeling more rapidly and provides residue specificity, 
although with lower generality than HDX because labeling by ·OH requires the presence of 
reactive side chain(s) in a peptide segment.  
FPOP was first developed by Hambly and Gross4 to utilize ·OH generated from photolysis of 
hydrogen peroxide (H2O2) to monitor solvent accessibility of the protein side chain. Compared to 
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synchrotron radiolysis of water or use of the Fenton reaction, FPOP permits tuning the timescale 
of footprinting by introducing a scavenger to control the lifetime of the radical. This allows 
investigation of the protein structure in its native or near-native state without sampling altered 
conformations induced by modifications.  
 
Figure 1.1. A standard workflow of protein footprinting by FPOP. (A) Two different states, 
A and B, of a targeted protein (gray ribbon) are labeled by FPOP. The hydroxyl radical abstracts 
a hydrogen from the protein, and a series of follow-up reactions occur subsequently to produce 
stable covalent modifications (red dots) on the protein. The peptides produced in digestion are 
shown as black lines. Signals of unmodified and modified peptides observed in the HPLC 
chromatograms are shown in gray and red, respectively. MS2 is used to identify the modified 
residues. The extents of modification are quantified based on the signals of the unmodified and 
modified species and compared for proteins in different states. (B) Representative extracted-ion 
chromatograms showing the separation of the unmodified (grey) and FPOP-modified (red) 
peptides from the tryptic digests of interleukin-6 receptor (adapted with permission from ref. 8. 
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Copyright 2017 American Chemical Society.). The peptide sequence and numbering are 
indicated above the chromatogram. The modified residues corresponding to each signal peak are 
labeled on the chromatogram.   
 
During the past decade, FPOP has been elaborated and applied to protein higher-order-structure 
characterization in both academic research and biotechnology development labs. Although most 
applications are occurring in biophysics, there is a significant need for new methods to support 
the discovery, development and quality control of protein therapeutics. In this review, we discuss 
the principles of FPOP and highlight selected applications including characterization of amyloid 
formation;5 of protein fast/slow folding;6-7 of protein-ligand interactions (emphasis on epitope 
mapping);8-10 and of protein dynamics and the identification of hidden conformations.11-12 These 
examples illustrate the power of FPOP to decipher the higher order structures of protein and 
protein complexes.  
 
1.3  FPOP Fundamentals 
1.3.1  FPOP setup 
The FPOP apparatus uses a 248 nm KrF excimer laser to cleave H2O2 at low concentration (15 
mM, 0.04%) (Figure 1.2). We chose 248 nm because the absorptions of water and most proteins 
are low at this wavelength. The laser beam is focused with convex lenses to give an exposure 
window of 2.0-3.0 mm wide on a 150 µM i.d. silica tubing (termed the FPOP capillary). The 
laser affords a high and converging flux of photons, maximizing the yield of ·OH in a small plug 
of an irradiated solution.  
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FPOP uses a flow system for protein footprinting, in which the capillary is placed perpendicular 
to the laser beam (Figure 1.2). Prior to FPOP, the protein is mixed with H2O2 and a radical 
scavenger (usually a free amino acid). The solution mixture is then immediately transported 
through the FPOP capillary by a syringe pump. When the solution passes the transparent window 
on the capillary, laser-triggered photolysis of H2O2 produces ·OH in nanoseconds. The radicals 
further undergo Haber-Weiss chain reactions in competition with self-quenching to re-form H2O2 
(Scheme 1.1).  
The hydroxyl radical induces protein oxidation by abstracting a hydrogen from the protein, 
which results in a protein radical that further undergoes a series of subsequent reactions to 
generate products with stable oxidation.2 Rate constants for reaction with individual amino acids 
range from 107 to 1010 M–1 s–1, serving as approximates of the intrinsic reactivities of protein side 
chains.2  
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Figure 1.2. FPOP setup. (A) Schematic of the FPOP platform. The laser beam (violet) 
generated from an excimer laser (blue square) is focused through an iris and then by two convex 
lenses. The FPOP capillary (blue line) made of silica tubing is connected to a syringe pump. The 
transparent window without polyimide coating indicates the location of laser irradiation (a blow-
up of the transparent window is shown in the dashed box). A tube containing catalase and Met is 
placed at the end of the FPOP capillary to collect the FPOP-modified sample. (B) Photo of the 
FPOP apparatus. Primary components are labeled, and the violet arrow represents a visual 
pathway of the laser beam perpendicular to the FPOP capillary.   
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Scheme 1.1. Chain reactions involved in the generation of ·OH by FPOP. The rate constant is 
shown below each reaction.13  
An external pulse generator is incorporated to control frequency of the laser pulse, which 
together with a proper flow rate of the solution minimizes multiple laser irradiation to the same 
solution plug. To further avoid “double shooting”, a small volume is intentionally excluded from 
laser exposure to create a “barrier” between each exposed plug (termed an “exclusion volume”). 
The outlet of the FPOP capillary is placed into a sample-collection tube containing catalase and 
free methionine in buffer to remove leftover H2O2  and to prevent post-footprinting oxidation 
artifacts from any remaining reactive species. The control sample, used for correcting the 
background oxidation (< 5%, mainly on Met) of the protein induced by H2O2 or in post-FPOP 
sample handling is prepared the exact same way as the experimental sample, except the laser is 
omitted during the FPOP workflow.       
If there is a concern that significant oxidation will occur when mixing the protein with H2O2, 
then H2O2 can be supplied prior to laser irradiation by using a T-shaped micromixer. In this setup, 
one syringe pump delivers the protein in buffer, and another delivers H2O2 and the scavenger for 
T-mixing prior to laser irradiation. This setup improves reproducibility by minimizing the 
exposure of the protein to H2O2 and hence any non-FPOP oxidation by the peroxide.
14 
HO• + H2O2 H2O + HO2• eq. 2
2HO• H2O2 eq. 4
2HO• eq. 1
hn
HO2• + H2O2 eq. 3
k1 = 2.7 × 10
7  M-1·s-1 
k2 = 7.0 × 10
9  M-1·s-1 
k3 = 4.7 × 10
9  M-1·s-1 
H2O + O2 + HO•
H2O2
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1.3.2  Timescale of the FPOP probe  
The radical lifetime in FPOP is tuned through varying the type and/or concentration of the 
scavenger.4, 15 In the absence of a scavenger, the radical lifetime in FPOP is limited by the 
recombination reaction and can extend to approximately 100 µs.  Allowing a protein to react for 
this time may lead to unfolding, exposing buried residues to solvent exposure. Addition of a 
scavenger (e.g., 20 mM Gln) to the protein solution effectively shortens the lifetime of the 
primary hydroxyl radical to ~ 1 µs, limiting the modification to reactive and solvent-exposed 
residues in the native conformation. Gau et al.16 studied the population distribution of the FPOP 
oxidation (0, +16, +32 Da etc.) for three oxidation-sensitive proteins (-lactoglobulin, apo 
calmodulin and lysozyme), and proposed that a fit of the distribution to a Poisson signals 
conformational homogeneity of the protein during FPOP labeling. That is, protein samples with 
FPOP properly conducted by including a radical scavenger and suitable quenching of peroxide 
(catalase and Met) undergo footprinting of a single conformational state without perturbing the 
native conformation during labeling. These results underscore the indispensable roles of the flow 
system, the radical scavenger, and the prompt removal of peroxide in FPOP.   
Any radical reaction leads to production of a secondary or higher order radicals, which have 
lifetimes in the millisec range.17 If these longer-lived radicals modify the protein, the time of 
labeling is longer than ~1 μs that we claimed.4 Unfortunately, there is little direct evidence that 
reactions of secondary radicals like ·OOH modify the protein. Some indirect demonstration of 
the rapid labeling, however, comes from the application of FPOP in probing protein fast folding 
(see “Protein folding” section)7. The clear time-dependence seen in that study suggests that the 
radical reactions are not continuing onto the millisecond time range. 
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Protein modification depends not only on lifetime but also the number of radicals produced by 
the laser. Using d0/d5 Phe as an isotope-encoded dosimeter, for 15 mM H2O2, we found that the 
initial concentration of ·OH is 0.95 mM.15 Because the amount of the radical scavenger is in a 
large excess with respect to the solvent-exposed, reactive sites in the protein (e.g., 20 mM free 
Gln vs. 10 µM protein), the dominating chemistry that controls the lifetime of ·OH in FPOP is 
the reaction with the scavenger. Therefore, moderate variations in the protein concentration or 
the presence of a ligand will not significantly affect the overall oxidative yield on the protein or 
the relative yields on various side chains.18 From our experience, this remains valid for 
compounds with a size up to that of an antibody (~ 150 kDa).19 Thus, observed FPOP variations 
between the protein in different conformational states (e.g., apo and holo) correlate only with 
their different solvent accessibilities. 
1.3.3  Post-FPOP proteomics workflow  
The FPOP-modified protein is usually analyzed by a bottom-up proteomics strategy to obtain 
sub-regional and residue-specific structural information (i.e., the footprint) (Figure 1.1). Owing 
to the covalent and irreversible modification by FPOP, many improvements made for analysis 
and determination of the primary structure (analytical proteomics) can be applied to facilitate the 
FPOP approach for higher order structure characterization. For example, the irreversible 
modification (unlike in HDX) offers high flexibility in proteolysis. Digestion with specific (e.g., 
trypsin, Asp-N), semi-specific (e.g., chymotrypsin) and nonspecific (e.g., pepsin) proteases can 
be performed in tandem or separately to generate overlapping peptide fragments that give 
comprehensive coverage of the protein sequence. Unlike identifying primary structure in 
proteomics, footprinting requires high coverage of the protein sequence, but this is manageable 
because usually a single, known protein or a simple mixture of proteins is used. 
12 
 
 The resultant peptides are analyzed by liquid chromatography and tandem mass spectrometry 
(LC-MS2) to identify the modification sites and to quantify the levels. Oxidation by FPOP makes 
the peptide less hydrophobic, permitting separation of the modified peptide from its unmodified 
form by reversed-phase LC (see Figure 1.1B for an example). Generally, the modified peptides 
elute earlier than the unmodified ones, which allows a clear identification of the modified 
peptide on the basis of its accurate mass and product-ion spectrum (MS2). We quantify the 
peptide modification level based on the primary modification species (i.e., products of OH 
substitution (+15.9949 Da)). To calculate the modification percentage for a specific peptide, 
signal intensities of the unmodified peptide (Iu) and its modified species (ΣIox) are taken as peak 
areas from extracted ion chromatograms (XICs). The modification fraction for a certain peptide 
is calculated from the following equation: Fraction-modified = ΣIox/(Iu + ΣIox). This algorithm is 
straightforward and sufficiently sensitive to report the solvent accessibility change.5  
 
1.4  Applications of FPOP   
To show that the method is reliable and versatile, we now review four topics that show the utility 
of FPOP in biophysics and structural proteomics. 
1.4.1 Amyloid protein aggregation 
Aggregation of amyloid beta (Aβ) is one of the primary pathogenic events leading to 
Alzheimer’s disease. Characterizing the products of Aβ aggregation, however, remains 
challenging owing to the vast heterogeneity and transient nature of the intermediate aggregates. 
We recently used FPOP to monitor amyloid formation and solvent accessibility of Aβ1-42, the 42- 
amino acid form of Aβ, at global, peptide, and amino-acid levels (Figure 1.3).5 FPOP 
footprinting immediately captures the solvent accessibilities of Aβ1-42 intermediates, filling in the 
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gap between solution NMR for the early state oligomers and solids NMR and cryo-EM for the 
final fibrils. The readout from FPOP is clear, because the irreversible modification by FPOP 
should not be affected by Aβ aggregation and/or conformational change occurring post-
footprinting.   
We modified Aβ1-42 aggregates in various oligomeric states by FPOP. Occurring are extensive 
modifications for Aβ1-42 monomer owing to its intrinsically disordered structure (Figure 1.3A). 
As Aβ1-42 assembles and reorganizes into higher order oligomers, the FPOP modification of Aβ1-
42 deceases owing to formation of secondary/tertiary structures (Figure 1.3B and C). At the end 
of aggregation, the modification extent decreases to a modest level (Figure 1.3D), indicating the 
formation of compact amyloid fibrils with a core structure that resists modification. A fit of a 
plot of FPOP modifications as a function of incubation time, adopting the conventional 
nucleation-condensation mechanism (Finke-Watzky), affords a sigmoidal curve that shows 
sequential formation of the major species of Aβ1-42 during aggregation (Figure 1.3E).  We also 
characterized the interconversion of those representative Aβ species by simulating their 
concentration change as a function of the incubation time (Figure 1.3F).  
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Figure 1.3. FPOP and kinetic modeling characterize the time-dependent aggregation of Aβ-
1-42 at protein, peptide and amino-acid residue levels. (A-D) Mass spectra showing extents of 
FPOP modification for intact Aβ1-42 (5+ charge) as a function of the incubation time. The 
determined modification percentage is shown in each panel. (E) Characterization of Aβ1-42 
aggregation on the global (full-polypeptide) level by a kinetic simulation. Points represent 
experimental data, and the solid curve is a model fit based on two auto-catalytic reactions. (F) 
Concentrations (in monomeric equivalents) change of representative Aβ1-42 species (M-monomer, 
D-paranuclei, D*-protofibrils and D**-fibrils) from kinetic simulation. (G-H) Aggregation 
curves of N-terminal region 1-15 and C-terminal region 28-42. (I-J) Aggregation curves of 
representative Aβ1-42 residues H6 and F19/F20. In G-J, the solid and dashed curves are model fits 
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independent of or constrained by the global rates, respectively.  Adapted with permission from 
ref. 5. Copyright 2016 American Chemical Society. 
 
FPOP also provides a high-resolution view of aggregation at regional and amino-acid levels for 
some residues. We characterized the modification of three Aβ1-42 sub regions, including the N-
terminal peptide 1-15, central domain 16-27, and C-terminal peptide 28-42 from digestion of the 
full-length Aβ1-42. FPOP modification for the N-terminal peptide remains high (~ 80%) with little 
variation as Aβ1-42 aggregates, indicating that the N-terminus remains structurally flexible and 
solvent accessible, with little participation in Aβ1-42 aggregation (Figure 1.3G). This finding is 
further supported by NMR results showing that the N-terminus of Aβ1-42 is disordered in a 
variety of oligomers and in the mature fibril. By contrast, the critical roles of the central domain 
and hydrophobic C-terminus in promoting self-association is highlighted by a dramatic decrease 
in FPOP modification from monomers to fibrils (Figure 1.3H). Furthermore, measuring the 
modification at the amino-acid level allows characterization of the aggregation tendencies for 
Aβ1-42 at a residue level. For example, H6 shows relatively constant FPOP modification, during 
aggregation, indicating little change in its solvent-accessibility and conformation (Figure 1.3I). 
On the other hand, F19/F20 are residues primarily responsible for the modification change 
observed for the central domain (Figure 1.3J), and we propose that interactions of F19/F20 
contribute a driving force for Aβ1-42 aggregation by serving as the hydrophobic nucleation 
interface.  
We envision that this FPOP platform can reveal how interactions of Aβ with other molecules 
affect site-specific aggregation.  Application to drug candidates and natural products that 
promote/inhibit oligomerization should be particularly fruitful.     
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1.4.2  Protein folding 
Protein folding and stability is crucial in understanding the biological effects of mutations and 
the pathogenesis of diseases associated with aggregation of misfolded proteins. Protein folding is 
transient and rapid (usually sub-millisecond), challenging structural characterization of kinetic 
intermediates formed during folding. Previously, spectroscopic methods, including fluorescence 
emission, circular dichroism, and electron-spin resonance, have provided insights into the 
underlying mechanism of protein folding. Approaches having high spatial resolution and 
sensitivity, however, are still sparse. Because the labeling speed of FPOP is faster than most 
protein folding, it should be effective in probing folding by measuring protein solvent-
accessibility changes accompanying the conformational change. Meanwhile, the high spatial 
resolution of FPOP allows direct assessment of the folding down to amino-acid residues in some 
cases.  
To explore this opportunity, we designed a two laser-based platform that combines a temperature 
jump (one laser) and FPOP (second laser) to study protein fast folding (Figure 1.4A).7 This 
platform employed a Raman-shifted Nd:YAG laser (1900 nm) to generate a nanosecond 
temperature jump (~ 20 C) in the buffer solution and initiate protein (barstar) refolding, 
followed by a folding time-dependent FPOP footprinting triggered by the KrF excimer laser. 
Control of the heating and the FPOP laser, and hence the folding times is achieved by two delay 
circuits, which are used to adjust the time between firing the two lasers. 
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Figure 1.4. Folding of barstar characterized by a T-jump FPOP. (A) Schematic 
representation of the two-laser FPOP platform. As in Figure 1.2A, the transparent window is 
located where the two laser beams (dash lines) are incorporated. (B) Left: FPOP modification 
percentage of two representative residues as a function of the protein (barstar) folding time. Solid 
lines in the plots are obtained from kinetic fitting. Right: Five critical residues identified by 
FPOP mapped on native barstar structure. Two views are provided to show the side chains of the 
amino acid L88 (red), F74 (cyan), I5 (blue), L20 (green), and W53 (purple). Adapted with 
permission from ref. 7. Copyright 2012 American Chemical Society. 
 
The test protein, barstar, a small globulin protein with a single domain structure composed of 
four -helixes and three -sheets, is a well-characterized model for protein folding. We probed 
its folding from a fraction of a ms to 2 ms, a time domain spanning its early folding and found 
residues with distinct kinetic features in terms of their solvent accessibility (Figure 1.4B). 
Modifications of H17, L20 and L24, all located in helix1, show an exponential decrease in the 
first 2 ms of folding (a control is represented by L88 in Figure 1.4B). Their modification at 2 ms 
time is attenuated owing to its folding. These residues showing dramatically decreased FPOP 
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modification are consistent with folding via hydrophobic interactions in the first 2 ms. Our 
findings agree with the spectroscopic results20 but bring spatial resolution, demonstrating that the 
hydrophobic collapse on helix1 is the initial step in barstar folding. 
FPOP can also be used to probe protein slow folding. An example is study of the refolding of a 
viral fusion protein, parainfluenza virus 5 F (PIV5 F).6 We triggered the irreversible refolding of 
PIV5 F by heat, and captured five conformations on the basis of their FPOP footprints: PIV5 F in 
the pre-fusion state (before heating), three intermediate states (45, 55, and 65 °C), and the post-
fusion state. The experiment required the FPOP capillary contiguous to the laser window to be 
placed in a heated chamber that maintains the temperature of the protein solution. The 
modification of the PIV5 F decreases upon transition from the pre-fusion to the post-fusion state, 
indicating that the structure of PIV5 F in the pre-fusion state is more open and solvent-exposed.  
The modifications of the PIV5 F peptides afford structural information on regions becoming 
solvent-exposed or protected along the refolding pathway. This allows us to propose a model 
describing the dynamic refolding of PIV5 F and to compare the differences in FPOP 
modification of the pre-fusion and post-fusion PIV5 F with changes in the solvent accessible 
surface area (SASA) from X-ray structures. There are greater changes in solvent accessibility for 
nine regions, as reported by FPOP but not predicted by SASA. This indicates an underestimation 
of the pre-fusion PIV5 F’s SASA calculated from the static crystal structure and points to a 
higher structural flexibility in solution. Interestingly, most of those regions contain the epitopes 
of PIV5 F for the prefusion-specific neutralizing antibodies, suggesting the importance of those 
regions for PIV5 F biological function.  
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1.4.3  Epitope mapping 
Understanding antibody action relies on identifying the binding sites of the antibody on the target 
antigen. Methods for this, called epitope mapping, include X-ray crystallography, NMR, site-
directed mutagenesis, and MS-based approaches. Those techniques offer complementary 
information on the epitope and on binding-induced conformational changes. To illustrate the 
capability of FPOP for epitope mapping, our lab has collaborated with Bristol-Myers Squibb and 
Genentech to characterize epitopes for a number of targets upon binding of protein therapeutics. 
Early in the development, we applied FPOP to investigate the epitope of human epidermal 
growth factor receptor (EGFR) for adnectin binding at both the peptide and amino-acid residue 
levels.10 The FPOP-determined binding interface involves various amino-acid and peptide 
regions near the N-terminus of EGFR. Our data correlate well with the previously determined 
epitopes from the crystal structure. Additionally, successful characterization of epitopes in 
thrombin19 and vascular endothelial growth factor 18 serves as other good examples of FPOP’s 
ability to identify both the epitope and regions with remote conformational changes.   
We later combined HDX-MS, site-directed mutagenesis, and FPOP to study the epitope of 
interleukin-23 (IL-23) upon binding of an anti-IL-23 antibody (Figure 1.5).9 Using HDX-MS, we 
found five peptide regions on IL-23 showing reduced backbone amide solvent accessibility upon 
antibody binding. Five different peptides of IL-23 are identified by FPOP, among which three 
regions are identified by HDX as well. Additional FPOP analysis at residue level allows us to 
assign potential critical-binding residues.  
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Figure 1.5. Epitope regions of IL-23 identified by FPOP, HDX-MS, and alanine shave 
mutagenesis. (A) Critical peptides discovered by HDX (top) and FPOP (bottom). These regions 
are mapped on the linear sequence of IL-23 (in orange for HDX results and blue for FPOP). (B) 
Critical residues identified by FPOP (top) and alanine-shave mutagenesis (bottom) mapped on 
the IL-23 crystal structure. Amino acids identified by FPOP are in blue, and by mutagenesis in 
green. Gray regions suggest no significant difference in the conformation of IL-23 upon binding 
with Fab.  Adapted with permission from ref. 9. Copyright 2017 American Chemical Society. 
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More recently, we implemented FPOP, HDX, and carboxyl group footprinting to map 
interactively the epitope of IL-6 receptor (IL-6R) for two adnectins with distinct affinities (Kd, 
Adnectin1 ∼ 6.2 pM vs Kd, Adnectin2 ∼ 46 nM).8 Besides identifying the epitope as a flexible 
loop that connects two β-strands in the cytokine-binding domain, our results reveal that two 
loops, located beyond the conserved epitope undergo reduced dynamic motion upon adnectin1 
binding. Those local effects on the IL-6R structure are attenuated or not observed in the case of 
adnectin2 binding. Apparently, binding of adnectin1, the stronger ligand, stabilizes IL-6R by 
reducing the flexibility of those dynamic regions.  
Outcomes from the above studies highlight the capability of FPOP as a sensitive tool for epitope 
mapping, motivating its further applications in protein discovery and development either as a 
stand-alone method or in conjunction with orthogonal structural approaches (e.g., X-ray, SAXS, 
EM) and other MS-based methods (e.g., HDX-MS, ion mobility). In addition, the combined use 
of MS-based methods provides critical information on therapeutic targets in the absence of an X-
ray structure, has high throughput, and may be a major advance for the discovery and 
development of biopharmaceuticals. 
1.4.4  Protein dynamics and hidden conformations 
  FPOP can report variations in protein dynamics and flexibility because its sampling time is 
short with respect to local dynamics of the protein.  For example, a study of the oligomerization 
interface of apolipoprotein E3 (ApoE3) reveals that the C-terminal helix of ApoE3 and an 
unstructured hinge region proceeding the helix undergo decreases in solvent accessibilities in the 
tetramer compared to a monomeric mutant.12 The C-terminal helix of ApoE3 has long been 
hypothesized to be the primary interface for self-association leading to tetramer formation. 
Evidence for the change in the mobility of the hinge region associated with oligomerization 
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cannot be seen by HDX and carboxyl group footprinting on ApoE3, done subsequently. Thus, 
the preceding hinge region is stabilized owing to formation of the oligomerization interface by 
the C-terminus of ApoE3. The inability to see this by HDX and carboxyl-group footprinting 
stems from their relatively long labeling time compared to that of FPOP.  
 
 
Figure 1.6. Modeling and FPOP reveal restricted motion in the Ω-loop in cefotaximase 
variant. A crystal structure of TEM-1 (blue) is overlaid with the two most populated structures 
taken from modeling of (A) the non-cefotaximase states (green, favored by wild type) and (B) 
cefotaximase states (orange, favored by the E104K/G238S). (C) Large structural rearrangements 
in the Ω-loop distinguish low-energy non-cefotaximase states from cefotaximase states. (D) 
FPOP data reveal experimentally the restricted motion in cefotaximase variant predicted from 
modeling. Hydroxyl labelling of TEM variants are shown as the difference in percent labelled 
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between cefotaximase variant and wild type. The Ω-loop (164–179) is shaded grey in the 
sequence and pink in the graph. Adapted with permission from ref. 11. Copyright 2016 Nature 
Publishing Group. 
 
FPOP also effectively reveals the difference in local dynamics between wildtype (WT) TEM-1 
and its cefotaximase variant. TEM β-lactamase is an enzyme responsible for the antibiotic 
resistance in pathogenic Gram-negative bacteria. The cefotaximase variant of TEM, favored by a 
E104K/G238S mutant, hydrolyzes cefotaxime 1,400-fold more efficiently than does WT TEM-
1.11 Although the function and specificity of various TEM variants can vary dramatically, no 
apparent conformational changes are found for those variants (Figure 1.6A and B). To uncover 
the structural difference between the cefotaximase variant and WT TEM-1, our collaborators, 
using Markov state models-based simulation, proposed that the decreased flexibility of the Ω-
loop in the cefotaximase variant is responsible for its high enzymatic efficiency by stabilizing the 
binding-competent state (Figure 1.6C). To test, we turned to FPOP and found significantly 
decreased FPOP modification on the Ω-loop itself and the region preceding the Ω-loop in the 
cefotaximase variant (Figure 1.6D). In addition, the decreased solvent accessibility pertains to 
the C-terminus, suggesting that the E104K/G238S substitution not only reduces the flexibility in 
the Ω-loop, but that of the C-terminus remotely via long-range interaction. In this case, FPOP 
provides a test for the theory from molecular dynamics simulation and demonstrates its 
capability in probing protein solution dynamics that are inaccessible by static crystal structures. 
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1.5  Conclusions and Outlook 
FPOP coupled with MS has emerged as a powerful approach to study protein higher order 
structures. The robustness of the platform has been further enhanced by recent advances in 
methodology, allowing the approach to provide improved quantitative information and broader 
coverage in footprinting for various types of amino acid residue.  
One example is incorporation of a reporter peptide into the protein sample to resolve 
discrepancies in the radical dosage. In this scheme, the protein and the reporter peptide are 
modified by FPOP simultaneously under the same condition. Thus, the modification extent of the 
reporter peptide correlates with the radical lifetime in the sample. By varying the scavenger 
concentration (i.e., the radical lifetime), the reporter peptide approach permits a normalized, 
time-dependent measurement of the modification on the protein.21 In addition, the FPOP 
platform has been extended by Jones to footprint live cells,22 allowing investigation of protein 
conformation and interactions in the native cellular environment. 
The versatility of FPOP to accommodate new reagents in addition to the ·OH is illustrated by the 
developments of the sulfate radial anion (SO4-∙)23 and iodine radical (I∙)24 as alternative 
footprinting reagents. We also adapted the carbene radical, a laser-based footprinting reagent 
developed by Schriemer25 using a Nd-YAG laser at 355 nm, into the FPOP platform to modify 
Asp/Glu.26 More recently, Cheng et al. developed trifluoromethyl radical (·CF3) as a novel 
reagent that can modify 18 of 20 amino acids residues, including Gly, Ala, Ser, Thr, Asp and Glu, 
which have low reactivities with ·OH.27  
The ability to accommodate new reagents on the FPOP platform allows construction of a “library” 
of reagents that offer different chemical reactivities and specificities to footprint proteins and 
distinguish structural changes that occur from apo to holo, bound to unbound, and wild type to 
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mutant. As these improvements grow, FPOP-based oxidative footprinting approaches will play 
an increasingly important role by serving as constrains of the macromolecule structure, much 
like chemical shifts do in NMR.  The ultimate goal is to use chemistry and MS-based proteomics 
to determine coarse-grained structure of proteins and their assemblies. This will require high 
coverage of the protein residues in footprinting and motivates continued development and 
application of FPOP.  
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Photochemical Oxidation of Proteins and 
Mass Spectrometry Characterize Amyloid 
Beta 1-42 Aggregation* 
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Conformational-Sensitive Fast Photochemical Oxidation of Proteins and Mass Spectrometry 
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2.1   Abstract  
Preventing and treating Alzheimer’s disease require understanding the aggregation of amyloid 
beta 1-42 (Aβ1-42) to give oligomers, protofibrils, and fibrils. Here we describe the footprinting of 
Aβ1-42 by hydroxyl radical-based fast photochemical oxidation of proteins (FPOP) and mass 
spectrometry (MS) to monitor time-course Aβ1-42 aggregation. We resolved five distinct stages 
characterized by two sigmoidal behaviors, showing the time-dependent transitions of monomers–
paranuclei–protofibrils-fibrillar aggregates. Kinetic modeling allows deciphering of the amounts 
and interconversion of the dominant Aβ1-42 species. Moreover, the irreversible footprinting probe 
provides insights into the kinetics of oligomerization and subsequent fibrillar growth by allowing 
the conformational changes of Aβ1-42 at sub-regional and even amino-acid-residue levels to be 
revealed. The middle domain of Aβ1-42 plays a major role in aggregation whereas the N-terminus 
retains most of its solvent-accessibility during aggregation, and the hydrophobic C-terminus is 
involved to an intermediate extent. This approach affords an in-situ, real-time monitoring of the 
solvent accessibility of Aβ1-42 at various stages of oligomerization, and provides new insights on 
the site-specific information on Aβ1-42  for a sample state beyond the capabilities of NMR or x-
ray crystallography. 
 
2.2   Introduction  
The aggregation of the amyloid beta (Aβ) into oligomers and fibrils is a key process associated 
with Alzheimer’s disease (AD) (Figure 2.1). Among Aβ isoforms that present in AD, Aβ1-42 is 
generally considered to be the most pathogenic.1 Extensive effort has focused on characterizing 
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the conformation, size, and shape of Aβ aggregates (e.g., as dimers, pentamers, dodecamers2-7 
and fibrils8-13) (Figure 2.2), and the outcomes show a complex picture of Aβ1-42 aggregation. 
Although soluble oligomers are thought to be the most critical players in the pathology of AD, 
large aggregates and fibrils may also be toxic.1, 14 Unfortunately, we know little of their rates and 
extents of formation. 
 
Figure 2.1. Aβ and AD. (A) Accumulation of Aβ peptide leading to the formation of Aβ plaque. 
Two major forms of Aβ peptide, Aβ1-40 and Aβ1-42, are derived from amyloid precursor protein 
(APP) by enzymatic cleavage. (B) Aβ peptides are implicated in AD pathogenesis. (C) 
Sequences of Aβ1-40 and Aβ1-42. (A) and (B) are adapted from Kung, H. F., ACS Medicinal 
Chemistry Letters 2012, 3 (4), 265-267. 
Aβ1-40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Aβ1-42   DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
B
C
A B
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Figure 2.2. Aβ and its aggregates. (A) Aggregation pathway of Aβ1-42 is a complicated 
multistep process. (B) Some proposed models of Aβ monomer, dimer, pentamer by solution-
phase NMR. (C) Three structures of Aβ1-40 fibrils reported by solid-phase NMR. Adapted from 
ref 6. 
 
The most common approach in methodology for characterizing structure is multiphase NMR and 
X-ray crystallography, giving an essential, high resolution picture of the final state of Aβ fibrils 
while addressing some intermediates or oligomerized states that can be retained under non-
physiologically relevant conditions. Owing to the vast heterogeneity and high aggregation 
propensity, however, the low molecular weight (low-MW) Aβ oligomers are not amenable to 
NMR or X-ray crystallography. Along a similar vein, atomic force microscopy (AFM) visualizes 
Monomer Dimer Paranulei Large oligomer Protofibrils Fibrils
Dimer PentamerMonomer
A
B
C
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morphology of the aggregates but provide no site specificity. More recently, Bowers et al.15 
implemented high resolution AFM to provide insight into Aβ1-42 and Aβ1-40 oligomers formed at 
early stage. The results with respect to the morphology is clear, but the process used to evaporate 
the droplet of Aβ solution before the visualization is not free of ambiguity.  
Fluorescence may be the most widely adopted approach to follow Aβ aggregation, offering a 
solution medium that affords more physiological relevance. The signature measurement for 
amyloid formation is the fluorescence-based Thioflavin T (ThT) labeling assay that shows two 
regions or stages of aggregation separated by a sigmoid (Figure 2.3)16. Recently, Frieden et al.17 
labeled Aβ with tetramethylrhodamine (TMR) as a novel fluorescent reporter for 
oligomerization. This method reports more details, showing a lag and growth phases in amyloid 
formation. Although those fluorescence-based methods inform on the states of aggregation, only 
low structural resolution data is available. Despite their ease of use, they require either adding a 
dye molecule, which affects the accuracy in measuring amyloid-ligand interactions because anti-
amyloid compounds such as polyphenols with strong absorption and fluorescence properties can 
significantly bias the fluorescence readout,18 or pre-modifying Aβ, a perilous approach given that 
addition or subtraction of one amino acid changes significantly the properties of Aβ.   
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Figure 2.3. Thioflavin T (ThT) fluorescence assay for monitoring amyloid fibrilization. (A) 
Structure of ThT. (B) A typical ThT fluorescence curve representing two stages in amyloid 
formation, including a lag phase and a growth phase. Adapted from ref 16. 
 
Mass spectrometry is now playing a role in understanding Aβ oligomerization, principally via 
measurements of the ion mobility of the gas-phase species.3  Most ion-mobility work reports on 
small oligomers and short Aβ fragments, whereas the full protein and its very large soluble 
oligomers (n~100) likely hold the secret of its debilitating role in the human brain. 
Contemporaneously with the application of the TMR fluorescence method, we applied MS-based 
pulsed hydrogen-deuterium exchange (HDX)19 and obtained similar results as Frieden et al. 
Although pulsed HDX avoids the problem of pre-modifying Aβ, the application of sophisticated 
proteomics for downstream protein analysis must be constrained to minimize the back-exchange 
resulted from hydrogen/deuterium scrambling.20 As an alternative, Axelsen et al.21 applied a 
A
B
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synchrotron-based hydroxyl radical footprinting to study Aβ1-40 fibril and compared the outcome 
with those of multiple NMR structural studies. Despite all these efforts, the techniques we have 
currently, however, do not fully address the intermediate conformational transitions of Aβ1-42 
during aggregation.  Thus, the transient aggregates of oligomerization remain insufficiently 
characterized, and our tools to characterize the oligomerization are temporarily exhausted.     
In this report, we describe a new platform based on fast hydroxyl-radical footprinting (FPOP) 
and mass spectrometry to follow the aggregation of Aβ1-42, which is regarded to be the most 
pathologically relevant Aβ isoform in AD. Unlike Aβ1-40, the folding and assembly of Aβ1-42 are 
highly complicated and multi-step process,2-3, 6-7, 13-14, 22 (Figure 2.2A). Here, we seek an 
informative, time-dependent approach that not only follows oligomerization but also can be 
extended to test the effects of other proteins, lipids, and potential drugs on the monomer/soluble-
oligomer transitions. The cutting-edge approach builds on proteomics measurements and MS-
based footprinting. It utilizes hydroxyl radical-mediated irreversible reactions23 initiated on a 
FPOP platform24 to footprint Aβ1-42 as it undergoes oligomerization. FPOP allows various Aβ1-42 
oligomeric species to be footprinted rapidly and irreversibly on amino-acid side chains. To locate 
the modified regions, we implemented Lys-N rapid digestion and LC-MS/MS to characterize Aβ-
1-42 fragments. Our hypothesis is that FPOP modifications sensitively respond to the solvent 
accessibility changes of Aβ1-42 upon self-association (Figure 2.4). This approach uses 
downstream sample processing independent of protein conformational changes occurring post 
footprinting to report changes on the Aβ1-42 side chains at the global, peptide regional, and even 
amino-acid levels. 
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Figure 2.4. Schematic of using FPOP to probe Aβ aggregation. As Aβ (blue sphere) 
undergoes self-association, its decreased solvent accessibility is reflected by changes in FPOP 
modification (green sphere). The FPOP-modified Aβ are denatured for measuring the averaged 
modification extent of the peptide using LC-MS.       
 
2.3   Materials and Methods  
2.3.1   Materials 
Synthetic wild type human amyloid beta 1-42 (Aβ1-42) was from AnaSpec (San Jose, CA). Lys-N 
protease was from Seikagaku Corporation (Tokyo, Japan). Hexafluoroisopropanol (HFIP), 
sodium hydroxide (NaOH), L-glutamine, L-methionine, catalase, hydrogen peroxide (H2O2), 
phosphate buffer saline (PBS, 10 mM phosphate, 138 mM NaCl, 2.7 mM KCl), urea, formic acid 
and trifluoroacetic acid were from Sigma Aldrich (St. Louis, MO).             
 2.3.2   Formation of Aβ1-42 aggregates 
The purchased Aβ1-42 was dissolved in HFIP at 1 mM and incubated at room temperature for 1 h 
to disrupt any pre-existing aggregates. The resulting solution was then aliquoted into tubes, and 
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the HFIP was evaporated in a fume hood. After solvent evaporation, a clear film of Aβ1-42 
remained at the bottom of the tube. HFIP treatment was then repeated two more times.  Samples 
were then frozen in -80 ⁰C for future experiments. Prior to incubation for aggregate formation, 
HFIP-pretreated Aβ1-42 was dissolved in 3 mM NaOH (pH 11.7) and incubated without stirring at 
room temperature for 3 min followed by sonication for 1 min. Aggregation was initiated upon 
diluting the Aβ1-42 NaOH solution by 20 fold (v/v) with PBS buffer (pH 7.4). The final Aβ1-42 
concentration after dilution was 10 μM.  Different extents of aggregation were achieved by 
varying the incubation time from 0 to 48 h in PBS buffer (25 oC or 37 oC).  For each time point, 
the incubation and analysis was done in triplicate.    
2.3.3   FPOP labeling of Aβ1-42 
At the various incubation times, Aβ1-42 was immediately submitted to FPOP labeling. FPOP was 
performed as previously described.25 Briefly, a KrF excimer laser (GAM Laser Inc., Orlando, 
FL, USA) generated laser beam with an excitation wavelength of 248 nM initiated H2O2 
photolysis to give hydroxyl radicals. The Aβ1-42 in PBS was mixed with 20 mM glutamine 
(scavenger) and 20 mM H2O2 just prior to injection into the flow tubing for FPOP. The flow rate 
was adjusted according to the width of the laser irradiation window to ensure 20% irradiation-
excluded volume and to   minimize repeated laser exposure. The total time for one sample to 
pass through the silica tubing was ~2 min.  After laser irradiation, the sample was collected in a 
tube containing 10 mM catalase and 20 mM methionine to decompose leftover H2O2 and prevent 
oxidation-artifacts during storage. For each aggregation time point, Aβ1-42 was incubated 
independently in triplicate and subjected to FPOP. In addition, control samples of Aβ1-42 were 
handled in the same manner in triplicates, but not laser-irradiated. Each FPOP-labeled sample 
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was transferred into aliquots for intact Aβ1-42 characterization and enzymatic digestion, 
respectively.  
2.3.4   Proteolysis 
Urea was added to each 20 μL aliquot of the FPOP-labeled Aβ1-42 sample to give a final 
concentration of 6 M. Lys-N was then added with an enzyme to protein ratio of 1:10 (w/w). The 
concentrated urea facilitated rapid digestion and prevented hydrophobic peptides from self-
assembly during digestion. Samples were incubated at 45 oC for 30 min. The digestion was then 
quenched by adding trifluoroacetic acid to a final concentration of 1% (by volume).  
2.3.5   Mass spectrometry 
For intact Aβ1-42 characterization, 20 μL of the FPOP-labeled sample was directly submitted to 
an Agilent 1100/1200 separation system at a flow rate of 200 μL before being admitted to a 
MaXis 4G quadrupole-time-of-flight (Q-ToF) mass spectrometer (Bruker Daltonics, Billerica, 
MA). Solvent A was water + 0.1% formic acid, and solvent B was 80% acetonitrile + 0.1% 
formic acid. The gradient started from 5% B and increased to 15% B in 0.3 min, ramped to 50% 
B in 5.2 min, increased to 100 % B in 0.5 min, held at 100 % B for 0.5 min, returned to 5% B in 
0.1 min and equilibrated at 5 % B for 2 min. The mass spectrometer was operated in the positive-
ion electrospray ionization mode at a mass resolving power of 30,000 (m/z 400). 
For peptide and residue level analysis, 5 μL digested sample was submitted to LC-MS/MS 
analysis. Samples were pre-concentrated on an Acclaim PepMap C18 column (Thermo 
Scientific, 100 µm × 2 cm, 5 μm, 100 Å) and desalted for 15 min before elution. Separation was 
performed on a 15 cm custom-packed C18 column (Magic, 75 µm × 15 cm, 5 μm, 200 Å) 
maintained at 65 oC by using a Nano UltiMate 3000 Rapid Separation system (Dionex, Co.). 
40 
 
Solvent A and B were the same as above. Peptides were eluted at a flow rate of 700 nL/min with 
the following gradient: 2% B to 20% in 1 min, ramped to 70% B in 10 min, increased to 90% in 
1 min, held at 90% for 3 min, returned to 2% B in 1 min, and equilibrated at 2% B for 4 min. LC 
separation was directly coupled to online detection using a Q Exactive Plus hybrid quadrupole 
orbitrap mass spectrometer with a Nanospray Flex ion source (Thermo Fisher, Santa Clara, CA). 
The top ten abundant ions seen in the mass spectrum were subjected to higher energy collision 
dissociation (HCD) for identification and characterization of possible FPOP modifications. The 
mass resolving power was 70,000 (m/z 400) for MS1 and 17,500 (m/z 400) for MS/MS.         
2.3.6   Data analysis  
Whole protein-level analysis with the custom program afforded the fraction of unmodified Aβ1-42 
after FPOP for all samples. Signal intensities for the modified (Iox) and unmodified species (I) 
were integrated from the raw data files, either with the custom program for the intact Aβ1-42  or 
Thermo Xcalibur for the digested peptide and residue-level analysis. The extent of modification 
was calculated by using the following equation, as previously described,25 
Eq. 2.1                                 % 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =
Σ𝐼𝑜𝑥
Σ𝐼𝑜𝑥+∑ 𝐼
 × 100  
For analysis of Aβ1-42 digested peptides, product-ion spectra obtained with the orbitrap mass 
spectrometer were searched for peptide identification by using Mascot (Matrix Science, London, 
UK) software. Mass of unmodified peptides and assigned modifications validated by manual 
inspection were input into an inclusion list to afford better sampling and identification of FPOP 
modifications. 
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Figure 2.5. An example of FPOP identification. (A) Mass spectra of peptide 16-27 (doubly 
charged), unmodified peptide (top), and modified peptide (bottom). (B) Product-ion spectra 
(MS/MS) of the unmodified (top) and modified (bottom) peptide 16-27. The MS/MS spectra of 
the modified peptide was integrated over the signal with the retention time of 10.2 min and 
indicates FPOP oxidation on F20 of Aβ1-42.  
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Modification sites on the peptide were assigned on the basis of product-ion (MS/MS) spectra 
(Figure 2.5). In a few cases, the location of a modification to a single residue was not possible 
owing to limited fragmentation information from MS/MS or to the presence of interference from 
co-elution of peptide isomers. In that case, the modification was indicated to occur on a set of 
possible residues. For any specific residues, the fraction modified was calculated by the 
following equation as the ratio of the signal of each peptide modified at that residue 
( Σ𝐼𝑜𝑥 𝑜𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑋 ) to the total intensity of modified and unmodified peptide signal spanning this 
residues.26 
Eq. 2.2            For amino-acid residue, % 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =
Σ𝐼𝑜𝑥 𝑜𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑋
Σ𝐼𝑜𝑥+∑ 𝐼
 × 100  
2.3.7   Kinetic Modeling 
The fraction of FPOP modified molecules was modeled on the basis of Scheme 2.1 by using six 
rate constants as model parameters (see “Fitting Parameters” in SI). The overall FPOP fraction 
modified F(t) was computed as shown in Eq. 2.3 from the species concentrations ([D], [D*], 
[D**]), which varied with time, and the species fraction-modified (𝐹0, ΔFD, ΔFD*, ΔFD**) that 
are also model parameters. 𝐹0 is the fraction modified for Aβ1-42 monomer. The monomer 
concentration [M] is implicated by the experimental starting concentration of the monomer MT.  
Eq. 2.3                    𝐹(𝑡) = 𝐹0 − (
𝛥𝐹𝐷∙2[D]
𝑀𝑇
+
𝛥𝐹𝐷∗∙2[D∗]
𝑀𝑇
+
𝛥𝐹𝐷∗∗∙2[𝐷∗∗]
𝑀𝑇
)   
The model curve fractions modified F(t) were calculated by solving differential equations (see 
“Fitting Parameters” in SI) representing each reaction in Scheme 2.1 with are time-dependent 
species concentrations and the postulated species fractions modified (𝐹0, ΔFD, ΔFD*, ΔFD**). 
The quantities of ΔFD, ΔFD*, ΔFD** are properties (in term of fraction modified) of the 
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proposed Aβ1-42 species in various oligomeric states (monomeric Aβ1-42 as the reference). Note 
that the definition of the fraction modified (Eq. 2.1) should not be interpreted in terms of intrinsic 
reactivities with the hydroxyl radical; that is, the differences in the fraction modified signaled the 
presence of different Aβ1-42 species with a characteristic protection level.    
The process for determining the model parameters and the kinetic curve was implemented in 
Mathcad v.14.0 M020 (Parametric Technology Corp.). The "Nonlinear Quasi-Newton" mode 
was used in the "Minimize" function in a search for the solution model parameters. In each trial, 
the postulated normalized rate constants were converted to their physical values by 
multiplication by the initial physical rate constants to accommodate the numerically large range 
of rate constants. The adaptive step-size fourth order Runge-Kutta "Rkadapt" function was then 
used to solve the system of ordinary differential equations corresponding to Scheme 2.1 with 
initial conditions that all concentrations were zero except [M] = MT = 10 μM. 
Generally, all ten model parameters were varied in a search to minimize the root-mean of the 
squares of the residuals between experiment data and model curve as shown in Figure 2.8 for 
Aβ1-42 and the solid curves shown in Figure 2.10 and Figure 2.11. For the dashed curves in 
Figure 2.10 and Figure 2.11, all rate constants were fixed to the values obtained from the model 
whose curve is shown in Figure 2.8A for Aβ1-42 while the four postulated species fractions 
modified were varied. 
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2.4   Results and Discussion 
2.4.1   Aggregation of Aβ1-42 at the global (protein) level 
Given that Aβ1-42 aggregation is time-sensitive and continues after footprinting, it is important to 
utilize an irreversible footprinting “snapshot” to capture accurately the oligomerization 
intermediates. In our triplicate experiments, formation of Aβ1-42 aggregates begins with 
incubating Aβ1-42 monomers in PBS buffer for up to 48 h (Figure 2.6), followed by footprinting 
of the protein occurring after irradiation by a labeling laser pulse in a flow system. MS analysis 
gives representative mass spectra of intact Aβ1-42 labeled by hydroxyl radical. The oxidative 
labeling occurs at solvent-accessible Aβ1-42 side chains to give variously labeled proteins 
observed as isotopic clusters (Figure 2.7).    
Figure 2.6. Preparation of Aβ1-42 aggregates for LC-MS analysis. 
 
Owing to its intrinsically disordered structure, 77% of unfolded Aβ1-42 monomers undergo 
modification (Figure 2.7B) at short times.  As Aβ1-42 adopts some conformational order by 
folding into higher-order oligomers, it loses solvent accessibility, gains protection, and 
undergoes correspondingly decreased FPOP modification (Figure 2.7C-E). At the longest 
incubation times, Aβ1-42 becomes highly resistant to modification, indicating formation of mature 
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aggregates, presumably with beta-sheet bundles (Figure 2.7F).10, 27 The FPOP modification 
pattern for various charge states of Aβ1-42 produced in the electrospray ionization are consistent, 
as expected, with a relative error of less than 2% for the calculated extent of modification of 
various charge states.  
 
Figure 2.7. Mass spectra showing extents of FPOP modification for intact Aβ1-42 (5+ 
charged) as a function of incubation time. (A) Aβ1-42 monomer as a control with all reagents, 
including H2O2, added and flowed through the FPOP tubing but without laser irradiation, (B) 
extensively hydroxyl radical-modified, unstructured Aβ1-42 monomers, (C-E) decreasing FPOP 
modification extents of Aβ1-42 aggregates, reflecting increasing structural protection to FPOP 
modification, (F) minimal Aβ1-42 modification, reflecting solvent-inaccessible, highly ordered 
core structure of the fibrillar aggregates that resist FPOP modification. In B-F, t represents the 
time of incubation. 
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We calculated the fraction modified of the full-length Aβ1-42 and its digested peptide (as 
discussed later) from the ratio of the signal of the modified peptide (Iox) to that of the total 
amount of the modified and unmodified peptides (I) (Eq. 2.1), as described in the experimental 
section. By adopting this metric, we can pursue the change in the amount of modified species 
raised from Aβ1-42 conformational change, regardless of the intrinsic reactivity or reaction 
kinetics of the peptide with hydroxyl radical. The use of the above metric for quantifying the 
level of modification is not unusual (see Xie and Sharp28). Here the fraction unmodified is 
directly inferred as one minus fraction modified, and for a given peptide or residue it increases 
monotonically (because it is the product of the fraction unmodified at each reaction site) as the 
reactivity of the overall peptide or specific residue decreases owning to Aβ1-42 association. The 
sensitivity of this metric to increasing reactivity diminishes, however, as the percent unmodified 
becomes very small. For small proteins like Aβ1-42 and, more importantly, for amino-acid 
residues, the relative amount of the unmodified species remains high; thus, this is of minor 
concern under the conditions of our footprinting. 
Another possible concern for processing modified peptides is that some residues can decrease in 
reactivity while others increase. One might suggest as a solution to this concern a metric in 
which the intensities of oxidized species are weighted by the number of oxygens.29 This would 
be analogous to the centroid calculation often used as an algorithm for HDX footprinting of 
proteins. This proposed solution does not always address the issue30 and has the potential to 
magnify uncertainties arising from signals with low signal-to-noise ratio.31 A similar problem 
applies to centroid calculations (i.e., weighing the intensities by the number of modifications) in 
hydroxyl radical footprinting. Therefore, we choose the metrics (Eq.1) that does not compromise 
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the accuracy in quantification and meanwhile sufficiently provides insights in reporting the 
conformational change of Aβ1-42 as it associates.  
The oxidation patterns of Aβ1-42 at various incubation times in the FPOP experiment follow a 
Poisson-distribution;25 that is, the signal of unmodified Aβ1-42 is the most intense, followed by 
those corresponding to the oxidized species with the mass shifts of +16, +32, +48 Da etc. in a 
sequentially descending manner. The patterns of various extents of oxidation follow this manner 
as the overall oxidation level decreasing owning to the folding of Aβ1-42. 
2.4.2   Structural Rationalization of Multiple Kinetic Phases 
The hydroxyl radicals are comparably sized as water molecules, allowing them to modify 
solvent-accessible side chains and report on the transient states of soluble aggregates. We chose 
to model the Aβ1-42 aggregation kinetics, observed at 25 oC (Figure 2.8A), on the basis of the 
nucleation-autocatalytic growth mechanism proposed by Finke et al.32 with modifications that 
address the transient stages observed in the present case.3, 33 This modeling approach is perhaps 
the simplest model that accounts for the various stages of aggregation.  Two nucleation and two 
autocatalytic reactions, as shown in Scheme 2.1, were used to describe the time-dependent 
aggregation of Aβ1-42, one more stage than seen by fluorescence and pulsed HDX. 
With kinetic modeling (see experimental section) based on Scheme 2.1 and support from other 
published work,3, 14, 33 we can follow the aggregation through five stages:  AB, BC, CD, DE, and 
EF (Figure 2.8A), instead of the four observed previously by pulsed HDX and fluorescence.17, 19 
In the modeling, our assumption is that the monomer concentration at time zero is 10 μM, which 
is the concentration upon diluting Aβ1-42 into the PBS buffer, and the solution at that time is free 
of oligomers. 
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Figure 2.8. Characterization of Aβ1-42 aggregation on the global (full-polypeptide) level by a 
kinetic simulation. (A) points represent experimental data (10 μM, 25 oC, pH 7.4, no agitation), 
and the solid curve is a model fit based on two autocatalytic reactions. The inset in (A) shows a 
comparison of the fitting with and without the consideration of the 2-min FPOP dead time. (B) 
Time-dependent concentrations of the various Aβ1-42 species from the solution to the differential 
equations of the fitted model in (A). M-monomer; D-dimer; D*-product of 1st catalytic reaction, 
D**-product of 2nd catalytic reaction. For each species, the concentration is of monomeric Aβ1-42 
equivalents. 
 
A
B
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The stage resolved additionally by FPOP is represented by transition from D to F, which leads to 
the formation of lateral protofibrillar and then to fibrillar aggregates, whereas the transition is a 
single growth phase in the pulsed HDX and fluorescence platforms. In Figure 2.8A, the first 
stage corresponds to (1) Aβ1-42 monomers assembling rapidly to form dimers and small 
oligomers. As the monomers continue to oligomerize, their solvent accessibility and concomitant 
FPOP reactivity decrease in a fast, exponential-like manner (AB).  (2) The early-formed small 
oligomers cooperatively nucleate to provide paranuclei-like “seeds” for subsequent aggregation 
(transition BC). During this time, the oxidation extent cannot significantly change because the 
monomers have almost ceased to disappear. (3) As the concentration of “seeds” reaches a critical 
threshold, larger oligomers form in an autocatalytic fashion (transition CD).34 (4) Lateral 
oligomers likely with the beta-strand structure associate, elongate into large 
aggregates/protofibrils presumably with in-register beta sheets (transition DE),33, 35 and (5) large 
aggregates/protofibrils further associate and catalyze the reorganization of other Aβ1-42 species 
into mature fibrils presumably with the well-defined beta-sheet structure (transition EF).10 
 
Transition A-B.       M + M ⇌ D                            (dimerization) 
Lag stage B-C.        D → D*                                  (1st nucleation) 
Transition C-D.       D + D* → D*+D*                  (1st autocatalytic reaction) 
Lag stage D-E.        D* → D**                             (2nd nucleation) 
Transition E-F.        D*+D** → D** + D**        (2nd autocatalytic reaction) 
 
Scheme 2.1 Proposed kinetic scheme for Aβ1-42 aggregation. 
M- monomer 
D- dimer 
D*- product of 1st catalytic reaction 
D**- product of 2nd catalytic reaction  
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We chose Scheme 2.1 to support the observation that there are additional stages reported in the 
aggregation kinetic curve while applying the principle of parsimony in modeling. The monomer 
to dimer transition (reaction A-B) is illuminated by the work of Frieden et al17, in which early 
changes in their kinetic curves with different starting Aβ concentrations behaved consistently 
with a model of dimer and trimer formation. Here we have not deployed the trimer formation 
component because we argue that the amount of additional protection afforded by the trimer over 
the dimer is not sufficiently large to justify the additional parameters that the trimer would 
require in the scheme. Visual inspection of the kinetic curves shows two steps; each step is 
characteristic of a slow nucleation phase (reaction B-C and D-E) followed by a rapid 
autocatalytic growth phase (reaction C-D and E-F). Given there are two steps, we invoked the 
Finke-Watzky two-step mechanism twice in succession, which might be described as double 
autocatalytic.36  
The use of the Finke-Watzky two-step mechanism does have limitations. It does not account for 
the equilibrium between the Aβ1-42 monomer and other species.37 An alternative and still minimal 
model that addresses this issue is by Crespo et al38. In addition, nucleation and autocatalysis 
models augmented with fibril growth and fragmentation fail to match correctly the lag time 
scaling as a function of monomer concentration for a number of fibrilizing protein systems.39 
The time for the each Aβ1-42 passing through the FPOP workflow is 2 min; thus, for each 
experimental time point, the FPOP fraction modified quantifies an assemble average of Aβ1-42 
conformations over that 2 min in addition to the reported aggregation time. Although this “dead 
time” in FPOP will have a minor influence on the samples with long-time incubation, it may 
affect the early-stage characterization of the curve as the monomer will aggregate to some extent 
in this short period of time. To test, we repeated the simulation by shifting the actual time of 
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aggregation by 2 min as a maximum and extrapolated the curve to the actual start point. We 
found the overall fitting of the aggregation curve is not significantly affected by considering the 
FPOP dead time. In a zoom-in view of the first 60 min (inset in Figure 2.8A), the “-2 min” on the 
time axis of the solid grey curve is regarded as the actual starting point of the aggregation that 
modeled in the testing trial. The outcomes overlap well with curve neglecting the 2 min (dashed 
blue) even for the early aggregation stage as one can think it as the aggregation curve is right-
shifted by 2 min. According to the kinetics revealed by TMR fluorescence, which does provide 
clearer time resolution for the first a few minutes of Aβ1-42 aggregation, the initial exponential 
decrease in fluorescence intensity representing the monomer-dimer-trimer transition proposed 
happens over 30-45 min for the Aβ1-42 with concentrations ranging from 0.5 μM up to 4 μM with 
stirring the solution.17 From the pulsed HDX results, although the initial phase is not well 
defined, it shows a burst tendency of increasing protection over 30 min for Aβ1-42 of 50 μM 
without any stir.19 Taken these observations together, we believe that it is unlikely that the dead 
time from the FPOP labeling has a substantial influence on the aggregation kinetics. If a burst 
phase occurred so rapidly in the 2 min prior to laser irradiation to initiate FPOP such that we no 
longer can explain transition AB, the kinetics will need to be addressed by involving a model 
justifying the additional conformation change in the burst phase as well as transition AB tandem 
to it.                               
Although we calculated the reaction rate constants for each stage by solving the differential-
equation for each reaction in Scheme 2.1, we are not quoting them because they do not directly 
relate to the actual rate constants.  Each rate constant in the model is condensed and simplified as 
a summary of many underlying reaction steps.32 The “dimer” species, for example, is expected to 
be made up of many species, each formation with its own rate constant. Others noted that 
52 
 
nucleation rate constants for the lag phase are unreliable.39 Reliable rate constants associated 
with the growth phases require representation of the maximum slopes during the growth phase, 
which are not present in the data. Nevertheless, we can specify the species concentrations as a 
function of the time obtained from the model and describe the disappearance of Aβ1-42 monomers 
(M) and the formation of various oligomer including paranuclei (D), protofibrils (D*) and fibrils 
(D**) (Figure 2.8B). In the experiment, the initial concentration of Aβ1-42 monomers is 10 μM. 
In the early oligomerization, ~30% of the monomers rapidly assemble into low-MW oligomers 
(solid black curve), followed by a lag phase during which low-MW oligomers slowly accumulate 
until the concentration is sufficient to catalyze (seed) the formation of larger oligomers (dashed 
black curve). As the amount of large aggregates/protofibrils reaches a concentration 
corresponding to ~80% consumption of the original monomer equivalents (dashed grey curve), a 
structural reorganization occurs to deplete the monomers and form rapidly mature fibrillar 
aggregates (solid grey curve). At the end of the aggregation, equilibrium is nearly achieved for 
fibrils and persistent, leftover monomers (~10%). At this stage, the rapid second autocatalytic 
reaction almost shuts down the first autocatalytic reaction, and, as a result, the monomer 
concentration becomes relatively stable.   
A previous study shows that Aβ1-42 and Aβ1-40 have distinct aggregation pathways.6 The assembly 
of Aβ1-42 involves formation of several distinct transient structures to form paranuclei that 
assemble further to form superstructures similar to early protofibrils, whereas Aβ1-40 mainly 
forms low-MW oligomers at a much slower rate than that of Aβ1-42 at similar concentration.3, 19 
We have preliminary results from the FPOP study of Aβ1-40 under the same conditions (10 µM, 
pH 7.4, 25 oC, no agitation) as for Aβ1-42  that this proteoform shows extensive but relatively 
constant FPOP modification over the time scale we investigated (0~48 h) (Figure 2.9A), 
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indicating that it is considerably less reactive than Aβ1-42 in term of the aggregation propensity. 
Further, we examined the aggregation of Aβ1-42 at 37 oC (Figure 2.9B). The higher temperature 
accelerated Aβ1-42 aggregation substantially without showing any lag or intermediate phases. 
Within the first 8 h of incubation, the FPOP fraction modified decreases sharply and then levels 
off, suggesting either the nucleation process happens so rapidly that no apparent lag phase is 
observed or the oligomerization pathway changed from a self-catalytic seeding mechanism. 
 
Figure 2.9. Aggregation of Aβ1-40 at 25 oC and of Aβ1-42 at 37 oC. (A) Mass spectra of Aβ1-40  
(5+ charged) with 0 min and 45 h incubation, 10 μM, 25 oC, pH 7.4, no agitation. (B) Aβ1-42 
aggregation curve, 10 μM, 37 oC, pH 7.4, no agitation. 
 
A
0
20
40
60
80
100
0 500 1000 1500 2000 2500 3000
Time (min)
%
 M
o
d
if
ie
d
B
866.8392
870.0374
873.2363
876.4354
879.8348 922.0104
934.4834 942.4812
922.0095
860 880 900 910
940
870 890850
Unmod.
+16 Da
t = 0 min
(83.3 1.3)% modified
t = 45 h
(84.1 1.8)% modified
54 
 
2.4.3   High Resolution View of Oligomerization 
The FPOP approach permits a high-resolution view of the oligomerization down to even the 
amino-acid level for some residues. To interrogate the conformational changes at a regional 
level, we proteolyzed the irreversibly footprinted protein and analyzed the resulting peptides by 
LC-MS/MS.  Normally, this is a straightforward process for soluble proteins, but Aβ1-42 and its 
hydrophobic C-terminal proteolytic fragments continue to associate during the digestion, 
resulting in appreciable resistance to long-term proteolysis, a loss in mass spectral signals, and a 
possible bias towards those regions that are less prone to association.19, 27 These compounded 
issues motivate a kinetic study that targets high structural resolution by effective and rapid 
digestion of Aβ1-42 aggregates. We used Lys-N protease under optimized digestion conditions to 
address successfully this issue. Taking advantage of Lys-N maintaining its high enzymatic 
activity in 6 M urea,40 we reconstituted a post-labeling aliquot of Aβ1-42 in 6 M urea and 
incubated it with Lys-N (enzyme: protein ratio of 1:10 (w/w)) at 45 oC to digest the Aβ1-42 as 
quickly as 30 min. The high-concentration of urea present in the digestion not only affords rapid 
proteolysis by denaturing Aβ1-42, but minimizes non-covalent association of the hydrophobic 
peptides. More importantly, Lys-N cleaves Aβ1-42 at the amino side of lysine residues, leaving 
the hydrophilic residue K28 on the highly hydrophobic C-terminal proteolytic fragment, thereby 
increasing the sensitivity by two orders of magnitude for the peptide covering this region 
compared to the corresponding peptide formed when trypsin is used (data not shown), improving 
quantification and accuracy. 
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2.4.4   Aggregation of Aβ1-42 at the Peptide and Residue Levels 
 
Figure 2.10. Time-dependent FPOP labeling of Aβ1-42 incubated at 25 oC, pH 7.4, no 
agitation and kinetic simulations for Lys-N digested Aβ1-42 peptides. Oligomerization of (A) 
N-terminal region 1-15, (B) middle region 16-27, and (C) C-terminal region 28-42. Solid curves 
are simulations that afford rates constants for each peptide treated independently, whereas the 
dashed curves are simulations constrained by global rates. 
 
We characterized further the conformational changes in aggregation for the regions represented 
by the three peptides resulting from Lys-N digestion (N-terminal region 1-15, middle domain 16-
27, C-terminal region 28-42). We simulated the kinetics for each region by using the model 
described above (Figure 2.10), both independently and constrained by the outcome of the global 
(protein)-level rate constants. As discussed above, we expect regions that undergo 
conformational changes and serve as oligomerization interfaces to exclude solvent and show 
decreased oxidative modification. The different scales of fraction modified for each peptide is 
related to the distinct reactivities of the corresponding Aβ1-42 sub-regions.  The reactivity is a 
function of: 1) the intrinsic reactivity of those sub-regions as contributed by the amino acid 
residues with respect to its primary sequence, and 2) the protection from the secondary and/or 
A B C
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ternary structure of Aβ1-42 for that sub-region. Given that FPOP modification of the N-terminal 
peptide does not change significantly as a function of aggregation time, this region must remain 
structurally flexible with little self-association and little loss of solvent accessibility as Aβ1-42 
associates. This is in accord with solid state-NMR data, indicating that the N-terminal region 
remains disordered in various Aβ1-42 oligomers and fibrils.2, 9 In contrast, the extent of FPOP 
modification significant decreases (protection increases) over time for the middle domain peptide 
16-27 and the C-terminal peptide 28-42 (6 and 2.5 times decreases in rate from Aβ1-42 monomers 
to fibrils, respectively). This indicates convincingly the importance of those two regions in Aβ1-42 
aggregation whereby the central region must play a prominent role and serve as the self-
association interface to drive aggregation. This is key experimental evidence that the middle 
region is a nucleation interface, as suggested by molecular dynamics studies.35, 41  
The peptide-level results are better modelled by allowing the rate constants for each peptide 
region to be independent (Figure 2.10, solid curves).  When the modeling is restricted by the rate 
constants from fitting for the whole protein, we find relatively pronounced discrepancies 
between the results and the simulated curves (Figure 2.10, dashed curves). Assuming the 
discrepancy is not solely contributed by any structural bias in the digestion, we suggest that 
regions of Aβ1-42 act nearly independently in the oligomerization of Aβ1-42 and that the local 
(regional) rates are not predictable from the kinetic results for the whole protein. Notice that in 
the pulsed HDX, the “half lives” of the peptide-level transitions are also different19 and show that 
the center and C-terminal regions are more important in the oligomerization than is the N-
terminus.  
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Figure 2.11. FPOP results for Aβ1-42 amino acid residues and kinetic simulations. (A) H6 
showing little participation in the oligomerization, (B) H13 showing slightly increasing 
modification initially and then level off, (C) and (D) F19/F20 and M35 showing large changes of 
solvent accessibility along with oligomerization (FPOP modifications on F19 and F20 were 
summed to improve accuracy in quantification). 
 
Furthermore, measuring the modification at the amino-acid level allows characterizing 
aggregation tendencies for Aβ1-42 at that level at least for some of the amino-acid residues 
(Figure 2.11). The oxidative modification on the residue level was assigned by using the product-
ion spectra of the modified peptide precursor ion. Their aggregation curves are generated based 
on measuring the ratio of the signal abundance from that specific oxidized residues to the total 
amount of the peptide observed that contained that residue (see experimental section). The 
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modification for H6, H13, F19, F20 and M35 are well resolved chromatographically with 
quantifiable extent of oxidation at better than a signal-to-noise ratio of 10:1. We also identified 
FPOP modifications on H12, L17, V18, V39/V40/I41. The extent of modification for those 
residues, however, is of very low abundance (less than 1%) and not well sampled; and thus in the 
present case not quantified.  
Residues H6 and H13 show an overall constant extent of FPOP modification during aggregation, 
indicating that few conformational changes occur for these two residues (Figure 2.11). 
Interestingly, for H13 despite showing little change in the fraction modified, this residue shows a 
clear trend of an initial increase in FPOP modification within the first 30 min, suggesting this site 
becomes relatively solvent-exposed and could be a critical nucleation site either to promote or 
delay the next transition. Note that the absolute FPOP modification extents for residues of the 
same type are only related to the surrounding steric environment and protection.  The 
modification extent of H6 is 40% and of H13 is 19%, whereas that of H12 is too low to 
characterize accurately. These results suggest that, although the N-terminal region remains 
structurally disordered during aggregation, the solvent accessibilities of these residues represent 
different microenvironments. H6 is the most solvent-exposed among the three, followed by H13 
and then H12. For F19 and F20 we summed the FPOP modifications before plotting those 
values. These two residues show a decrease in FPOP modification extent by 4.5 times in going 
from monomers to fibrils, and M35 from the C-terminal region showed a similar decrease of 2.5 
times (Figure 2.11). For the middle domain of Aβ1-42 represented by peptide 16-27, the 
difference in modification largely occurred on F19/F20, because not only is phenylalanine highly 
reactive to hydroxyl radical compared to other nearby residues42, but their high hydrophobicity 
potentially driving the oligomerization. We envision that the ability of FPOP to reveal the site-
59 
 
specific aggregation can be applied to understand interactions of Aβ with other molecules, 
especially drug candidates that affect oligomerization. 
2.4.5   Results from Complementary Biophysical Tools 
Many available biophysical tools provide complementary results in tracking Aβ assembly. We 
are limiting our comparison to those that can follow the time course of aggregation under 
physiologically relevant condition. We are not considering the many approaches that view Aβ as 
its initial, largely low-MW oligomers (e.g., solution NMR) or in its final aggregated state (e.g., 
solid state NMR). Among the methods tracking aggregation, ThT dye fluorescence is regularly 
used to follow amyloid formation. The dye undergoes a large enhancement in fluorescence upon 
binding to amyloid fibrils, making it a particularly powerful and convenient tool. A typical ThT 
fluorescence curve reports a single sigmoid including a lag phase and a rapid growth phase to 
form fibrils. Because ThT primarily interacts with β-sheet structure, this method is less suitable 
to study the amorphous oligomers lacking well-defined β-strand structure. ThT does not give 
site-specific information on the oligomerization. Furthermore, because ThT bears structural 
similarities to many amyloid inhibitors, it is possible that ThT can influence the fibril structure 
and the formation kinetics.18  
The recent development of TMR, as an alternative fluorescence dye, affords a more informative 
sigmoidal curve. In this experimental design, Aβ was pre-modified to carry an extra lysine 
residue that was covalently linked to the TMR molecule at the N-terminus of Aβ.17 Unlike in the 
ThT assay, fluorescence quenching due to the proximity of the TMR molecules was detected as 
Aβ associates. This assay characterized the early-stage oligomer formation by showing an initial 
exponential drop in TMR fluorescence intensity before the emergence of the first lag phase.  
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This, like all the fluorescence methods, however, suffers from the need to modify the Aβ, a 
polypeptide whose aggregation is highly sensitive to its length and size (consider the difference 
between Aβ1-42 and Aβ1-40).  
We found similar results with pulsed HDX as with TMR. In the pulsed HDX method, the 
hydrogen on Aβ backbone amide is in exchange with the deuterium in the solvent, and the level 
of deuterium-uptake within a certain short time window reflects changes in the conformation of 
the polypeptide backbone.19  This approach, although yielding regional information, is not highly 
sensitive. 
More recently, using high resolution AFM, Buratto, Bowers, and co-workers15 found that Aβ1-42 
hexamer- and dodecamer-sized structure become dominant in as short as 5 min, and the density 
of large spherical aggregates termed preprotofibrils grows considerably by 20 min. This result 
brings new insight, but it may be confounded by surface effects because a subset of protein 
aggregates may be preferentially deposited on the surface for AFM and the interactions between 
the protein and the sample surface can affect aggregate morphology and formation kinetics.43-44 
Therefore, comparisons of solution measurements by fluorescence and MS footprinting with 
measurements from using sample deposition will require careful interpretation. The former 
approaches map co-populated species in a mixture, and report Aβ1-42 conformation quantitatively 
as an assemble average of structural protection in bulk solution without pointing to individual 
oligomers; the latter provides a visualization of the oligomer morphology at certain oligomeric 
orders (e.g. hexamer and dodecamer). Note, as we discussed above, the initial burst phase of the 
early oligomerization is represented by an exponential decrease in fluorescence intensity in the 
TMR assay and a rapid increase in the structural protection in pulsed HDX experiment. This 
phase occurs over a time scale of 30-60 min, with our outcome from the FPOP experiment 
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falling in the same range. Considering the vast complexity and high sensitivity of Aβ1-42 
oligomerization towards external conditions, experimental phenomena observed in various 
approaches are not necessarily proportionate in terms of the time scale, and it is sensible for us to 
the set our sights on the general trends.  
More importantly, caution is needed to correlate the “phases” observed using various available 
tools. The molecular-level mechanisms of the probes used in each method discussed above, 
including FPOP, differ significantly. The aggregation of Aβ, especially of Aβ1-42 under study, is a 
process highly sensitive to buffer conditions, concentration, temperature, pH, agitation etc. 
Therefore, the observed phases uncovered by these methods can be different. For example, using 
an equivalent Aβ1-42 system, the growth phase indicated by ThT fluorescence comes later than 
that observed in the TMR assay.17 In addition, we do not expect the fluorescence and HDX data 
to fit into Scheme 2.1 because we invoked the double-catalytic reactions to address the five 
distinct stages revealed uniquely by FPOP. In the FPOP approach, the footprinting reagent, here 
a hydroxyl radical, is comparably sized to water molecules and directly modifies the solvent-
accessible amino-acid side chains of Aβ1-42. The probe is sensitive to subtle conformational 
changes involving the transient states, especially those in which Aβ1-42 side chains are involved 
(e.g., several protofibrillar filaments twist to form bundles of mature fibrils, in which case the 
polypeptide backbone stays relatively unchanged.10-11).  
 
2.5   Conclusions 
FPOP footprinting provides new, in-depth insights into Aβ1-42 conformational changes and its 
aggregation by affording structural resolution even down to the amino-acid residue level. It not 
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only defines the early oligomerization stages but also reports subtle conformational changes that 
occur after early beta-strand formation, allowing the intermediate transitions to be effectively 
resolved to reveal the multi-step nature of oligomerization.  We chose to model the aggregation 
curve by two autocatalytic reactions based on a modified Finke-Watzky mechanism, being 
attracted by the simplicity of this model.  The successful fit of the observed aggregation kinetics 
to two-sigmoid model provides more insight on the molecular mechanisms involved in Aβ1-42 
self-assembly.  
The FPOP approach overcomes most of the weaknesses of other methodologies used to study the 
time-dependent amyloid formation by affording a direct, real-time, fast, and accurate 
measurement of the solvent accessibility of Aβ. Moreover, applications of the platform can be 
extended to address the effects of pH, concentration, agitation, and Aβ modification on 
aggregation. We expect this measurement strategy to be utilized further to guide the design of 
optimal compounds that inhibit Aβ aggregation and/or toxicity, and to be extended to the 
evaluation of other amyloidogenic proteins.     
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Chapter 3: Fast Photochemical Oxidation of 
Proteins Characterizes the Interaction of a 
Small Molecule Inhibitor on Amyloid Beta 1-
42 Aggregation  
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3.1  Abstract 
Significant evidence has linked aggregation of amyloid beta (Aβ) to the pathogenesis of 
Alzheimer's disease, motivating the development for small molecules that prevent aggregation. 
Study of anti-amyloid compounds suggest that many small molecules may re-direct the 
aggregation cascade rather than completely inhibiting it. Here, we describe an application of Fast 
Photochemical Oxidation of Proteins (FPOP) to evaluate the effect of a polyphenolic compound 
derived from curcumin in remodeling the aggregation pathway of Aβ1-42. We find that the small 
molecule inhibits aggregation by maintaining Aβ1-42 in LMW oligomers, resulting in an extended 
lag phase prior to the rapid formation of fibrils. The compound presumably interacts with the N-
terminus of Aβ1-42, “caps” oligomers, and slows down stacking of oligomers, as evidenced by the 
reduced solvent accessibility of the N-terminal region in the remodeled Aβ1-42. The compound 
also destabilizes the middle region, which has been hypothesized to serve as the nucleation 
interface, whereas the C-terminal region is minimally affected. FPOP effectively reveals the 
effect of the compound on aggregation by accurately reporting the solvent accessibility changes 
of Aβ1-42  with peptide and even some amino-acid readouts, providing insights into the pathway 
of Aβ1-42 aggregation and the mechanism of inhibition of anti-amyloids. Our approach 
overcomes major limitations of the widely-used Thioflavin T fluorescence assay for monitoring 
amyloid formation, including low spatial resolution and biased readout due to presence of 
exogenous inhibitors with intrinsic fluorescence (e.g., polyphenols).  
 
 
 
69 
 
3.2  Introduction 
Accumulation and aggregation of Aβ peptides in the brain are critical pathogenic events in 
Alzheimer's disease. The exact pathway of Aβ aggregation, however, is not fully understood. A 
general view of Aβ aggregation involves formation of dimers and soluble oligomers followed by 
growth into protofibrils and fibrils via a complex multistep-nucleated polymerization.1-3 From 
previous studies in the aggregation mechanism of Aβ  as well as from the insights described in 
Chapter 2, this process involves the following features: (i) nucleation dominated by a fast, short 
initial phase to form soluble, low-molecular-weight (LMW) oligomers, (ii) assembly of the 
LMW oligomers into larger oligomeric states with defined beta-sheet structure, (iii) association 
and elongation of the β-sheet-rich oligomers into higher-order protofibrillar aggregates, and (iv) 
reorganization of the higher-order intermediate aggregates to form mature fibrils.  
Initially, fibrils were considered to be the molecular culprit in AD. The accumulation of amyloid 
plaque, however, does not correlate well with AD pathogenesis.4 More recent evidence has 
supported that the soluble Aβ oligomers or prefibrillar aggregates are the causes of synaptic loss 
and cognitive impairment.5-6 Although precise relationships between the oligomeric states of Aβ 
aggregates and the disease remain to be established, the connection between Aβ aggregation, 
cellular dysfunction, and AD suggests that anti-AD drugs targeting soluble Aβ oligomers could 
hold considerable promise and ultimately lead to therapeutics that prevent and/or treat AD.   
Over the past decade, significant research effort was made toward discovering and developing of 
compounds that inhibit aggregation of amyloid proteins. These compounds, known as anti-
amyloids, show efficacy in preventing amyloid formation, disaggregating pre-formed fibrils and 
reducing amyloid-induced cytotoxicity.7-8 Natural polyphenols, a class of compounds abundant 
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in wine, tea and spices have captured considerable attention owing to their effective suppression 
of amyloid formation.9 Inhibitory effects of several natural polyphenols, such as (-)-
epigallocatechin-3-gallate (EGCG), resveratrol, and curcumin (Figure 3.1) have been extensively 
studied.10-13 Polyphenol inhibitors exhibit different interaction patterns and inhibition 
mechanisms, but presumably remodel aggregation by interacting with the β-sheet, maintaining 
the protein in a non-aggregated, soluble form or yielding nontoxic, off-pathway oligomers or 
high-molecular-weight (HMW) aggregates.  
The heterogeneity of Aβ aggregates, however, represent important challenges in structural and 
functional characterization. In vitro aggregation assays require tools for detecting Aβ 
oligomers/fibrils and monitoring the dynamic process in real time. In Chapter 2, we described the 
development of the FPOP platform to monitor Aβ1-42 self-association by probing the solvent 
accessibility change of the peptide. In this chapter, we describe an extension of the platform by 
evaluating the effect of a curcumin derivative on Aβ1-42 aggregation. Curcumin (diferulomethane) 
(Figure 3.1), found in the spice turmeric, is a potent antioxidant possessing anti-inflammatory 
activities. It has been shown that curcumin directly binds to small Aβ species, prevents 
oligomerization, and protects against Aβ-induced neurotoxicity.13-14  
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Figure 3.1 Structure of curcumin, EGCG, resveratrol, compound 1, and compound 2.  
 
Curcumin, however, does not have good therapeutic perspective owing to its poor metabolic 
stability and limited blood–brain barrier penetration.15 Here, we studied two novel curcumin 
derivatives, (4aR,9R,9aR)-7-hydroxy-9-(4-hydroxy-3-methoxyphenyl)-8-methoxy-4,4a,9,9a-
tetrahydro-1H-fluorene-1,3(2H)-dione (compound1) and (4aR,9R,9aR)-7-hydroxy-9-(4-hydroxy-
3-methoxyphenyl)-6-methoxy-4,4a,9,9a-tetrahydro-1H-fluorene-1,3(2H)-dione (compound 2) 
(Figure 3.1), on Aβ1-42  aggregation. Compound 1 and compound 2 are structural isomers 
obtained from acid-catalyzed cyclization of curcumin. Our collaborator, Dr. George Mathai, 
hypothesized that treating curcumin in acid would mimic the condition when curcumin is 
ingested into the stomach. In our study, we first performed Thioflavin T (ThT) fluorescence 
1 2
curcumin EGCG
resveratrol
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assays to identify preliminarily in vitro the most potent inhibitors among curcumin and its two 
derivatives. We then applied MS-based FPOP to investigate the effect of compound 1, the most 
potent inhibitor among the three, on Aβ1-42 aggregation and reveal changes in the behavior of 
Aβ1-42 sub-regions in the presence of compound 1. This study, together with that detailed in 
Chapter 2, demonstrates the capability of the FPOP platform as a sensitive tool to monitor 
amyloid formation and to evaluate crucial factors affecting the aggregation.   
 
3.3  Materials and Methods 
3.3.1  Materials 
Synthetic human amyloid beta 1-42 (Aβ1-42) was from AnaSpec (San Jose, CA). Curcumin, 
compound 1 and compound 2 were synthesized by our collaborator, Dr. George Mathai. 
Hexafluoroisopropanol (HFIP), sodium hydroxide (NaOH), ThT, L-glutamine, L-methionine, 
catalase, hydrogen peroxide (H2O2), phosphate buffer saline (PBS, 10 mM phosphate, 138 mM 
NaCl, 2.7 mM KCl), urea, formic acid and trifluoroacetic acid were from Sigma Aldrich (St. 
Louis, MO). Lys-N protease was from Thermo Scientific (Waltham, MA). 
3.3.2  ThT fluorescence assay 
To investigate the effect of the test compounds on Aβ1-42 fibrilization, 5 μL HFIP-pretreated Aβ1-
42  dissolved 3 mM NaOH was sequentially mixed with 1 μL containing the test compounds in 
PBS (or 1 μL PBS only for the control) and 1 μL ThT (1.5 mM in water), followed by a 1:20 
dilution with PBS buffer to initiate aggregation. The final concentration of Aβ1-42 and ThT after 
dilution were 20 μM and 15 μM, respectively. For each compound, two molar ratios, including 
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1:1 and 1:5 of Aβ1-42 to the small molecule were examined. ThT fluorescence was measured in 
duplicate using a SpectraMax M2e plate reader (Molecular Devices, San Jose, CA). Excitation 
and emission wavelengths were 440 and 485 nm, respectively.    
3.3.3  Sample preparation for FPOP 
HFIP-pretreated Aβ1-42 was dissolved in 3 mM NaOH and incubated without stirring at room 
temperature for 3 min followed by sonication for 1 min. Aggregation was initiated upon diluting 
Aβ1-42 by 10 fold (v/v) with compound 1 in PBS (pH 7.4). The final concentrations of Aβ1-42  and 
compound 1 after dilution were 20 M and 100 M, respectively. The solution mixture was then 
incubated at 25 °C without stirring. For each time point, the incubation and analysis were done in 
duplicate.   
3.3.4  FPOP 
At the various incubation times, Aβ1-42  was immediately submitted to FPOP labeling. FPOP was 
performed as previously described,16 except no scavenger was added. This is because compound 
1 is a hydroxyl radical-reactive polyphone and serves as the radical scavenger in FPOP. Briefly, 
a  laser beam from a KrF excimer laser (GAM Laser Inc., Orlando, FL, USA) of wavelength 248 
nM was used to initiate H2O2 photolysis to give hydroxyl radicals. The Aβ1-42 in PBS was mixed 
with 20 mM H2O2 just prior to injection into the flow tube for irradiation with the laser. The flow 
rate was adjusted according to the width of the laser irradiation window to ensure 20% 
irradiation-excluded volume and to minimize repeated laser exposure. The oxidatively modified 
sample was collected in a tube containing 10 mM catalase and 20 mM methionine to decompose 
leftover H2O2 and prevent oxidation-artifacts during storage. Control samples of Aβ1-42 in the 
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presence of compound 1 were handled in the same manner as the experimental ones, but not 
laser-irradiated.  
3.3.5  LC-MS/MS 
Digestion of the FPOP-modified Aβ1-42 and the subsequent LC-MS/MS analysis were adopted 
from the previous established protocols described in 2.3.4 and 2.3.5 in Chapter 2. 
3.3.6  Data analysis 
Quantification of the FPOP modification was adopted from the previous established protocol 
described in 2.3.6 in Chapter 2. 
 
3.4  Results and Discussion 
3.4.1  Potency of compounds active for inhibition of Aβ1-42 aggregation 
ThT is a benzothiazole dye that undergoes enhanced fluorescence upon binding to amyloid 
fibrils. It is the most commonly used probe for monitoring fibrillization kinetics in vitro. Using 
fluorescence spectroscopy with ThT, we performed a global examination of the effects of 
curcumin, compound1 and compound 2 on the aggregation of 5 μM Aβ1-42 incubated at 25 °C, 
pH 7.4 (Figure 3.2). In our measurement, the fluorescence intensity at long times decreases 
owing to precipitation of mature fibrils. Despite this, all the ThT fluorescence curves of Aβ1-42 
incubated under our conditions follow a characteristic sigmoidal curve representing a lag phase 
and a growth phase in aggregation, consistent with the nucleation-dependent polymerization. In 
the presence of curcumin or compound 1, the ThT fluorescence at the final equilibrium level are 
lower than that in the ligand-free sample (Figure 3.2A and B), presumably due to the effective 
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inner quenching of the ThT fluorescence by curcumin and compound 1 upon binding and 
stacking in fibrils. This is, however, not observed in samples incubated with compound 2 (Figure 
3.2C).  
 
Figure 3.2. ThT fluorescence analysis of Aβ1-42 (5 μM) at 25 °C, pH 7.4. Aβ1-42 was incubated 
in the absence and presence of 5 μM or 25 μM (A) curcumin, (B) compound 1, and (C) 
compound 2.  Data points are the mean of two independent measurements. 
 
Despite the reduced fluorescence intensity at equilibrium owing to binding, curcumin did not 
significantly affect the length of the lag phase prior to fibrilization. This observation is consistent 
with the previous ThT study on the effect of curcumin on remodeling Aβ aggregation13. For the 
inhibitory effect of curcumin, controversies arise as some results shows curcumin inhibits both 
oligomers and fibrils formation14, whereas others found that curcumin inhibits oligmerization but 
not fibrilization20. These variable results are likely to result from the different conditions (e.g., 
concentration of Aβ, agitation) used in the experiments.    
In contrast, Aβ1-42 incubated with a 25 μM solution of compound 1 at high stoichiometry (1:5 
molar ratio of Aβ1-42 to compound 1) displays a prominently extended lag phase compared to 
those in the ligand-free sample and the sample incubated with 5 μM compound 1 (1:1 molar 
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ratio) (Figure 3.2B). This suggests that compound 1 is effective in stabilizing soluble oligomers 
in a dose-dependent manner, resulting in a longer lag phase to achieve fibrilization, but 
eventually allowing conversion of Aβ1-42 into fibrils. In addition, Aβ1-42 incubated with 5 μM or 
25 μM of compound 2 also undergoes a delay in fibrilization (Figure 3.2 C), but a high 
concentration of compound 2 at 25 μM does not result in an extension of the lag phase that is as 
pronounced as that for compound 1 does at the same concentration.  
ThT fluorescence, however, is not highly suitable for mechanistic studies primarily owing to its 
inability to report on early steps of oligomerization that occur prior to fibril formation.17 In 
addition, problems arise when relying on ThT fluorescence to assess the anti-amyloid activity of 
the polyphenol compounds. Polyphenols can be chromophoric or even intrinsically fluorescent 
because they have strong π-π* electronic transitions via conjugation of the phenolic aromatic 
rings upon binding to amyloids.18 Actually, the spectroscopic properties of curcumin 
significantly interferes with the fibril-associated ThT fluorescence by absorbing both the 
excitation an emission lights of ThT.19 We thus turned to FPOP for an accurate characterization 
of the inhibitory effect, taking advantage of the ability of FPOP to follow Aβ in-vitro without 
requiring binding of a fluorophore. The method provides a sensitive, clear readout on the 
changes in Aβ solvent accessibility in the presence or absence of a ligand or inhibitor. 
3.4.2  Characterization of the effect of compound 1 on Aβ1-42 aggregation by 
FPOP 
Preliminary results from ThT fluorescence indicate an apparent delay in Aβ1-42 fibrillation in the 
presence of compound 1 at 1:5 molar ratio of Aβ42: compound 1. We, thus, chose to characterize 
the effect of compound 1 at this ratio by FPOP. To allow formation of aggregates, 20 µM Aβ1-42 
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was incubated with 100 µM compound 1 for various times. Upon completion of the incubation, 
Aβ1-42 was immediately mixed with H2O2 and submitted to FPOP. The modified Aβ1-42 was then 
digested using Lys-N, the aggregation was followed using the measured modification levels of 
the three peptide fragments as determined by LC-MS/MS (Figure 3.3 A-C).  
The aggregation 20 μM Aβ1-42 in the presence of compound 1 (Figure 3.3 A-C) shows 
significantly different characteristics than in the absence of compound 1 (data taken from our 
previous FPOP study for a concentration of 10 µM, Figure 3.3 D-F, adapted from Chapter 2). 
There are two variables, a higher starting concentration of Aβ1-42 at 20 μM, which should 
accelerate the aggregation and shorten the time required for fibrillation. For ease of comparison, 
we “normalized” the plots to have the same width although the time scales are different in Figure 
3.3.  
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Figure 3.3. Changes in the FPOP modification of Aβ1-42 sub-regions as a function of 
incubation time. Aggregation at 25 °C in the presence (A-C) and absence (D-F) of compound 1 
in PBS solution (pH 7.4) without stirring. Three peptide fragments, 1-15, 16-27 and 28-42, 
obtained from Lys-N digestion of the full-length Aβ1-42 are colored in red, blue, and green on the 
Aβ1-42 sequence, respectively. (A-C) Aβ1-42 incubated in the presence of compound 1, with initial 
concentrations of Aβ1-42 and compound 1 at 20 µM (equivalent to monomeric Aβ1-42) and 100 
µM, respectively. (D-F) Aβ1-42 incubated in the absence of compound 1 (adapted from Figure 2.5 
in Chapter 2), with an initial concentration of Aβ1-42 at 10 µM (equivalent to monomeric Aβ1-42).   
 
There are modest variations in the parameters of FPOP (e.g., laser energy, focusing lens) and 
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radicals in each sample. This would provide a mean to normalize the extents of modification 
between different samples. The method requires spiking in a fixed amount of a short peptide 
(e.g., Leu-enkephalin) into each protein sample prior to the laser irradiation (for an example of 
using a reporter peptide to assist FPOP quantification, referred to 5.4.2 in Chapter 5). Adding a 
reporter peptide into the sample may influence Aβ self-association. Additionally, the reporter 
peptide exhibits poor reproducibility in terms of its signal intensities in LC-MS and the 
modification levels, presumably because the reporter peptide interacts and possibly co-
aggregates with Aβ1-42 and its oligomers. The outcome indicates incorporation of a reporter is not 
feasible in study of an extremely hydrophobic peptide like Aβ1-42.    
Despite the small variations in FPOP parameters, we conclude that the modification levels of the 
C-terminal fragment (peptide 28-42) are nearly the same in the presence and absence of 
compound 1 (Figure 3.3 C and F). Specifically, the C-terminal region of the compound 1-
remodeled Aβ1-42 shows nearly the same extent of change in solvent accessibility as in the ligand-
free sample during the monomer-to-fibril transition (both showing an absolute decrease of ~ 35% 
in modification extent from monomers to fibrils) (Figure 3.3 C and F). Those results indicate that 
the C-terminal region of Aβ1-42 is unaffected or only affected to a modest extent by compound 1.   
In contrast, the modification extent of the N-terminal region (peptide 1-15) is considerably 
reduced in the presence of compound 1. This dramatic decrease is likely due to 1) compound 1 
binding to the N-terminal region, leading to protection from free-radical reactions, 2) compound 
1 interaction of Aβ1-42 at sites other than the N terminus, causing remote conformational changes 
that reduced its flexibility or solvent accessibility, leading to protection, or 3) a combination of 
these effects. Although the aggregation curves are remarkably displaced, their shapes as Aβ1-42 
transitions from monomers to fibrils are nearly identical in the presence and absence of 
80 
 
compound 1 (in both showing an absolute decrease of ~ 20% in modification). This phenomenon 
is more likely if compound directly binds to the N-terminal region of the monomer. This 
proposed mode of action is similar to that of its precursor curcumin as revealed by atomic force 
microscopy21.  
On the other hand, the middle domain (peptide 16-27) exhibits an opposite trend as the N-
terminus. It shows a significant increase in FPOP modification in the compound 1-remodeled 
Aβ1-42, indicating that binding of compound 1 results in increasing solvent exposure, flexibility 
and possibly decreasing oligomerization involving this central region.  
Moreover, the FPOP aggregation curves indicate that the lag phase for nucleation of LMW 
oligomers is prominently extended in the presence of compound 1, which is observed for all 
three regions (Figure 3.3). After an initial decrease in modification during the first 60 min of 
incubation, the modification extent, a measure of the solvent accessibility of Aβ1-42, becomes 
nearly constant, displacing a long plateau (60 ~ 1100 min) stage. Finally, a sharp decrease in 
modification takes place at long times, indicating a rapid transition of LMW oligomers to fibrils 
(Figure 3.3). During this process, there is little evidence for a clear phase of formation of HMW 
protofibrillar aggregates prior to fibrillation. Thus, we propose that compound 1 remodels Aβ1-42 
aggregation by stabilizing LMW oligomeric conformers.  
We note that these results do not inform us on the exact conformation or biochemical properties 
of the compound-1-remodeled oligomers, or if those aggregates are on- or off-pathway. This 
means those oligomers could be similar to or different from the small oligomers formed in the 
absence of compound 1. In addition, FPOP indicates that under our condition and in the presence 
of compound 1, Aβ1-42 eventually matures structurally as fibrils. This is consistent with the 
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outcome from the ThT fluorescence (Figure 3.2 B), and the relatively rapid oligomerization is 
due to the high concentration of Aβ1-42 used in those in-vitro assays. 
 
3.5  Conclusions 
Compound 1 is capable to remodel Aβ1-42 aggregation by maintaining Aβ1-42 in LMW oligomers, 
presumably via interacting with the N-terminal region. Binding of compound 1 also results in 
deprotection and destabilization of the central domain, which was previously proposed to play an 
important role in Aβ1-42 self-association by serving as a folding nucleus or interface for 
oligomerization.22-23 The C-terminal region is minimally influenced by compound 1.  
In terms of methodology development, we have extended the FPOP platform for monitoring 
amyloid formation (Chapter 2) to evaluate the effect of a polyphenolic inhibitor on Aβ1-42 
aggregation and reveal changes in the behavior of Aβ1-42 sub-regions modulated by the inhibitor. 
This study demonstrates that FPOP is an effective and sensitive tool for probing the effect of 
potential therapeutic agents on Aβ aggregation in vitro. In addition, FPOP can be combined with 
other biophysical tools (e.g., atomic force microscopy, fluorescence spectroscopy) and 
biochemical assays (e.g., SDS-PAGE, immunoblotting) to obtain a comprehensive understanding 
of the properties of Aβ species and the mechanism of amyloid inhibition. For example, a 
previous study indicates that small, aromatic compounds lead to remodeling of Aβ soluble toxic 
oligomers into alternative conformers with reduced toxicity.24 For our work, neurotoxicity of the 
intermediate LMW oligomers remodeled and stabilized by compound 1 can be further assessed 
by using the cytotoxicity assay. Last but not the least, we speculate that our FPOP approach 
would be applicable for studies of many amyloid inhibitors, not only small molecules, but also 
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peptides and antibodies against Aβ, providing valuable insights for the rational design of anti-
amyloids therapeutics. 
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Based Footprinting for Epitope Mapping and 
Structural Characterization: The IL-6 
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C.; Deyanova, E. G.; Beno, B. R.; O’Neil, S. R.; Tymiak, A. A.; Gross, M. L., Orthogonal Mass 
Spectrometry-Based Footprinting for Epitope Mapping and Structural Characterization: The IL-6 
Receptor upon Binding of Protein Therapeutics. Anal. Chem. 2017, 89 (14), 7742-7749.  
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4.1   Abstract  
Higher order structure (HOS) is a crucial determinant for the biological functions and quality 
attributes of protein therapeutics. Mass spectrometry (MS)-based protein footprinting approaches 
play an important role in elucidating the relationship between protein biophysical properties and 
structure. Here, we describe the use of a combined method including hydrogen-deuterium 
exchange (HDX), fast photochemical oxidation of proteins (FPOP) and site-specific carboxyl 
group footprinting to investigate the HOS of protein and protein complexes. The work focuses 
on implementing complementary solution-phase footprinting approaches that differ in time scale, 
specificity for protein residue side chains vs. backbone as well as selectivity for different residue 
types to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins 
with distinct affinities (Kd, Adnectin1 ~ 6.2 pM vs. Kd, Adenctin2 ~ 46 nM), and evaluate the resultant 
conformation/dynamic change of IL-6R. The suggested epitope, which is conserved for 
adenctin1 and adenctin2 binding, is a flexible loop that connects two β-strands in the cytokine-
binding domain (DII) of IL-6R. We also found that adnectin1, the more strongly binding ligand, 
induces structural perturbations on two unstructured loops that are distally located beyond the 
epitope. Those changes are either attenuated or not detected for the case of adnectin2 binding. In 
addition to providing credibility in epitope determination, utilization of those combined 
approaches reveals the structural effects that can differentiate protein therapeutics with similar 
apparent biophysical properties. 
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4.2   Introduction 
In Chapter 2-3, we focus on the development and application of hydroxyl radical footprinting, 
specifically FPOP to follow protein aggregation. In this chapter, and the following chapter 5, we 
implement FPOP with another two commonly used footprinting approaches, HDX and carboxyl 
group footprinting, to gain complementary insights into protein-ligand interaction and protein 
higher order structures.  
Protein higher order structures describes the three-dimensional arrangement of a protein structure 
required for biological function. Monitoring protein higher order structures is critical for 
understanding the impact of molecular conformation on biotechnological applications in the 
protein-discovery pipeline.1-2 Furthermore, maintaining protein higher order structures presents 
one of the key challenges for achieving robust and stable formulations of therapeutic proteins.3 
For the design of monoclonal antibodies (mAbs) and other therapeutic protein products, protein 
higher order structures is essential because binding of the therapeutic to the target is based on the 
specific recognition of the epitope on the protein. This is not only related to the primary 
sequence but also to conformation and post-translational modifications.4  
Although atomic-level mapping of a protein or a protein complex can be achieved by high-
resolution X-ray crystallography, the resulting static structure may have limited biological 
relevance and not reveal solution phase dynamics or long-range protein-protein interactions.5-6 
The complexity and low-throughput of X-ray crystallography restrict its application in the initial 
research stages where many potential therapeutic protein candidates may be of interest. 
Spectroscopy-based approaches including circular dichroism (CD),7 infrared (FTIR)8 and 
fluorescence spectroscopy9 provide quick, global measurements of protein conformation, but the 
profile obtained from those methods often contains no local or regional structural information. In 
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contrast, protein footprinting, an evolving bioanalytical tool in structural biology, can reveal 
coarse-grained structural information relevant to proteins and their complexes. High sensitivity 
and fast data acquisition recommend MS-based footprinting for characterization of protein 
structure and macromolecular interactions at regional and even residue-specific levels of 
detail.10-12  
Here, we describe a combination of MS-based protein footprinting methods, including hydrogen-
deuterium exchange (HDX), fast photochemical oxidation of proteins (FPOP) and carboxyl 
group footprinting for mapping the extracellular region of human interleukin-6 receptor α-chain 
(referred as IL-6R hereafter) interacting with adnectins. Interleukin-6 (IL-6) plays critical roles 
in the pathogenesis of multiple myeloma, autoimmune diseases, and prostate cancer, appearing 
in abundant IL-6/IL-6R complexes.13 Inhibition of the IL-6/IL-6R complex is a primary goal to 
antagonize the action of IL-6 in vivo.14 The interacting partners of IL-6R selected for this study, 
adnectins, belong to a class of therapeutic proteins designed based upon the 10th human 
fibronectin type III domain.15 The two adnectins (adnectin1 and adnectin2) bind to IL-6R with 
picomolar and nanomolar affinity, respectively. X-ray structures of the IL-6R/adnectin 
complexes are not available, however, further motivating protein footprinting.  
Among the methods to footprint IL-6R in this work, HDX is already well-established for protein 
HOS characterization.16-17 HDX occurs via formation of covalent bonds in a reversible manner.18 
Its sensitivity to structural change is high provided there is little back exchange due to the labile 
nature of the N-D bond. HDX may be insensitive to subtle differences in conformation or 
dynamics when the exchange at the local region is low or rapid with respect to the HDX 
timescale.19  
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As an alternative to HDX, footprinting by incorporating irreversible modifications is emerging 
because it provides site-specific information by targeting amino acid side chains. Unlike HDX, 
irreversible labeling can survive extensive sample treatment and digestion. Footprinting by the 
hydroxyl radical, a common approach, involves irreversible oxidation of surface-accessible 
amino acid side chains as the primary product formation pathway. The radical probe has high 
reactivity with many residues, particularly those with sulfur-containing, aromatic, and aliphatic 
side chains.20 FPOP, the method used to generate hydroxyl radicals in this work, utilizes pulses 
of 248 nm KrF laser radiation to induce photolysis of hydrogen peroxide.21 As discussed in 
Chapter 1, the lifetime of labeling with primary hydroxyl radicals can be controlled within 
microseconds by introducing a radical scavenger.22 To date, FPOP has been implemented for 
protein higher order structures characterization of several therapeutic targets23-26 (referred to 
1.4.3 in Chapter 1 for more details), showing its suitability for proteins of interest in drug 
discovery.  
As a complement to free-radical footprinting, a variety of chemical reagents that target amino 
acid residues in a site-specific manner (e.g., N-ethylmaleimide27 and diethylpyrocarbonate28-29) 
can also provide information on site-specific solvent accessibility but react with protein 
substrates more slowly than do  free radicals.30 In this work, we performed carboxyl group 
footprinting with glycine ethyl ester (GEE) to corroborate the findings from HDX and FPOP, 
taking advantage of the presence of the many Asp/Glu residues in the flexible loops of IL-6R. 
The chemical modification occurs for solvent-accessible Asp/Glu side chains (and the C-
terminus) as a result of activation by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
through formation of an O-acylisourea intermediate, which is subsequently displaced by the 
amine group of a GEE molecule via nucleophilic attack.31 The labeling product, which is stable 
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and remains intact in post-sample handling and digestion processes, can be quantified to 
determine the solvent accessibility at various carboxylic acid sites.32-33  
In practice, application of protein footprinting to structural characterization projects including 
epitope mapping requires careful consideration of time and resource allocation because, at this 
stage, experiments still require considerable instrument and interpretation time. Questions arise 
whether time is better spent doing many replicates or time points with one approach or instead 
employing other complementary approaches each in a less rigorous manner.  Although an 
exhaustive evaluation by one approach will often provide an answer, we have chosen an 
integrative course, and the results presented here demonstrate the value of applying that approach 
for epitope mapping and HOS characterization.  
 
4.3   Materials and Methods 
Recombinant human IL-6R alpha extracellular region (residue 20-358, referred as IL-6R below) 
was purchased from R&D systems (Minneapolis, MN). Adnectin1 (Kd ~ 6.2 pM) and adnectin2 
(Kd ~ 46 nM) were expressed and purified at BMS as previously described.
34 All surface 
plasmon resonance (SPR) experiments for binding affinity measurement were performed using a 
Biacore T100 instrument (GE Healthcare) (details of SPR can be found in SI Materials and 
Methods). To form the IL-6R/adnectin complex, bound state IL-6R was prepared by mixing 50 
μM IL-6R with adnectin1 or adnectin2 at a 1:1 molar ratio and incubated at room temperature for 
1 h.   
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4.3.1   H/D exchange 
HDX was performed by following a standardized protocol (see SI Materials and Methods). 
Briefly, a mapping experiment of IL-6R peptic peptides was performed under non-denaturing 
condition, and the common peptides identified were further monitored for their deuterium uptake 
levels with a Synapt G2 High Definition mass spectrometer (Waters). HDX was initiated by 
mixing the labeling buffer (10 mM phosphate buffer in D2O, pD 6.99) with the protein solution. 
The labeling reaction was allowed for different periods of times: 20 s, 1 min and 10 min.  
4.3.2   FPOP 
Prior to injection into the FPOP tubing, the protein sample in PBS was mixed with 20 mM H2O2 
and 500 μM histidine. The final concentration of IL-6R for FPOP labeling was 10 μM. No 
dosimeter or reporter peptide was used (see SI for explanation). To avoid repeated laser 
exposure, the flow rate was adjusted to give ~20% irradiation-excluded volume. The laser beam 
was from a KrF excimer laser (GAM Laser Inc.), providing an excitation wavelength of 248 nM 
to initiate H2O2 photolysis into hydroxyl radicals. After laser irradiation, the sample solution was 
collected in a tube containing 10 mM catalase and 20 mM Met to remove leftover H2O2 and 
prevent post-labeling oxidation artifacts. Control samples of IL-6R with all the reagents added 
(including H2O2) were handled in the same manner, but not laser-irradiated. Samples of each 
state were subjected to FPOP in triplicate. 
4.3.3   Carboxyl Group Footprinting 
For carboxyl group labeling, glycine ethyl ester (GEE), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) stock solutions were prepared freshly in PBS buffer. GEE was added to 
each pre-equilibrated sample to a concentration of 200 mM, followed by adding EDC to a 
concentration of 50 mM. The final concentration of IL-6R was 10 μM. In this reaction regime, 
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the by-products of the reaction (e.g., Lys-Asp/Glu cross-links) were essentially eliminated 
because the excessive amount of GEE dominates the cross-linking reactions.35-36 Time-
dependent labeling was carried out at room temperature and quenched at 1 min, 3 min and 10 
min by adding an equal volume of 1 M ammonium acetate. Samples were further desalted using 
a Zeba column (Thermo Scientific, Rockford, IL).  
4.3.4   Mass Spectrometry 
FPOP or GEE-labeled protein was deglycosylated using PNGas F (New England Biolabs, 
Ipswich, MA) and digested using Trypsin/Lys-C or chymotrypsin (Promega, Madison, WI). In 
LC-MS/MS analysis, peptide fragments were separated on a custom-packed C18 column (CSH, 
75 µm × 15 cm, 3.5 μm, 130 Å) using a Nano UltiMate 3000 Rapid Separation system (Dionex 
Co.) and analyzed with a Q Exactive Plus Orbitrap mass spectrometer (Thermo Scientific). The 
relative FPOP or GEE modification fraction was calculated by dividing the intensity of modified 
peptide/residue (Iox) by the summed intensity of modified and unmodified peptides (Iu) (i.e., 
fraction of modified = Iox/(Iox + Iu)). A detailed description of MS methodology and data analysis 
of FPOP and GEE footprinting is given in SI Materials and Methods.  
 
4.4   Results and Discussion 
4.4.1   HDX mapping 
HDX is a widely used method for exploring protein conformation and monitoring protein-ligand 
interactions based on mapping the hydrogen bonding of protein backbone amide; a number of 
examples of using HDX MS for epitope mapping were reported.37-40 We first applied HDX to 
probe the structure of IL-6R and its complexes with the adnectins and found modest changes in 
the region 130-141 (Figure 3.1A). Although there is usually a more significant change in 
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protection (reduction in HDX rates) of the amide backbone with epitope binding37-39, the results 
clearly suggest an epitope at this site.  At this point, we considered repeating the HDX study and 
extending it over longer times with improved sequence coverage (78% residues mapped by 
peptic peptides (Figure 3.2)) by using other acid-insensitive proteolysis enzymes.41 We reasoned, 
however, that more time points or higher coverage would not alter our conclusion about the 130-
141 region or address the distinctive affinities of adnectin 1 and adnectin 2.  In fact, HDX kinetic 
curves often show convergence at longer times owing to fast off rates, suggesting that extending 
the time for HDX is not productive.24, 37, 39 Furthermore, all other detected regions follow 
identical HDX kinetics for the apo and holo forms (see Figure 3.1B as an example). We were 
thus motived to seek orthogonal footprinting methods to provide corroborating evidence for the 
epitope determination as well as to uncover conformational effects that may impact the binding 
of the two adnectins.  
 
Figure 4.1. Representative HDX kinetics for IL-6R. (A) Region 130-141 shows reduced rates 
or extents of exchange in the holo (bound) states. (B) Region 111-123 shows no difference 
providing an example of a region that is not involved in or affected by adnectin binding.  
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Figure 4.2. Sequence coverage of IL-6R in HDX.  
4.4.2   FPOP mapping  
FPOP is capable of reporting on protein transient dynamics, including fast folding42 and 
alteration in side-chain flexibility43. We also showed that FPOP reveals fast fluctuations 
occurring remotely upon ligand binding, which is undetectable by slower footprinting methods24. 
Thus, we applied FPOP as a probe with high sensitivity to monitor changes in structure and 
dynamics of IL-6R. To obtain structural resolution spanning the IL-6R sequence, we chose two 
separate proteolysis experiments with Lys-C/trypsin and chymotrypsin. In the LC-MS/MS 
analysis, peptides and their modifications were identified by relying on their accurate (< 5 ppm) 
mass and the product-ion spectra (see Figure 4.3 for an example). In the bottom-up strategy, all 
tryptic peptides, including those with one missed cleavage site, provide > 90% sequence 
coverage of IL-6R. By contrast, chymotryptic cleavage is less specific. We found that 
chymotryptic digestion of IL-6R provides a better overall regional resolution by yielding 
peptides with shorter average length, the signal intensities for some regions are dispersed among 
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a greater number of overlapping chymotryptic fragments. With 80% sequence coverage from 
chymotrypsin digestion, we observed loss in the signal intensities for some chymotryptic 
peptides. This phenomenon is particularly pronounced for modified peptides of low abundance. 
Nevertheless, performing two sets of digestion experiments afforded a combined coverage of 
96% of IL-6R sequence (Figure 4.4), permitting a detailed investigation into the local structure 
of IL-6R. In the data analysis, we only selected representative peptides that were relatively short 
and had desirable signal-to-noise ratios for accurate, label-free quantification (Table 4.1).  
 
253DLQHHCVIHDAWSGLR268
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
Retention time (min)
Unmod.
W264
W264
W264
W264 H256/H257
A
B
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Figure 4.3. Representative LC-MS/MS identification of the peptide and its FPOP 
modification. (A) Extracted ion chromatogram of the unmodified peptide 253-268 (top, m/z = 
486.7378) and its mono-oxidized (+15.9949 Da) form (bottom). Labels on the chromatogram 
indicate signal of site-specific oxidation determined by the product ions. (B) Product-ion spectra 
of the unmodified peptide 253-268 (top) and its modified form with oxidation identified on 
Trp264 (bottom).  
 
FPOP clearly shows differential modification of peptides from regions in IL-6R (Figure 4.5A 
and B). Some regions (e.g., 61-65, 119-126, 232-237) are “FPOP-silent”; that is, we could detect 
no FPOP modification even though we saw signals from the unmodified peptides. We found 
small modification extents for other regions that are either shielded in the inner core of IL-6R 
(PDB: 1N26) and not solvent-accessible, or mainly composed of residues less reactive to 
hydroxyl radicals (e.g. Glu, Ser, Lys and Thr). By contrast, we observed high levels of 
modifications (modified fraction > 50%) for the C-terminus (288-296 and 301-319), because this 
region not only contains highly reactive Met292, Trp296 and Met312 residues but also diversified 
loops and random coils that are inherently flexible and expected to be reactive with short-lived 
radicals.  
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Figure 4.4. Sequence coverage of IL-6R in FPOP. Tryptic peptides are shown in green and 
chymotryptic peptides are shown in blue.  
 
 
 
 
 
 
 
 
 
 
Tryptic
Chymotryptic
Combined coverage 96% 
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Peptide Sequence 
5-13 RCPAQEVAR 
17-26 TSLPGDSVTL 
27-41 TCPGVEPEDNATVHW 
45-54 KPAAGSHPSR 
55-60 WAGMGR 
61-65 RLLLR 
66-79 SVQLHDSGNYSCYR 
80-104 AGRPAGTVHLLVDVPPEEPQLSCFR 
105-118 KSPLSNVVCEWGPR 
119-126 STPSLTTK 
127-132 AVLLVR 
135-148 QNSPAEDFQEPCQY 
133-154 KFQNSPAEDFQEPCQYSQESQK 
156-168 SCQLAVPEGDSSF 
170-183 IVSMCVASSVGSKF 
186-210 TQTFQGCGILQPDPPANITVTAVAR 
214-231 WLSVTWQDPHSWNSSFYR 
232-237 LRFELR 
245-252 TFTTWMVK 
253-268 DLQHHCVIHDAWSGLR 
269-274 HVVQLR 
274-284 RAQEEFGQGEW 
288-296 SPEAMGTPW 
301-319 SPPAENEVSTPMQALTTNK 
320-327 DDDNILFR 
 
Table 4.1. Peptides from IL-6R digest selected for FPOP quantification. 
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Figure 4.5. FPOP modification extents of IL-6R peptide regions and the locations of the 
regions showing altered solvent accessibility. (A) Regions of IL-6R without significant change 
in their extent of FPOP modification. (B) Regions of IL-6R with significantly decreased (**Δrel. 
> 40%, p < 0.005) FPOP modification, indicating reduced solvent accessibility upon 
adnectin1/adnectin2 binding. (C) Regions in (B) mapped onto IL-6R (PDB: 1N26) are colored 
blue. The three domains of IL-6R are referred as DI, DII and DIII on the structure.   
    
Regions 27-41, 274-284 and 135-148 in adnectin1-bound IL-6R, and regions 274-284, 135-148 
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40%, p < 0.005 in Student’s t-test) (Figure 4.5B), suggesting those regions undergo major 
conformational changes introducing reduced solvent accessibility upon adnectin binding (Table 
4.2 summarizes the FPOP modifications of those regions exhibiting statistically significant 
differences in solvent accessibility upon adnectin binding). We also observed minor differences 
in FPOP modification for region 301-319 in the adnectin1-bound state, which is likely attributed 
to minor structural or dynamical perturbation on this region upon adenctin1 binding. The 3D 
structure of IL-6R consists of three domains including the N-terminal Ig-like domain (DI) and 
two cytokine-binding domains (DII and DIII). All the regions for which solvent accessibility is 
significantly altered in FPOP adopt a flexible loop structure (Figure 4.5C). In addition, we found 
the overlapping tryptic and chymotryptic peptides (e.g., tryptic peptide 133-154 and 
chymotryptic peptide 135-148) reveal correlated trends of FPOP modification change (Figure 
4.6). This indicates that the observed difference is due to structural changes of IL-6R in the holo 
states, instead of structure-based proteolytic bias caused by the FPOP modification.    
Ligand 
IL-6R 
peptide 
Sequence 
Relative 
difference 
(%) 
p-value 
Adnectin1 
27-41 TCPGVEPEDNATVHW 67 0.001 
274-284 RAQEEFGQGEW 61 0.004 
135-148 QNSPAEDFQEPCQY 50 < 0.001 
Adnectin2 
135-148 QNSPAEDFQEPCQY 54 0.001 
274-284 RAQEEFGQGEW 42 0.004 
 
Table 4.2. Summary of the regions showing significant changes in conformation and/or 
dynamics identified by FPOP. 
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Figure 4.6. Correlation in FPOP quantification for overlapping peptides. The overlapping 
regions covered by tryptic (red triangle) and chymotryptic (blue diamond) fragments show 
correlated trend in term of the change in the FPOP modification. For example, region represented 
by tryptic fragment 14-44 are covered by two chymotryptic fragment 17-26 and 27-41, whereas 
FPOP quantification on the shorter chymotryptic fragments indicates the decreased solvent 
accessibility upon adnectin binding is attributed to region 27-41, with the solvent accessibility of 
region 17-26 remains unchanged.  
 
A significant advantage of FPOP is that it provides residue-level information (Figure 4.7). His40 
and Trp41 are the residues that are predominantly modified by FPOP in region 27-41 
(TCPGVEPEDNATVHW). The two residues are located at the front end of a β-stand connected 
to the loop. The side chain of His40 is exposed on the protein surface, and the aromatic side chain 
of Trp41 is largely protected inside the protein core. Note that the amino acid residues from the 
sequence that compose the loop (30GVEPEDNAT38) on region 27-41 are much less reactive than 
His and Trp, with the most reactive Val and Pro being ~ 20X and 6X less reactive compared to 
Trp and His, respectively.20 Therefore, the hydroxyl radical preferentially modifies His40 and 
Trp41 rather than the less reactive ones from the loop. The local selectivity is also pronounced for 
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some Met containing regions (e.g., 245-252 and 288-296). Moreover, the product-ion spectrum 
does not definitively indicate what residue is modified on region 274-284, but it does show that 
the FPOP modification occurs on either Pro138, Phe142, Pro145 or Tyr148.  
 
Figure 4.7. FPOP modification level for IL-6R residues. 
 
Although peptide regions in Table 4.2 undergo significantly reduced FPOP modification in the 
holo states, one should be cautious in interpreting the data because the change in FPOP extent 
may result either from the epitope binding, or from decreased dynamics and flexibility induced 
remotely from the adnectin binding site. For the residues with high intrinsic reactivity with the 
hydroxyl radical, a relatively modest change in their solvent accessibility in response to the 
dynamic motion can result in a dramatic difference in their FPOP modification.44-45 Our 
hypothesis is that dynamic motions occurring within the sub-second time range will be 
differentiated by fast labeling but not by slow labeling that presents an averaged view over 
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seconds, and applying orthogonal footprinting can distinguish binding from remote dynamics 
change. 
There are ways to improve the confidence in the FPOP experiment.  For example, the 
footprinting can be done as a function of time to give outcomes similar to those typically 
obtained for HDX. Assigning differences can be elaborated further with kinetic curves46 (e.g., 
five time points) rather than single point, but this requires considerable investments in 
LC/MS/MS analysis time, data processing, and interpretation as well as more sample.  At this 
point, we decided to turn instead to another type of footprinting. 
4.4.3   Carboxyl group footprinting 
The effectiveness of protein footprinting to map the epitope and conformational changes depends 
on whether the reagent-active residues are located on those regions.12 Although residue-specific 
labeling provides less structural information due to limited numbers of target residues on the 
protein surface, fortuitously, the regions of IL-6R with significant changes in the solvent 
accessibility mapped by FPOP (27TCPGVEPEDNATVHW41, 274QNSPAEDFQEPCQY284 and 
135RAQEEFGQGEW148) are rich in Asp/Glu as potential GEE modification sites, and we expect 
carboxyl group footprinting, as an orthogonal approach to provide more site-specific insights for 
those acidic regions. 
In the GEE reaction, carboxyl groups of Asp/Glu located on the surface are readily modified, 
whereas ones surrounded by hydrophobic amino acids or buried in the interior of the structure 
undergo less or even no modifications (assuming there is no additional steric restrictions 
prohibiting the access of EDC and the GEE molecules).33, 47 To investigate the kinetics of the 
labeling, we performed sparse, time-dependent GEE footprinting (1, 3 and 10 min) on the apo 
and adnectin-bound IL-6R. Given that for 16 Asp/Glu-containing chymotryptic peptides, 17-26, 
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109-134, 247-254, 255-264 and 297-315 have no detectable modification, we performed 
quantification for the other 11 peptides.  
 
Figure 4.8. GEE labeling kinetics for selected IL-6R peptides in the ligand-free (gridded 
circle), adnetin1-bound (triangle) and adnetin2-bound state (diamond) state. (A) Region 
135-148 shows decreased GEE incorporation upon adnectin1/adnectin2 binding, whereas (B) 
region 274-284 shows increased GEE modification upon adnectin1 binding. (C) A representative 
peptide region without differentiable GEE modification extent between apo and holo as the 
control. Dashed trend curves in (A), (B) and (C) are generated by linear or 2nd-degree polynomial 
fitting. (D) Region 135-148 and 274-284 mapped onto IL-6R. (E) Microenvironments of Glu140, 
Asp141 and Glu144.  
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From the time-dependent GEE footprinting, we found two regions 135-148 on DII and 274-284 
on DIII show a clear difference upon binding of either adnectin1 or adnectin2 (Figure 4.8A and 
B). The two regions are mapped onto the IL-6R structure in Figure 4.8D. The rates of GEE 
incorporation for region 135-148 in the two holo states decrease significantly with a relative 
change of 30% at 10 min of labeling, and the differences are made more apparent by the time-
dependent results, indicating prominently decreased solvent accessibility of the region upon 
adnectin binding. Region 135-148 contains Glu140, Asp141 and Glu144 as possible GEE 
modification sites, but we found the modification is exclusively on Glu140. The structure of IL-
6R indicates that the GEE-modified Glu140 is on the surface of a loop with a flexible carboxyl 
group amenable to EDC/GEE reaction (Figure 4.8E). By contrast, Asp141 is involved in the front 
end of a β-strand with its side-chain hydrogen bonded to Arg132, and Glu144 is also located on the 
same β-strand with its side chain occluded by surrounding residues Phe142, Gln158 and Leu159. 
The GEE labeling reaction requires activation of the carboxyl group by EDC, and the sizes of 
EDC and GEE are larger than the small reagents in FPOP and HDX, suggesting steric 
requirements for the reaction. We reason that although Asp/Glu as charged residues are often 
prone to be on the protein surface, their solvent accessibility can be largely diminished or even 
completely blocked by their microenvironments.  
We found region 247-284 to be slightly deprotected in the adnectin1-bound state (Figure 4.8B) 
as reported for the acidic residues. Due to a steric effect similar to that described above, Glu283, 
which is located on the unshielded surface loop, is readily modified by GEE.  Glu277 and Glu278, 
however, which are located on or close to the end of a β-strand, remain unmodified owing to the 
protection from the surrounding loops and hydrogen bonds. The increased solvent accessibility 
can thus be attributed to the side chain of Glu283. Interestingly, residue-level analysis of FPOP 
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modifications on the same region shows that the Phe279/Trp284 side-chain solvent accessibilities 
are reduced (Figure 4.7), and the analysis and interpretation for the motion of the region will be 
discussed later in section 4.4.4.  
By contrast, a majority of peptides, as represented by 27-41, show nearly identical labeling 
kinetics for bound and unbound states, supporting their role as controls and suggesting their local 
conformations remain unchanged upon adnectin binding (Figure 4.8C and Figure 4.7). The 
labeling extents of those regions at 10 min, at which time the difference in modification is 
expected to be greatest, are not differentiable (Figure 4.10). Unlike FPOP labeling, which is 
often performed over a single exposure time, kinetic curves of GEE labeling provide statistical 
weight by tracking the labeling over a time course. We also found the GEE modification extent 
generally increases with the reaction time, but the labeling of some peptide regions can occur 
very rapidly. For example, regions 1-16, 288-296 and 316-326 show bursts in their GEE 
incorporation at the first 1 min of the reaction (Figure 4.9), indicative of their flexible loop or 
coil secondary structures. 
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Figure 4.9. Representative GEE labeling kinetics for selected IL-6R peptides without 
differentiable GEE modification extent. Ligand-free (gridded circle), adnetin1-bound 
(triangle) and adnetin2-bound state (diamond).  
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Figure 4.10. Regions without appreciable difference in their modification extent between 
the ligand-free and adnectin1/adenctin2-bound IL-6R. Samples are labeled with GEE for 10 
min. 
4.4.4   Structural features from complementary footprinting  
HDX rates of exchange of labile amide hydrogens are characteristic of local backbone 
conformations and related to its hydrogen-bonding pattern and solvent accessibility, which are 
affected by protein binding. In highly dynamic, unstructured regions, the exchange reaction 
proceeds on the millisecond to second timescale, whereas amides that are hydrogen bonded will 
exchange more slowly (minutes to days).48 With comparable reaction rates to HDX, GEE targets 
solvent-accessible carboxyl group side chains. Labeling by FPOP, however, is considerably 
faster than HDX and GEE because the lifetime is microseconds for the primary hydroxyl radical 
and milliseconds for all radicals.22, 49 Hydroxyl radicals react with a variety of amino acid 
residues, and the labeling extent of a particular residue site is a function of the inherent reactivity 
and solvent accessibility of the amino acid side chain. Clearly the approaches are complementary 
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in location of footprinting (protein backbone vs. side chain), residue specificity, and rate of 
reaction. The more rapid approaches offer an opportunity to understand protein dynamics and 
minor structural fluctuations.43  
The epitope and critical contacting residues   
In FPOP and GEE footprinting, region 135-148 becomes significantly protected upon binding of 
adnectin1 or adnectin2, whereas HDX focuses on region 130-141 (region 142-147 does not 
change). Taken together, the integrated outcome strongly suggests the short segment 
135QNSPAED141 to contain the critical binding epitope. The suggested epitope is conserved for 
adnectin1 and adenctin2 binding. Mapping the proposed epitope onto the IL-6R structure 
highlights a loop on the DII domain of IL-6R (Figure 4.11).    
A closer examination of the residue-specific data may reveal the contacting residues. Generally, 
FPOP modification on a residue is assigned when a +15.9949 Da shift is observed in the product-
ion series of the modified peptide. For peptide 135-148, each of FPOP modified residues 
Pro138/Phe142/Pro145/Tyr148 produces multiple +16 Da products as structural isomers (e.g., by 
o-/m-/p- oxidation of Phe). Those isomers of peptide 135-148 cannot be distinguished by mass 
and give very slightly different retention times. The complicated chromatogram for oxidized 
peptide 135-148 makes FPOP quantification of a specific residue difficult. As for the suggested 
epitope 135-141, however, we identified Pro138 to be the modified residue responsible for the 
changes in FPOP. Carboxyl group footprinting also slows for the proposed epitope, but the 
information is restricted to Glu140 as it is the only residue modified in region 135-148. Although 
there are Asp141 and Glu144 as potential GEE modification sites in this region, no modification is 
detected for the two residues owing to shielding of their microenvironments as discussed above.   
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Summarizing the information from the complementary methods, we posit that 135QNSPAED141 
represents the region containing the epitope of IL-6R, with Pro138 and Glu140 being possible 
binding residues or closely adjoining the critical binding residues (Figure 4.11 shows Pro138 and 
Glu140 in the surface presentation with side chains extruding). At this time, we cannot rule out the 
residues on region 135-141 that are not mapped by the hydroxyl radical or GEE probe (e.g., Gln 
135, Asn 136, Ser137 and Ala139), but we can potentially identify some key interacting residues as 
well as narrow down the epitope to a short segment by FPOP and GEE-reactive residues that are 
involved in binding. Note that HDX fails to report the backbone solvent accessibility of Pro138 
owing to its lack of an amide hydrogen atom, which may account for why the putative epitope 
region 130-141 only shows a modest protection in HDX, despite the two adnectins both being 
high-affinity ligands against IL-6R. 
 
Figure 4.11. Structural change of IL-6R (PDB: 1N26) upon adnectin binding in the surface 
representation. IL-6R consists of three domains. DI, DII and DIII are located from the top to 
the bottom on the structure. (A) Front view and (B) side view of the regions that undergo 
P138
E140 E140
P138
90 
A B
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conformational change in structure or dynamics upon adnectin binding. Close-up views of the 
region in (A) shows the secondary structure of the region and the side chain orientation. Region 
135-141 as the proposed epitope for adentin1/adnectin2 binding are colored in blue with Pro138 
and Glu140 highlighted in cyan. Region 27-41 and 274-284 (located on DI and DIII respectively) 
whose conformation is affected by adnectin binding are colored in coral.   
Conformational dynamics and side-chain motion of IL-6R loop regions  
Protein structure fluctuations will be affected by protein binding.50 If the sampling time of a 
footprinting reaction is long with respect to the protein dynamics, differences will be averaged 
and no effect seen. FPOP is capable of reporting on regions showing fast dynamics because its 
sampling time is short with respect to local motions.19, 42, 51 In the adnectin1-bound IL-6R, the 
decreased solvent accessibility reported by FPOP for region 27-41 is not observed by HDX or 
carboxyl group footprinting, indicative of fast changes in the conformational dynamics of region 
27-42 upon adenctin1 binding. Region 27-41 is located on the DI domain of IL-6R as a surface-
exposed loop (Figure 4.11B) where changes in dynamics are likely to happen.  
For amino-acid residues with high intrinsic reactivities with the hydroxyl radical, drastic changes 
in their modification occur in response to modest change in the solvent accessibility,45 whereas 
differences in modification extent of less reactive residues (e.g., Leu, Pro and Val) is expected to 
be observed for large conformational changes. His40 and Trp41 are the only two residues 
modified by FPOP in region 27-42, and they do exhibit dramatic differences in FPOP 
modification with a relatively decrease of 67% in the adenctin1-bound state. The observed 
protection on the two residues with high susceptibility to the hydroxyl radical suggests relatively 
modest changes in the structure or dynamics upon adnectin-1 binding. Considering the binding 
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strength of adnectin1 (Kd ~ 6.2 pM) is greater than that of adnectin2 (Kd ~ 46 nM), we posit that 
the binding of adnectin1 stabilizes IL-6R more by reducing the local flexibility of region 27-41.  
Interestingly, in contrast to the decreased FPOP modification of residue Phe279/Trp284 in region 
274-284 in adnectin1 bound IL-6R, the GEE labeling of Glu283 increases slightly for the 
adnectin1-bound state, but not for adnectin2, whereas no difference in HDX occurs for this 
region. This suggests that region 274-284 undergoes minor structural perturbation in dynamic 
and/or sidechain reorientation upon adnectin binding, which may not cause changes in the amide 
hydrogen-binding pattern. Considering the hydrophobicity of Phe/Trp and the polarity of Glu, it 
is possible that the binding causes side-chain motions involving inward rotation of Phe279/Trp284 
with its solvent accessibility decreasing, whereas the side chain of Glu283 rotates outward and 
becomes relatively solvent exposed. These solution-state motions would not be reflected in a 
single static 3D-structure. Furthermore, region 274-284 spans a flexible loop, where side-chain 
rotation is more facile than for a more rigid α-helix or β-sheet. This may have implication in the 
low-affinity binding of IL-6 to IL-6R that precedes the binding to a signal-transducing molecule 
gp130 to form high-affinity functional complex.52-53 An investigation into the structure of the IL-
6R/IL6/gp130 complex (PDB: 1P9M) further reveals that the loop region represented by peptide 
274-284 serves as one of the interfaces with IL-6 in this biologically-relevant complex (Figure 
4.12). The structural changes adopted by this region may be inferred by the therapeutic efficacy 
of the adnectins to block IL-6-mediated signal transduction through inhibiting the binding of IL-
6 to IL-6R.  
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Figure 4.12. Cocrystal structure of IL-6R/IL6/gp130 complex. Region 135-148 and 274-284 
(magenta) on IL-6R (blue) both closely interact with IL-6 (cyan) as shown in the 3D-structure of 
the biologically-relevant human IL-6/IL-6R/gp130 (2:2:2 stoichiometry) hexameric complex. 
The complex consists of two IL-6, IL-6R, and gp130 hetero-trimers (PDB: 1P9M, only one copy 
of the hetero-trimer is shown for clarity). IL-6 and the signal transducer glycoprotein 130 
(gp130) is in cyan and red respectively. Domain DI of IL-6R is absent in this 3D-structure.  
 
4.5   Conclusions 
Solution-state protein-protein interactions and related conformational changes can be 
interrogated with high spatial resolution by using orthogonal footprinting and structural mapping. 
We proposed the epitope of IL-6R is in the region 135-141 and concluded that adnectin binding 
affects fast dynamics and side-chain reorientation of some of IL-6R’s flexible loops. Those 
“hidden” motions in structure and/or dynamics are invisible to a relatively slow footprinting 
method like HDX. The results support a more comprehensive understanding of IL-6R HOS and 
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highlight the sensitivity of FPOP towards fast structural changes owing to the short half-life of 
hydroxyl radicals and higher coverage compared to HDX and site-specific carboxyl group 
footprinting. Their combined use not only serves to categorize and interpret changes in 
footprinting as due to protection from binding or to remote structural changes occurring with 
binding, but also adds confidence to assign the epitope where any stand-alone method has 
uncertainty. This integrated approach shows great utility for charactering protein and protein 
complex, which can be applied efficiently to assist understanding and optimizing the design of 
protein therapeutics.       
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Chapter 5: Mapping Hydrophobic 
Interactions of Human Bromodomain with a 
Small Molecule Inhibitor by Hydrogen-
Deuterium Exchange and Hydroxyl Radical 
Footprinting Mass Spectrometry  
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5.1  Abstract 
Mass spectrometry-based protein footprinting, a valuable structural tool in mapping protein-
ligand interaction, has been extensively applied to protein-protein complexes, showing successes 
in mapping large interfaces. Here we compared hydrogen-deuterium exchange (HDX) and 
hydroxyl radical footprinting using fast photochemical oxidation of proteins (FPOP), as a proof-
of-concept study, to characterize the interaction of human bromodomain-containing protein 4 
(BRD4) with a hydrophobic benzodiazepine inhibitor. HDX does not provide strong evidence for 
the location of the binding interface, presumably because the shielding of solvent by the small 
molecule is not large. Instead, HDX suggests that BRD4 appears to be stabilized by showing a 
modest decrease in dynamics caused by binding. In contrast, FPOP points to a critical binding 
region in the hydrophobic cavity, also identified by crystallography, and, therefore, exhibits 
higher sensitivity than HDX in mapping the interaction of BRD4 with compound 1. In the 
absence of or under low concentrations of the radical scavenger, FPOP modifications on Met 
residues are significantly different with respect to a minor change in protein conformation. This 
problem can be avoided by using a sufficient amount of proper scavenger, as suggested by the 
FPOP kinetics directed by a dosimeter of the hydroxyl radical.  
 
5.2  Introduction 
Despite the rapid development of protein-based therapeutic biologics, small molecules are still 
remarkably dominant in development pipelines of the biopharmaceutical industry, making up 
over 90 percent of the therapeutics in use.1 Small-molecule drugs have relatively stable chemical 
property and are mostly non-immunogenic. Their tiny size and chemical composition make them 
easy to penetrate cell membranes and reach desired delivery destinations. Generally, design of 
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small-molecule drugs is based on specific macromolecules as targets for inhibition or 
modulation. Thus, characterization of the interaction between a small molecule and its target 
macromolecule is important for drug development, as knowledge in their interaction is essential 
for understanding the mechanism of action. Compared to Chapter 4 discussing protein-protein 
interaction, this chapter is focused on evaluating MS-based protein footprinting, including FPOP 
and HDX to probe protein-small molecule interaction. From a method development perspective, 
this is also the first example of applying FPOP to investigate the direct binding interface of a 
protein with its small molecule ligand. 
MS-based protein footprinting is a valuable tool to characterize protein structure and dynamics. 
Hydrogen-deuterium exchange (HDX) and hydroxyl radical footprinting are the two most 
commonly applied protein footprinting methods. HDX reports the stability and structural 
protection of the protein by measuring the exchange of amide hydrogens with deuterium on the 
protein backbone.2 Its utility has been established by extensive applications in studying protein-
protein, protein-DNA, protein-membrane interactions,3-4 showing successes in probing large 
interfaces in protein-ligand complexes. Using HDX to probe protein-small molecule interfaces is 
challenging, however, possibly owing to the relatively small protection afforded to the protein by 
the small molecule. Hernychova et al.5 applied HDX to the interaction of the protein MDM2 
with a small molecule, Nutlin3, and observed reduced HDX kinetics upon ligand binding in 
regions surrounding the pocket only at relatively high protein-to-ligand ratio (1:4). Wang et al. 6 
used HDX with ligand titration to obtain the affinities of a small molecule drug with 
Apolipoprotein E3 at the peptide-level, obtaining convincing changes in HDX at the binding 
sites. Despite these successes, direct mapping of a small molecule interaction when the binding is 
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hydrophobic may be particularly difficult because the binding interface does not involve 
hydrogen bonding of the protein backbone, explaining the lack of sensitivity in HDX. 
By contrast, hydroxyl radical footprinting reports changes in solvent accessibility of amino-acid 
side chains via covalent and irreversible oxidative modification.  Here differences in bound vs. 
unbound states are less dependent on H bonding.  Furthermore, hydrophobic side chains (Phe, 
Leu, Ile, Val) are reactive with •OH, leading to potentially sensitive indications of binding.7  
Here we describe the implementation of fast photochemical oxidation of protein (FPOP), which 
uses laser-induced hydrolysis of hydrogen peroxide to generate hydroxy radicals.8 Using a 
radical scavenger, we varied the time scale of labeling, determined by the lifetime of the radical, 
is tuned to be faster than protein conformational change or unfolding induced by modification.9 
Although FPOP has been applied to protein folding, protein aggregation,10-12 protein-ligand 
interactions including epitope/paratope mapping,13-16 to our knowledge, FPOP, and hydroxyl 
radical footprinting in general, have not yet been applied to protein-small molecule interactions. 
Thus, we want to explore this opportunity and test the capability of the method for this 
application.    
We chose to evaluate HDX and hydroxyl radical-based FPOP to characterize binding of a 
benzodiazepine inhibitor, benzyl (1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-
a][1,4]diazepin-4-yl)carbamate (referred to as compound 1 hereafter), to human bromodomain-
containing protein 4 (BRD4). BRDs are protein interaction modules that specifically recognize 
acetylation motifs, a key event in the reading process of epigenetic marks.17 Inhibitors targeting 
BRD have therapeutic efficacy as anti-inflammatory, antiviral, and anticancer 
agents.18 Compound 1 is a potent (nM) inhibitor that disrupts the function of the bromodomain 
family (BRD2, BRD3, and BRD4). A cocrystal structure of the bromodomain 1 of BRD4 and 
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compound 1 shows that the inhibitor occupies the central hydrophobic cavity of the protein used 
for acetyl-lysine recognition, thus directly antagonizing the interaction between the 
bromodomain and the acetylated histone peptides by steric competition.18 The outcome of this 
comparative study is not only valuable for understanding the principles of HDX and FPOP but 
also should provide insights into the analytical capabilities of the methods, guiding the choice of 
suitable MS-based footprinting methods for investigating protein structure and interactions. 
  
5.3  Experimental  
5.3.1  Materials  
The bromodomain 1 (residue 41-168) of human BRD4 (refereed to as BRD4 hereafter) and 
compound 1 were provided by Bristol Myers Squibb. L-Glutamine, L-methionine, catalase, 
hydrogen peroxide (H2O2), trifluoroacetic acid (TFA), formic acid (FA), phosphate buffer saline 
(PBS, 10 mM phosphate, 138 mM NaCl, 2.7 mM KCl), urea, dithiothreitol and iodoacetamide 
were from Sigma Aldrich (St. Louis, MO). Trypsin and chymotrypsin were from Promega 
(Madison, WI).             
5.3.2  HDX  
To prepare compound1-bound BRD4, the protein solution and compound 1 were combined to 
form a 40 µM:48 µM concentration ratio and incubated at 25 °C for 30 min to allow formation of 
the complex.  Aliquots of 3 µL of 40 µM BRD4 with and without the complex were then 
continuously labeled in 37 µL of 1 × PBS in 99.9% deuterium oxide (pD =7.4), at 25 °C, at 10 s, 
30 s, 1 min, 2 min, 15 min, 1 h, 2 h, 4 h, and 6 h time points.  The reaction was quenched by 
adding 60 µL of 3 M urea and TFA (final pH = 3.0).  Samples were then flash frozen in liquid 
nitrogen and stored at -80 ⁰C.  Control samples were prepared in like fashion by using 1 x PBS in 
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water in place of deuterium oxide.   Each sample was thawed immediately prior to LC-MS 
analysis. The protein was digested by pepsin by using a custom-packed pepsin column (2 mm x 
20 mm) at a flow rate of 100 µL/min. The resulting peptic peptides were then trapped on a 
Zorbax Eclipse XDB-C-8 trap column (2.1 x 15 mm, 3.5 µm) and desalted for 3 min, followed 
by separation of the peptides on a Hypersil Gold C-18 analytical column (2.1 x 50 mm, 2.5 µm) 
by using a gradient of 4-80 % acetonitrile with 0.1% formic acid at a flow rate of 100 µL/min. 
Peptides were detected using a LTQ XL Orbitrap mass spectrometer (Thermo Fisher Scientific), 
at a mass resolving power of 100000 at m/z 400. The capillary temperature and voltage for ESI 
were 275 °C and 49 V, respectively. All experiments were performed in duplicate.  
5.3.3  HDX data analysis 
To identify the peptic peptides generated from the protein and to provide a list of peptides to be 
followed during HDX, peptide mapping with a non-deuterated protein sample was conducted. 
The product−ion mass spectra were acquired in a data-dependent mode, with the six most 
abundant ions from each scan selected for MS/MS. Peptides, as identified using Mascot (Matrix 
Science, London, UK), were used to guide the HDX setup.  The HDX mass spectra were 
analyzed with HDX Workbench (Scripps, Jupiter, FL). All experiments were performed in 
duplicate.   
5.3.4  FPOP  
A complex of bound BRD4 with compound 1 was prepared by incubating 20 μM BRD4 with 
compound 1 in a 1:1 molar ratio for 30 min at 25 °C in PBS. Unbound BRD4 was prepared as a 
20 μM stock solution in PBS. Just prior to injection into the flow tube for FPOP, H2O2 was 
added to a final concentration of 20 mM. FPOP was performed as previously described8, expect 
that for each state of the protein, FPOP was conducted in duplicate each for four different 
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concentrations of His (0, 0.3, 3, 30 mM) as the radical scavenger. The final concentration of 
BRD4 for FPOP labeling was 10 μM. After laser irradiation, the sample was collected in a tube 
containing 10 mM catalase and 20 mM Met to react with any leftover H2O2 and prevent 
oxidation artifacts. In addition, control samples of BRD4 with all the reagents (including H2O2) 
added were handled in the same manner in duplicate, but not laser-irradiated.  
5.3.5  LC-MS/MS  
For each 20 μL aliquot of the FPOP sample, urea was added to a final concentration of 6 M to 
denature the protein. Cysteines of the protein were reduced by adding dithiothreitol to a final 
concentration of 5 mM, and samples were incubated at 37 oC for 30 min. Iodoacetamide was 
subsequently added to a concentration of 15 mM to alkylate the free cysteines. Samples were 
incubated in the dark at room temperature for 30 min. PBS was added to dilute the urea to 1 M. 
Samples were digested overnight with trypsin or chymotrypsin at 37 oC with a protease-to-
protein ratio of 1:25 (w/w). The digestion was terminated by acidifying the sample with 1% 
trifluoroacetic acid. The sample was then vacuum-dried on a speedvac, and each peptide digest 
was reconstituted with 60 μL 0.1% FA in water for LC-MS analysis.   
An aliquot of 5 μL of  protein digest was submitted to LC-MS/MS analysis. For the elution, 
solvent A was water with 0.1% (v/v) FA, and solvent B was 80% (v/v) acetonitrile with 0.1% 
(v/v) FA. Peptides were pre-concentrated on an Acclaim PepMap C18 column (Thermo 
Scientific, 100 µm × 2cm, 5μm, 100 Å) and desalted for 10 min at a flow rate of 4.5 μL/min by 
using solvent A. Separation was performed on a custom-packed C18 column (CSH, 75 µm × 15 
cm, 3.5 μm, 130 Å) at a flow rate of 400 nL/min with a gradient of 2-65 % solvent B in 90 min 
using a Nano UltiMate 3000 Rapid Separation system (Dionex, Co.). The solution flow was 
directed with a Nanospray Flex source coupled for online detection using a Q Exactive Plus 
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orbitrap mass spectrometer (Thermo Scientific) with a spray voltage of 2.5 kV and a capillary 
temperature of 250 oC. In the data-dependent mode, the 15 most-abundant ions were submitted to 
higher energy collision dissociation (HCD) with an isolation window of m/z 1.5 and a 
normalized collisional energy of 30%. Resolving power was 70,000 (at m/z 400) for MS1 and 
17,500 (at m/z 400) for product ions in MS/MS.   
5.3.6  FPOP data analysis 
Identification of the unmodified peptides and assigned modifications were done by using 
Byologic (Protein Metrics) and further validated by manual inspection. Modification sites were 
identified based on MS/MS. Signal intensities of the unmodified peptide (Iu) and its modified 
species (Iox) were integrated using Byologic (Protein Metrics) from the extracted ion 
chromatograms (XICs). The FPOP modification level of a peptide was calculated using the 
following equation: % modified = Iox/(Iox + Iu)×100. Quantification of the modified species was 
based on the dominant FPOP products with oxygen addition/substitution(s) (+15.9949 Da, + 
31.9898 Da, etc.).  
 
5.4  Results and Discussion 
5.4.1  Mapping by HDX 
In our model system, benzyl (1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-
4-yl)carbamate (compound 1) (Figure 5.1A) is a BRD competitive inhibitor that possesses a 
binding cavity for acetyl-lysine recognition (Figure 5.1B).18 The structure of bromodomain 
adopts a left-handed four-helix bundle topology. Overlapping the compound 1-bound BRD4 
(bound) with the ligand-free protein (unbound) shows the two structures are nearly identical 
131 
 
(Figure 5.2C), indicating no significant structural rearrangement of the protein that is caused 
compound 1 binding.  
 
Figure 5.1. Binding of BRD4 to compound 1. (A) Molecular structure of compound 1. (B) 
Crystal structure of BRD4 in complex with compound 1 (PDB 2YEL), referred as “bound” 
hereafter. Secondary structures and surface presentation of the protein are shown in cyan and 
white, respectively. (C) Bound BRD4 in cyan is overlaid with the ligand-free BRD4 in orange 
(PDB 4LYI), referred as “unbound” hereafter.  
In the HDX experiment, the hydrophobic core of BRD4 is expected to show very slow rate of 
deuterium uptake owing to its solvent accessibility. Thus, we extended the time course of D2O 
exposure to 6 h to allow exchange to occur in the hydrophobic cavity. In accord with the nearly 
identical structures of BRD4 in the unbound and bound states, most regions in BRD4 shows no 
change in HDX kinetics upon compound 1 binding, as represented by peptides in Figure 5.2A-C. 
By way of contrast, we found some regions exhibit slightly reduced rates and extents of 
exchange in the bound state (Figure 5.2E-J). The differences in those regions, however, are still 
too modest compared to what we would typically expect for a binding interface.19-21 Instead, 
HDX shows that BRD4 only undergoes a slight decrease in H-bonding and flexibility upon 
compound 1 binding, and we conclude that the overall structures of the unbound and bound 
90 
A B C
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BRD4s are very similar.  Indeed, we are seeking a binding scenario such as this to test whether 
protein footprinting is sensitive to small-molecule binding. 
 
Figure 5.2. HDX kinetics of BRD4 upon binding of compound 1. Comparison between the HDX of 
unbound (blue) and bound (orange) BRD4 reveals representative peptide regions (A-D) that do not show 
changes in HDX upon binding, and regions (E-J) showing small changes upon binding to compound 1. 
Amino-acid numbering and charge state of the peptide from pepsin digestion of BRD4 are shown above 
each plot. 
Given the small changes in HDX resulting from binding, we turned to FPOP to probe the 
interaction of BRD4 with compound 1. Compared to HDX that interrogates the structure and 
dynamics of backbone amide, we expect FPOP to show higher sensitivity in mapping the binding 
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cavity of BRD4 with the compound 1, because the binding interface may involve sidechain 
interactions and, moreover, many of the hydrophobic residues are reactive with the OH radicals 
used for footprinting. 
5.4.2  Mapping by FPOP using a reporter peptide strategy 
 
 
Figure 5.3. Global FPOP modification of BRD4 as a function of the scavenger concentration. 
Mass spectra of unbound BRD4 (+14 charged). FPOP was done without addition of the 
scavenger in the protein sample (A), and with 0.3, 3, 30 mM His used as scavenger (B-D). (E) 
Control sample of BRD4 (with addition of H2O2) submitted to the same FPOP workflow as the 
experimental group except the laser was turned off. (F) starting state of BRD4 in PBS buffer. 
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To obtain FPOP kinetic curves of the unbound and ligand-bound BRD4, we performed the 
labeling experiment with various concentrations (0, 0.3, 3, 30 mM) of histidine as the radical 
scavenger to give different timescales of labeling. Mass spectra of the intact BRD4 shows that 
the extent of FPOP modification gradually attenuates in respond to increased amount of the 
scavenger (Figure 5.3). To track the lifetime of the hydroxyl radical in the sample, we used Leu-
enkephalin (YGGFL) as a peptide reporter for the hydroxyl radical22 by mixing each protein 
sample with a fixed amount of Leu-enkephalin prior to FPOP. Upon laser irradiation, the reporter 
is competitively labeled with BRD4 by the hydroxyl radical under the same condition, and thus 
the reporter-% modified can be used to follow the hydroxyl radical lifetime in the sample.  
Compound 1, a polyphenol molecule, is likely to be reactive with the hydroxyl radical, and if so 
this ligand will quench some of the radicals.  Thus, there may be a different overall oxidation 
potential for the bound-sample solution compared to that containing the unbound. The 
modification of compound 1 will not compromise our efforts to locate the binding provided the 
count of radicals available to the protein can be normalized for the unbound and bound states. In 
fact, the “unintended” quenching effect of compound 1 is negligible under high concentrations of 
scavenger (3 and 30 mM His) as indicated by the equal modification extents of the reporter for 
the unbound and unbound samples when submitted to FPOP (Table 5.1). In absence of the 
scavenger (His = 0 mM), however, the reporter for the bound sample is significantly less 
modified than for the unbound BRD4 (relative difference 32%). In the presence of 0.3 mM His, a 
small variation in the reporter-% modified is observed. Those results demonstrate that in these 
FPOP experiments, the modification extent is well-controlled because the dominating chemistry 
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that controls the lifetime of the hydroxyl radical is the reaction of the radical with the large-
excess scavenger rather than that with the protein or ligand. 
His  
(mM)  
   Averaged % modified ± S.D.  
of the reporter 
Unbound hBRD4 Bound hBRD4 
0 22.40 ± 0.12 15.31 ± 0.53 
0.3 14.92 ± 0.05 12.40 ± 0.11 
3 6.69 ± 0.01 6.60 ± 0.36 
30 1.85 ± 0.08 1.88 ± 0.02 
Table 5.1. FPOP modification levels of the reporter peptide.  Extent of modification of the 
reporter in the unbound and bound BRD4 sample. Scavenger concentrations of His are 0, 0.3, 3 
and 30 mM respectively. FPOP labeling was done in duplicate. 
 
To obtain comprehensive coverage across the BRD4 sequence in the bottom-up proteomics 
strategy used for analysis, we performed digestion with trypsin and chymotrypsin separately. 
Plotting the % modified of BRD4 peptide as a function of the reporter-% modified provides a 
“time-course” for the FPOP modification.  The curves are similar to the HDX kinetic curves 
characterized by deuteration extents at different deuterium exposure times (Figure 5.4), curves 
that are commonly viewed in the field.  
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Figure 5.4. FPOP kinetic curves of BRD4. The x-axis of each curve is the % modified of the 
reporter peptide, which correlates with the lifetime of the hydroxyl radical. The y-axis is the % 
modified of the peptide from the FPOP-modified BRD4 in unbound (blue) and bound (orange) 
states, respectively. Numbering and sequence of the peptide from digestion of BRD4 are shown 
above each plot. Identified residues with FPOP modification are highlighted in red on the peptide 
sequence.   
We find that for peptide regions not containing Met, the % modified for the protein shows a 
linear correlation with that of the reporter (Figure 5.4 A-F, I and K). Among those regions, 76-83 
clearly exhibits reduced modification in the bound state. Therefore, this region is likely part of 
the binding site.  
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In contrast, FPOP modifications of peptide regions that contains one or more Met (e.g. 99-114, 
100-112, 121-133 and 149-156) saturate and decrease as the lifetime of the hydroxyl radical 
becomes longer. (Figure 5.4 G, H, J and L). Because the modification on those regions occurs 
nearly exclusively on Met residue(s), we first hypothesized saturation and turnover of the 
modification extent are due to a switch of the Met oxidized products to higher oxidation states 
(e.g., + 32 Da, + 48 Da) as the labeling time increases (peptides with multiple oxidation are very 
rare, so they are generally not considered in the algorithm for peptide-level quantification).  By 
manual search of the data, we found no detectable signals in LC-MS/MS for FPOP products in 
higher oxidation states (e.g., +32, +48). Although the reasons for such trends observed for Met-
containing peptides is unclear, we are considering two explanations: 1) As the lifetime of the 
hydroxyl radical becomes longer, oxidation by FPOP on Met produces oxidized species that are 
not yet known. 2) Met-containing regions in the protein have affinity with H2O2, and thus the 
radicals are generated in the immediate vicinity of Met.  In the latter case, the reactions of Met-
containing regions with the hydroxyl radical is no longer limited by diffusion of the radical, but 
by the local concentration of H2O2 that surrounds the Met.   
5.4.3 Correlating HDX and FPOP mapping with BRD4 structures 
A co-crystal structure of the complex indicates that compound 1 binds to the acetyl-lysine 
recognition pocket of BRD4. Using proximity of hBRD4 residues with compound 1 as a 
criterion, we considered that residues of the protein within 4 Å from compound 1 could be key 
contacts. Using this criterion, we identified W81 (3.6 Å), P82 (3.9 Å), F83 (3.7 Å), L92 (3.7 Å) 
and N140 (3.3 Å) as key residues that directly interact with compound 1 from the crystal 
structure (Figure 5.5A).  
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Figure 5.5. Correlation of the footprinting results with BRD4-compound 1 interaction. (A) 
Key contacts (magenta) of the protein (cyan) in contact with compound 1 (blue) according to the 
X-ray structure. The distance criterion for a contact was chosen to be 4 Å.  (B) Peptide regions 
that showing reduced rates of HDX in the bound state (Figure 2 E-J) mapped onto the BRD4 
structure (PDB 2YEL). Regions with low and intermediate extents of HDX (i.e., relative HDX of 
the peptide in the bound or unbound state instead of the difference in HDX between the two 
states) are colored in green and salmon, respectively. 
5.4.3.1. HDX:  Mapping the peptide regions that show reduced HDX in the bound (Figure 5.2E-
J) onto BRD4-compund 1 complex indicates that those regions span the binding pockets and the 
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surrounding sequence (Figure 5.5B). As discussed earlier, the differences in HDX, however, are 
subtle and do not provide high confidence that a binding pocket has been identified.  This may 
because 1) the protein only undergoes subtle structural change upon compound 1 binding, as 
indicated by the nearly identical crystal structures of the unbound and bound protein, 2) the size 
of the ligand is too small to provide efficient shielding from the solvent at the binding interface, 
and 3) the binding is not significant involved with peptide bonds but rather with side-chain 
interactions.  
Despite these uncertainties, the kinetics of HDX provides information on the secondary structure 
elements of the region based on their effects on HDX. For example, regions 124-136 and 149-
153 that are comprised of a two α-helix bundles that are structurally rigid (Figure 5B) resist 
solvent contact and show low extents of HDX (Figure 5.2 G, H and J). By contrast, region 119-
124 is a loop located on the surface of the protein. Its flexible structure and solvent exposure 
allow the region to uptake rapidly deuterium and undergo extensive HDX even at short times 
(Figure 5.2C). Regions represented by peptides 72-88 and 137-145 cover both fast and slow 
exchangers and show intermediate rates of HDX (Figure 5.2E and I).  
5.4.3.2. FPOP:  Differential labeling by FPOP shows that region 76-83, containing key contacts 
W81, P82 and F83 is decreased for the bound state (Figure 5.4D), clearly indicating a binding 
interface. Further residue-specific analysis of this region indicates the FPOP modification occurs 
only on W81, which is at the entrance of the binding pocket and accessible to the solvent (and 
H2O2) (Figure 5.2A). No modifications were detected on P82 and F83 presumably because the 
two residues are buried deep in the hydrophobicity pocket and have low solvent accessibility 
(Figure 5.5A). Actually, the three residues W81-P82-F83 constitute the conserved WPF shell 
motif in the bromodomain family; this domain plays an important role in positioning inhibitors 
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through hydrophobic van der Waals interactions.23-24 Our finding confirms that role of W81 is 
critical for substrate recognition and binding.  
In addition, for L92 and N140 that have also been identified to be in contact with compound 1 
based on the crystal structure, regions covering the two residues (84-92 and 138-148) show 
overlapping FPOP kinetic curves in unbound and bound (Figure 5.4 E and K). Although 
modification was detected on L92, we found no difference in its modification levels between 
unbound and bound protein. This is likely due to the insufficient solvent protection from 
compound 1 and the structural flexibility of L92 in a dynamic loop (Figure 5.5A). Meanwhile, 
owning to the low intrinsic reactivity of Asn with the hydroxyl radical, N140 did not undergo 
modification in FPOP. Instead, modification was detected on K141 and P142 nearby (Figure 
5.4K). In this case, we lack information on N140 because the residue is not reactive with the 
hydroxyl radical probe.  
Interestingly, all the covered Met residues of the protein (e.g., M105, M107, M132 and M149) 
show reduced rates of FPOP modification in the bound state (Figure 5.4G, H, J and L). 
According to the x-ray structure, there is no significant alteration in their conformation or side 
chain orientation upon compound 1 binding (Figure 5.1C). Thus, we indicate that the difference 
in FPOP labeling associated with those Met residues should NOT be attributed to a major change 
in protein structure or protection caused by compound 1 binding. Instead, given the similar 
unbound and bound structures of BRD4, the decreased modifications on Met in the ligand-bound 
state are more likely to result from the increased stability of the protein upon compound 1 
binding, as revealed by reduced HDX in regions containing M105, M107, M132 and M149 
(Figure 5.2F, H and J). Those changes in protein dynamics are not necessarily reflected by 
crystal structures that capture only a single low-energy state of the protein.  
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Furthermore, previous studies showed that Met tends to exhibit large change in FPOP 
modification in response to a minor structural perturbation, presumably owing to its high 
intrinsic reactivity with the hydroxyl radical.14, 25 Therefore, caution is needed when interpreting 
changes in modification extents on Met and associating it with a major structural effect. 
Furthermore, although FPOP can potentially result in a “false positive” in suggesting a 
conformational change associated with Met, this problem can be avoided by performing the 
experiment under a high concentration of the scavenger (e.g., ~ mM His), because at short 
labeling times the modification extents on the Met for unbound and bound are more modest and, 
importantly, are identical (Figure 5.4G, H, J and L).  More research is required to understand this 
effect of Met on FPOP yields. 
 
5.5  Conclusions 
In this chapter, we applied two most commonly used protein footprinting methods, HDX and 
hydroxyl radical footprinting to interrogate the epitope of BRD4 for a small molecular inhibitor. 
Results from HDX show very similar kinetics for the unbound and compound-1 bound BRD4, 
indicating the sensitivity of the method is not sufficient in this case to map directly the 
intermolecular interface between the protein and small molecule ligand presumably because the 
shielding of solvent by the small molecule is ineffective. In FPOP, the region containing the 
conserved WPF shell and residues nearby show a clear decrease in FPOP modification upon 
compound 1 binding, consistent with the predicted interactions at the binding interface 
determined by crystallography. Although there may be other residues in the vicinity of the 
binding, they do not variations in their solvent accessibility reported by FPOP.  
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In addition, regions containing Met residues display distinct chemical kinetics in FPOP, 
including saturation in the modification at extended labeling time and a relatively large 
difference in modification as an effect of a modest change in protein dynamics. Those 
differences seem to be false positives and require further evaluation.  
Although the interactions of the protein BRD4 with the small molecule (compound 1) are 
difficult to decipher by FPOP and particularly by HDX, the small differences nevertheless 
provide valuable constraints of how the small molecule is poised with respect to the protein. 
Those constrains can be used to guide molecular dynamics simulation to pinpoint the binding site 
especially in the early stages of research or when a high-resolution structure from X-ray/NMR 
cannot be obtained. 
In addition to providing insights into protein structure and properties, this chapter, together with 
Chapter 4 gives us a better understanding in the sensitivity, spatial resolution, applicability and 
limitation of each protein footprinting method for protein structure characterization.  
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Chapter 6: Identify Key Salt Bridges 
Controlling the Gating of Major Facilitator 
Superfamily Transporters Using Mass 
Spectrometry-Based Live-Cell Footprinting 
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6.1  Abstract 
The major facilitator superfamily (MFS) transporters move a wide range of substrates across 
biological membranes. They function through an alternating access motion, during which the 
protein progresses through a series of conformational states to accomplish substrate translocation. 
Those conformational changes are mainly orchestrated by salt-bridge interactions between the N-
and C-terminal domains of the transporter. Even with a structure from X-ray crystallography, 
however, identification of the key salt bridges of MSF transporters remains challenging. Here, 
we report the development of a MS-based live-cell footprinting approach, combined with 
suspension cell expression, green florescence protein (GFP) tagging and optimized in-gel 
proteolysis to probe the structures of MFS transporters in their native cellular environment. As a 
proof of concept, we applied carboxyl group footprinting to probe the formation and breakage of 
the salt bridges of human glucose transporters (GLUTs) during the transportation cycle. 
Substrates/inhibitors stabilizing the inward- or outward-open conformations generate distinct 
modification patterns, revealing the key salt-bridge interactions that control the gating of those 
transporters. We identified key salt bridge interactions in GLUT1 and GLUT5 on both its 
intracellular and extracellular sides. Remarkably, mutations disrupting the salt bridges located at 
the two opposite sides of membrane have opposite effect to the transporter activity. Mutants (at 
the cytosolic side) disputing the outward-facing conformation are inactive, suggesting that this 
conformation need to be stabilized. Conversely, mutants (at the extracellular side) disrupting the 
inward-facing conformation are hyperactive, suggesting that this alternative conformation needs 
to be maintained transient, because removal of the salt bridges normally stabilizing this state 
facilitates the transporter motion. Thus, the rocker-switch motion is asymmetrical in time, a 
mechanism probably adopted by most MFS transporters. This structural mechanism has evaded 
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extensive structural investigation of MFS transporters for decades, demonstrating again the 
powerful capability of our method to investigate the conformations, interaction and dynamic 
motion of membrane proteins in live cells. 
 
6.2  Introduction 
The major facilitator superfamily (MFS) is the largest group of secondary active transporters 
found in nearly all living organisms. This superfamily represents about one quarter of known 
membrane transport proteins,1-3 with 85 subfamilies being identified to date 
(http://www.tcdb.org).4 Each functionally characterized subfamily transports a certain set of 
substrates, including ions, sugars, nucleotides, amino acids, peptides, vitamins, and drugs. This 
broad range of substrates are transported across the membrane via structural motions of MFS 
proteins.  
Crystal structures and functional analysis show that MFS proteins mediate substrate transport by 
an alternating-access mechanism. These transporters share a canonical MFS fold consisting of 12 
transmembrane helices (TM); the N- and C-terminal halves of the proteins, each containing 6 
TMs, form two pseudo symmetrical domains surrounding a translocation pore. The substrate is 
bound at a single site in this pore, and is transported through a rocker-switch rotation of the two 
protein halves that alternatively exposes the substrate to promote its binding or release at each 
side of the membrane. Thus, inward-open and outward-open occur as two major conformations 
during the transport cycle, with substrate-occluded conformations as intermediate states.  
Formation and breakage of critical salt bridges controls the rocker-switch rotation and the gating 
of the translocation pore.5  In proton-coupled transporters, such as LacY6-7, GlpT5 and POT8, the 
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protonation state of key residues and changes in their salt bridges were proposed to induce 
significant structural rearrangements. The salt bridges provide part of the driving force, or even 
act as the pivot, to flip the transporters between inward- and outward-facing conformations. In 
GLUT5,9 a glucose uniporter, an outward-facing conformation is stabilized by interdomain salt 
bridges between Glu and Arg residues, which are strictly conserved as part of the sugar porter 
signature. These residues, however, in the inward-facing conformation are too far apart to form 
salt bridges. Conversely, disruption of a salt bridge by a Glu329Gln mutation in GLUT1 
stabilizes its inward-facing conformation, permitting the determination of its crystal structure.10 
MFS transporters still hold specific challenges in structural biology compared to soluble proteins. 
For example, the conformation of MFS transporters is sensitive to extraction, solubilization and 
purification. Obtaining the crystal structure of the MFS transporters, particularly for eukaryotes 
is primarily limited by their hydrophobic surface, intrinsic flexibility, and lack of stability. 
Despite advances in X-ray crystallography11, identification of alternating salt bridges during the 
rocker-switch motion remains a challenge. Until 2013, none of the MFS proteins had structure 
captured in more than one conformational state. Today, structures of 15 MFS proteins are 
available, including a handful of eukaryotic proteins (mostly glucose transporters), among which 
GLUT5 is the only one determined in the two alternating conformations. Additionally, crystal 
structures capture only a single low-energy state, which heavily depends on the crystallization 
conditions, such as pH12, mutation (e.g., conformationally restricted E329Q in hGLUT1)10, 
presence of an antibody, and crystal packing, all of which may perturb the native state of the 
protein. Furthermore, the surrounding lipids in their native environment are likely to affect the 
function, kinetics, or even thermodynamics of the transporter. Owing to these limitations, one 
can turn to molecular-dynamics simulation to rationalize the formation and breakage of salt 
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bridges implicated in biochemical studies.13 Direct evidence of such subtle changes, however, 
especially in a native cellular environment, remains enigmatic for MFS transporters.  
Recently, MS-based methods are showing potential for membrane protein characterization. 
Membrane proteins and their complexes can be interrogated in gas-phase under non-denaturing 
condition by intact mass analysis (native MS). The method allows membrane protein complexes 
to be released from detergents, bicelles or nanodiscs after collisional activation in the gas phase 
for MS detection. The approach provides insights into the subunit composition and lipid 
interactions of membrane protein complexes.14-15 Native MS can also be coupled with ion 
mobility to obtain information on membrane-protein conformation and dynamics.16 As an 
alternative, MS-based “bottom-up” proteomics identifies the proteolytic peptides of a membrane 
protein.17 This approach, used with chemical footprinting are usually performed on purified 
protein in buffer solution, as exemplified by Chapter 2-5. For study of membrane proteins, the 
protein is usually stabilized by detergent or nanodiscs in buffer for characterization. In this 
chapter, we develop a novel way to apply protein footprinting by using it to label live cells. This 
should give results on the structure of the membrane protein and its modifications in the native 
cellular environment with high spatial resolution detailed to sub regions or even amino-acid 
residues. 
Because salt bridges are formed or broken between basic and acidic residues, the study and 
identification of exposed carboxyl side chains can be achieved by chemical reactions 
(footprinting) with a nucleophilic compound, glycyl ethyl ester (GEE). This carboxyl group 
footprinting approach has been applied and discussed in Chapter 4, and showed its simplicity to 
be performed as a bench-top method. This is advantageous for studying a complicated biological 
system like the cell. In the footprinting reaction, the small chemical probe (GEE) irreversibly 
153 
 
modifies Glu and Asp residues, made more quantitative with isotopic encoding.18 Although the 
GEE method was originally developed for soluble proteins in vitro,19 we are motivated to 
conduct this labeling under mild conditions that we find compatible with human cells. Here we 
describe an in cellulo GEE footprinting method using mass spectrometry (MS), with GFP-aided 
enrichment, to obtain nearly complete sequence coverage of these membrane proteins analysis. 
This enables us to identify key salt bridges in both GLUT1 and GLUT5, including some missed 
by crystal structures. Substrates and inhibitors stabilizing the inward- or outward-open 
conformations generate distinct modification patterns, indicating specific changes of salt bridges. 
The native cellular state of GLUT1 and GLUT5 appears to contain both conformations. The 
results demonstrate that GEE MS-based footprinting is a novel and effective approach to study 
alternating salt bridges, in living cells, that govern the transport of numerous MFS proteins. 
 
6.3  Methods  
6.3.1  Cell culture and virus transfection 
GLUT1/GLUT5 knockdown HEK293 cells were cultured in MEM medium added with 3mg/L 
puromycin dihydrochloride from Streptomyces alboniger, 10% FBS, 1% Pen/Strep, 1% L-
glutamine (fresh) and 1% non-essential amino acids. Cells were grown at 37 oC, 5% CO2, 
followed by adding 5% (v/v) virus GLUT1/GLUT5 after the density of cells reached 90%. After 
8 h incubation, 0.5% (v/v) Na-butyrate was added, and the cells were incubated for another 36 h 
at 30 oC in 5% CO2. Cells were plated into 25 μg/mL PEI (in 150 mM NaCl)-treated 24 wells 
plate, with 400,000 cells in each well. Cells were then incubated for 24 h at 37 oC, 5% CO2 for 
cells adhesion onto the bottom of the plate.  
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6.3.2  Live-cell membrane protein footprinting  
For each sample, 250 mL suspension cells are required. Cell suspension was centrifuged at 200× 
g, 4 oC for 5 min resulting in a cell pellet. After removal of the supernatant, the pellet was 
resuspended in 10 mL culture media. In separate experiments for the substrate-bound hGLUT, 
D-glucose, D-maltose or cytochalasin B were added to the cell media to final concentrations of 
200 mM, 200 mM and 100 μM, respectively. Cell suspensions were incubated at 37 oC for 30 
min for substrate binding. Control sample (unbound) was prepared in the same manner as above 
except no substrate was added. A subsequent centrifugation at 200×g for 5 min resulted in a cell 
pellet. The pellet was washed with 20 mL ice-cold PBS (10 mM, pH 7.4) and resuspended in 3 
mL PBS containing 0.025% (w/v) digitonin. To drive the binding equilibrium and maintain 
GLUT in its bound form, the substrate was again added to the PBS solution to the same 
concentrations as above. 
 For protein footprinting, 500 μL light and heavy GEE mixture (1:1 molar) stock solutions were 
added to the cells to a total concentration of 300 mM, followed by adding 300 µL EDC to give a 
final concentration of 50 mM. Cells were labeled (footprinted) for 20 min at 25 oC while the 
sample tube was rotated. The reaction was then terminated by adding 3 mL 1 M ammonium 
acetate to quench the GEE footprinting, and samples were incubated at 25 oC for 10 min. This 
quench step simultaneously diluted the concentration of digitonin and allowed the permeabilized 
plasma membrane to “heal”. 
6.3.3  Post-labeling protein purification  
Immediately after footprinting, GLUT1/GLUT5 were solubilized with 1% (w/v) n-dodecyl β-D-
maltoside (DDM) in PBS and incubated for 1 h at 4 oC. The mixture was centrifuged at 20000×g 
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for 10 min, and the supernatant containing the solubilized membrane protein was collected. 
Cobalt affinity resin (300 µL) was added to the supernatant and the mixture was incubated for 30 
min at 4 oC. The cobalt resin bound with the target membrane protein was then loaded onto a 
pre-equilibrated chromatographic column and washed at 4 oC with a buffer containing 10 mL 
PBS and 0.04% (w/v) DDM. The resin was immediately subjected to reducing SDS-PAGE to 
enrich further the protein. The green florescence of the GFP-tagged GLUT was excited under 
UV irradiation to reveal the corresponding gel band of the GFP-tagged protein, which was 
excised for in-gel digestion.      
6.3.4  In-gel digestion 
Two sets of enzymatic digestions, with chymotrypsin and trypsin, were performed separately to 
yield complementary sets of peptides, affording high sequence coverage of the membrane 
protein in LC-MS/MS analysis. Digestion was performed as previously described20 with 
modifications. Briefly, gel pieces were digested for 8 h at 37 oC with 0.02 µg/mL chymotrypsin 
(Promega) in a buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM CaCl2 and 0.1% RapiGest 
SF surfactant (Waters), or with 0.025 µg/mL trypsin/Lys-C mix (Promega) in a PBS buffer (pH 
7.4) and 0.1% RapiGest SF surfactant. The digestion was quenched by adding formic acid to a 
final concentration of 1% (by volume). The solutions of peptides released by digestion were 
directly used for MS and MS/MS bottom-up proteomic analysis.   
6.3.5  Mass Spectrometry 
Mass spectrometry analysis was performed on an Orbitrap Q Exactive plus mass spectrometer 
(Thermo Fisher Scientific) coupled to a Nano UltiMate 3000 Rapid Separation system (Thermo 
Fisher Scientific). The peptides were pre-concentrated on an Acclaim PepMap C18 column 
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(Thermo Scientific, 100 µm × 2cm, 5μm, 100 Å) and desalted for 10 min. Peptides were then 
loaded on to a custom-made column (75 μm × 200 mm) packed with reversed-phase C18 
material (Symmetry, 100 Å,5 μm) and separated at a flow rate of 500 nL/min by a gradient from 
2 to 60% B in 80 min. Solvent compositions for solutions in channels A and B were water with 
0.1% (v/v) formic acid and 80% (v/v) acetonitrile with 0.1% (v/v) formic acid, respectively. Full 
mass scans were performed at a resolution of 70,000 after accumulation to an automated gain 
control (AGC) target value of 3 × 106 or a maximum injection time of 150 ms. In the data-
dependent mode, the 15 most-abundant ions were isolated by using a quadrupole mass filter with 
an isolation window of 3 m/z and an isolation offset of 1 m/z and submitted to “higher energy 
collisional dissociation” (HCD) at a normalized collision energy (NCE) of 30% of the maximum. 
Dynamic exclusion was set to be 8 s for the selected ions. 
6.3.6  Data Analysis in LC-MS/MS 
Unmodified peptides and assigned modifications on the peptide were identified by Byonic 
(Protein Metrics) based on the accurate m/z of the peptide and the product-ion spectra (MS/MS) 
and further validated by manual inspection. Reaction of GEE with the side chain of Asp/Glu 
results in primary products with a mass shift of +85.0527 Da (light, +C4H7NO) or +88.0527 Da 
(heavy, +C2
13C2H7
15NO). For some modifications, the ester bond in the primary products 
underwent hydrolysis under the acidic conditions, resulting in secondary products with a mass 
shift of +57.0214 Da (light, +C2H3NO) or +60.0251 Da (heavy, +C
13CH3
15NO).  
Peptide signals represented by the peak area from the extracted ion chromatogram (XIC) based 
on the accurate mass were integrated by Byologic (Protein Metrics). In the quantification, total 
signal (Atotal) of a certain peptide includes the unmodified form (Au), the primary (Apri) and 
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secondary (Asec) products on all modified D/E residues (namely x, y, … if more than one D/E 
present) in that peptide (i.e., Atotal = Au + Σ (Apri,x + Asec,x + Apri,y + Asec,y +…). For a certain 
residue x, signals of its primary (Apri) and secondary (Asec) products, each including the light and 
heavy forms were summed to count as the total modified signal of residue x. The fraction 
modified of residue x was then calculated by the following equation: fraction modified = (Apri,x + 
Asec,x)/Atotal where A refers to an integrated signal intensity. 
6.3.7  Substrate uptake assay 
The medium for cell culture was first removed from the plate wells, followed by rinsing and 
resuspending the cells by using glucose/fructose-free HEPES (pH 7.3). Cells were starved for 30 
min at 37 oC. To monitor GLUT1 and its mutant uptake activity, 2-Deoxy-D-glucose (2DOG, 
cold) and 3H-2DOG (hot) mixture were added to final concentrations of 0.5 mM and 13 μCi/mL, 
respectively. To monitor the uptake activity of GLUT5 and its mutants, D-fructose (cold) and 
3H-D-frucose (hot) were added to final concentrations of 0.5 mM and 13 μCi/mL, respectively. 
The plate was incubated for 4 and 2 min, respectively, before measuring the uptake levels of 
GLUT1 and GLUT5, respectively. The substrate uptake levels of GLUT1/GLUT5 were then 
measured at 0, 10 s, 20 s, 40 s, 1 min, 2 min, 4 min, 8 min. In the kinetic assays, a series of 
concentrations of 2DOG/D-fructose (0, 0.625, 1.25, 2.5, 5.10, 20, 40, 80 mM) were added to 
GLUT1/GLUT5. After incubation of the cells with the substrate, the plate was washed with cold 
PBS several times and gently knocked to remove the remaining solution. Triton X-100 (1%) in 
PBS was added to each well. The plate was shaken at room temperature for 20 min for cell lysis. 
The supernatant was transferred into scintillation-counter fluid for measuring the uptake activity 
of GLUT1/GLUT5.   
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6.4  Results and Discussion 
6.4.1  Footprinting design of MFS transport in living cells 
 
Figure 6.1. The alternating access model of MFS transporters. (A) The overall structure of 
MFS transporters, exemplified by human GLUT3 (PDB 4ZW9). The N- and C-domain TM 
bundles are colored in orange and yellow, respectively. The intracellular helical (ICH) domain 
on the cytoplasmic side is not shown for clarity. The substrate, D-glucose is bound in the central 
cavity formed by residues from both N- and C- domains, and shown by stick structure in red. (B) 
A schematic illustration of the alternating access (rocker-switch) model of MFS transporters. The 
motion and conformational change of the N- and C-domain of the protein translocate the 
substrate (red sphere) across the biomembranes (depicted by black lines). 
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The structures of MFS transporters are comprised of the N-domain and C-domain, each 
containing 6 TM helices, centered on a rotation axis that crosses the central substrate-binding site 
at the interface of the two half domains (Figure 6.1A).11 Substrate translocation of MFS transport 
is mediated by an alternate access mechanism known as the ‘rocker-switch’ rotation. This model 
incorporates alternate movements of the N-domain and C-domain to create access on two sides 
of the membrane, allowing uptake of the substrate from one side of the membrane to the binding 
pocket and then release of the substrate to the other side of the membrane (Figure 6.1B).2, 21 This 
alternative-accessing mechanism prevents simultaneous opening of both sides, preserving 
essential electrochemical gradients across biological membranes. During the transportation cycle 
enabled by alternating access, the inward-open and outward-open conformations occur as two 
major conformations, with the ligand-bound occluded conformations as intermediates. The 
inward-open and outward-open conformations are characterized by interactions, particularly of 
salt bridges, between the N-domain and C-domain of the transporter.2, 5, 21 Formation and 
disruption of salt bridge upon substrate binding may play a role in controlling the conformational 
change required for substrate translocation in several MFS transporters, including Lac Y, GlpT 
etc.5-6  
Choosing the human glucose transporters (hGLUTs) as models to evaluate the effectiveness of 
MFS transporter footprinting, we designed a MS-based living-cell footprinting approach to probe 
the structure of MFS transporters in the native cellar environment and to identify the key salt 
bridges controlling their rocker switch motion. The GLUT family, exemplified by GLUT1-5 
belong to the solute carrier 2 family (SLC2). GLUT proteins translocate glucose and other 
monosaccharides including fructose, myo-inositol, and urate across the biological membrane in 
mammalian cells.22 All GLUT proteins appear to share a similar structure, one that typically 
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contains 12 TM helices for MFS transporters. Recently, a number of crystal structures of GLUTs, 
including GLUT1 in the inward-open conformation10, 23, GLUT3 in the outward-open and 
outward-occluded conformations24, and GLUT5 in both outward-facing and inward-facing 
conformations9 were determined. Those structures serve as valuable models for understanding 
MFS transporters as well as for bench-marking our protein footprinting results. Among 
eukaryotic MFS transporters, GLUT5 is the only protein whose structures have been reported in 
two alternating confirmations.  
In our design, we carried out live-cell protein footprinting with MFS protein over-expressed in 
HEK293 cells (Figure 6.2). The MFS transporter (e.g., GLUT) was engineered to carry a green 
florescence protein (GFP) tag followed by a poly-His tag on the C-terminus of the protein. The 
outward- or inward-facing conformation of the protein in solution is favored by binding of a 
ligand (e.g., substrate or inhibitor), allowing us to interrogate the protein conformation in 
different functional states. Prior to chemical footprinting, we permeabilized the cell plasma 
membrane of by treating cells with a low concentration of digitonin. Digitonin is a nonionic 
detergent that reversibly permeabilizes the plasma membrane of mammalian cells without 
significantly affecting their functional integrity.25 Permeabilization of cells allows the chemical 
reagents for protein footprinting to diffuse passively into the cell and modify the cytoplasmic 
portion of the membrane protein. 
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Figure 6.2. Schematics of the MS-based live-cell footprinting of membrane transporters. 
The MFS protein (e.g., GLUT) is over expressed in HEK293 cell. The protein is engineered to 
carry a GFP tag followed by a poly-His tag at the C-terminus. For protein footprinting, the 
plasma membrane of HEK293 cells is permeabilized by treating cells with digitonin, followed by 
modification of Asp/Glu side chain via the EDC-mediated GEE reaction using an isotopic 
mixture of a 1:1 molar ratio of “light” and “heavy” GEE. The protein after GEE footprinting is 
purified and enriched by Co-affinity and SDS-PAGE. Proteolytic peptides of the protein from in-
gel digestion are analyzed by LC-MS/MS to quantify the modification extent of the labeled 
Asp/Glu residues. These extents are compared between protein samples in different functional 
states. 
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In protein footprinting, we submitted the cells to chemical modification with an isotopic mixture 
of “light” and “heavy” (1:1 molar) GEE (Scheme 6.1). GEE labels the acidic residues (Asp and 
Glu) that may involve a salt bridge. In the reaction, the carboxyl side chain of the acidic residue 
is first activated by forming an O-acylisourea intermediate with EDC. This intermediate quickly 
reacts with GEE to produce the primary labeling product with a chemical tag of + C4H7NO 
(+85.0527 Da for “light”, or +88.0564 Da for “heavy”).26-27 In the downstream sample handling 
procedures, hydrolysis of the ester bond in the product may occur, which results in a secondary 
product with a chemical tag of + C2H3NO (+57.0214 Da for “light”, or + 60.0251 Da for 
“heavy”).  
 
Scheme 6.1. EDC-mediated GEE carboxyl group footprinting. GEE reacts with Asp and Glu 
side chains to produce the primary products with a stable chemical tag. Some of the primary 
products undergo hydrolysis in the down-stream sample handling to produce the secondary 
products. Both primary and secondary products are encoded by the reaction with a 1:1 mixture of 
“light” and “heavy (C13×2 and N15×1)” GEE. The locations of the “heavy” isotopes are 
highlighted in red circles.  
 
Primary product (R’= CH2CH3)
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Light: + 57.0214 Da
Heavy:  + 60.0251 Da
hydrolysis
163 
 
After quench of the reaction and dilution of digitonin, we extracted the membrane proteins from 
the plasma membrane of the cell into a buffer solution for purification and enrichment using Co-
affinity and gel electrophoresis (SDS-PAGE) (Figure 6.2). Based on the fluorescence of its GFP 
tag, the target protein in the gel was immediately visualized by UV irradiation. We digested the 
proteins in the gel spots and submitted the proteolytic fragments to LC-MS analysis. 
Identification of the GEE-modified peptide is made as certain as possible by using the accurate 
mass of ions encoded with characteristic isotopic patterns. By comparing the modification 
extents of Asp/Glu in distinct functional states of the protein, we are able to determine the 
solvent accessibility changes regions containing Asp and Glu and map the motion of those 
residues. 
 
Figure 6.3. Morphology and viability of the cells exposed the carboxyl group footprinting 
reagents. (A) HEK293 cells exposed to 50 mM EDC and 300 mM GEE in PBS buffer. The cell 
morphology is depicted by the green fluorescence of the GFP-tagged GLUT on the plasma 
membrane. (B) Viability of HEK293 cells exposed to 50 mM EDC and 300 mM GEE in PBS 
buffer. Cell viability was normalized to the control sample in PBS buffer without the addition of 
EDC and GEE. 
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The chemical reagents, EDC and GEE are potentially toxic to cells as determined by their 
concentration and resident time in the cell.  Thus, we investigated whether the integrity and 
viability of the cells are affected during protein footprinting. We treated the HEK293 cells with 
various concentration of the footprinting reagents, and we found the morphology of cells remain 
intact in 50 mM EDC and 300 mM GEE for up to 25 min (with observation of fluorescence 
photobleaching in the sample owing to long-term excitation) (Figure 6.3A). This length of time 
is sufficient for completing the GEE footprinting. In addition, the viability assay shows that 
despite a 25% decrease in viability owing to the addition of 50 mM EDC and 300 mM GEE, a 
majority (75%) of the cells remain alive for up to 25 min (Figure 6.3B). This ensures that the 
protein conformation and cell activity that we are probing are biologically relevant.  
6.4.2  Proteomics strategy for high sequence coverage of MFS in structural 
analysis 
“Bottom-up” proteomics analysis affords high structural resolution by providing details on sub-
regions or even amino-acid residues of the protein. Difficulties in characterization of MFSs 
transporters, however, arise from their high hydrophobicity, a common problem for membrane 
proteins. MFS transporters have 12 α-helical TM domains, making them poorly soluble in 
aqueous solution and immune to proteolysis, thus limiting the sequence coverage in “bottom-up” 
proteomics. 
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Figure 6.4. Post-labeling purification and proteolysis of hGLUT1. (A) SDS-PAGE separation 
shows a band near 70 kDa visualized by the inherent fluorescence of the GFP-tagged hGLUT1 
under UV irradiation. (B) The tryptic (green bar) and chymotryptic (blue bar) peptides of 
hGLUT1 detected in LC-MS/MS. The twelve TM domains are indicated in the GLUT1 sequence 
above. Asp and Glu are in red on the sequence.  
 
We used SDS–PAGE separation and multi-enzyme digestion to improve the sequence coverage 
of GLUTs in bottom-up proteomics. SDS-PAGE, in addition to Co-affinity purification, provides 
enrichment of the protein, and removes salts and detergents that interfere with downstream 
proteolysis and LC-MS analysis. Meanwhile, SDS-PAGE strongly denatures the membrane 
protein, enhancing its solubility and making the protein more susceptible to proteolysis. Taking 
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advantage of the GFP tag, we can directly visualize the gel band containing the target MFS 
transporter (Figure 6.4A).  
In a previous LC-MS study, hydrophilic peptides of the membrane protein were not adequately 
covered.28 The outcome usually suffers from a lack of cleavage sites (e.g., Arg or Lys for trypsin 
in the TM regions) and the tendency of hydrophobic peptides to aggregate in aqueous solution 
after removal of detergents. In our LC-MS analysis, we see some lengthy peptides (> 40 residues) 
from the TM regions of GLUTs. They are not selected for label-free quantification owing to their 
poor reproducibility in reversed-phase chromatography and/or the low signal intensity in MS and 
MS/MS. Proteolysis of the protein with chymotrypsin, which cleaves at Tyr, Phe, and Trp, 
significantly favors proteolysis in the TM regions due to the frequent presence of hydrophobic 
residues. Thus, proteolysis of GLUTs, as well as other membrane proteins using trypsin and 
chymotrypsin offers the advantage of creating overlapping peptides throughout the membrane 
protein sequence. We found that digestion with Lys-C/trypsin and chymotrypsin separately on 
the GLUTs generates properly-sized peptides that maximize the sequence coverage of hGLUT1 
and hGLUT5 to 95% (Figure 6.4B) and 93%, respectively (Figure 6.5).   
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Figure 6.5. Sequence coverage of hGLUT5 achieved in LC-MS/MS analysis. Peptide 
fragments from digestion with (A) trypsin and (B) chymotrypsin. 
A
B
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6.4.3  Isotope-encoded MS identification of GEE-modified peptides 
 
Figure 6.6. Representative LC-MS/MS analysis for GEE footprinting. The tryptic peptide 
459TFDEIASGFR468 of hGLUT1 is shown as an example. (A) Extracted ion chromatograms 
(EICs) of (from top to bottom) the unmodified peptide (m/z = 571.7774), mono-modified 
peptides with the GEE tag on either Asp461 or Glu462 (primary product of m/z = 614.3038; 
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secondary product (*) of m/z = 600.2882), and doubly-modified peptide with GEE tags on both 
Asp461 and Glu462 (primary product of m/z = 656.8302; the secondary product has low signal, 
comparable to the noise). All m/z values are for [M + 2H]2+ ions, and the sites of modification 
were identified by MS/MS, and the fragment series is labeled above each signal peak. The 
“heavy” labeled peptides co-elute with their “light” equivalent and are not shown. (B) The 
mono-modified peptide (top) shows an isotopic doublet of 1:1 ratio in their intensities, and the 
doubly-modified peptide (bottom) shows an isotopic triplet with 1:2:1 ratio in their intensities. 
(C) The product-ion (MS/MS) spectrum of the precursor ion of m/z = 614.3038 indicates a mass 
shift of + 85.0527 Da on Asp461 that designates the GEE modification onto that site. 
 
Labeling by GEE on Asp and Glu is covalent and stable (irreversible). Thus, the modification 
made on the protein in live cells is preserved in the downstream sample handling processes of 
purification, proteolysis and LC-MS analysis. This insures that the modification readouts from 
MS analysis report on the structure of the protein in its native cellular environment. In LC-MS 
analysis, a GEE-modified peptide is separated with the unmodified form (i.e., have different 
retention times (Figure 6.6 shows the LC-MS analysis of peptide region 459TFDEIASGFR468 in 
hGLUT1 as an example). This region contains Asp461 and Glu462 as two potential acidic sites for 
GEE modification. We found the modified forms of the region include peptides with one GEE 
tag on both Asp461 and Glu462, and a peptide with double GEE tags on both sites (Figure 6.6A).    
Peptides of GLUT from the digestion contains a high content of hydrophobic peptides from the 
protein TM domains. Those hydrophobic peptides generally exhibit low solubility in the aqueous 
solution and poor ionization efficiency in electrospray ionization (ESI). Those problems lead to 
difficulties in identification of the GEE-modified peptide, because the modified forms of those 
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peptides are even less abundant. To identify unambiguously and to quantify accurately the GEE 
modification, we employed isotope encoding to enhance the delectability of the low-abundance 
modified peptide. Carboxyl group footprinting using a mixture of “light” and “heavy” GEE in 
1:1 molar ratio produces labelling products that display isotope-encoded signals in MS.  
6.4.4  Intracellular salt-bridge interaction stabilizes GLUT1 in the outward-
facing conformation 
GLUT1 specifically translocases glucose across biomembranes in mammals. We performed live-
cell GEE footprinting on hGLUT1 in the ligand-free state as the control, and then in three ligand-
bound states with D-glucose, maltose and cytochalasin B, respectively. Maltose, a condensation 
of two D-glucoses (Figure 6.7A), functions as an exofacial and competitive inhibitor for glucose 
transport by GLUTs.29 The crystal structure of GLUT3 in complex with maltose shows that the 
one of the constituent glucoses is sufficient to occupy the glucose-binding pocket, causing the 
interactions between GLUT3 and maltose to be nearly identical to those of D-glucose.24 
Therefore, maltose binding, similar to that of glucose, favors the outward-facing conformation 
that allows substrate binding. In contrast, cytochalasin B (Figure 6.7A), a cell-permeable 
mycotoxin, binds to GLUT1 in the inward-open state and favors the inward-facing 
conformation.23, 29 
LC-MS/MS analysis of the post-labeling hGLUT1 reveals that 28 of 31 Asp/Glu residues are 
covered in peptide mapping. GEE modification is detected on 19 Asp/Glu residues (Figure 6.7B, 
D and Figure 8). GEE modification dominantly occurs on residues occupying the periphery of 
the protein, because Asp and Glu, as polar residues, tend to appear on the protein surface in 
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contact with aqueous solution. The only acidic residue in the TM domains of hGLUT1 is E380 
(TM10), and it is not modified.   
In hGLUT1, we found two residues, E299 and E329, that show differential modifications in 
distinct functional states of hGLUT1 (Figure 6.7B and D). We identified from the crystal 
structure an intracellular salt bridge between E329 and R333, and an extracellular one between 
E299 and K38, both located near the translocation pore (Figure 6.7C and E). The outward-facing 
conformation, favored by glucose or maltose binding, is stabilized by inter-TM bundle salt 
bridging on the intracellular side involving E329 (TM9), R333 (TM9) on the C-domain and the 
backbone of G154 (TM5) of the N-domain (Figure 6.7C). Formation of the salt bridge results in 
decreased GEE modification consistent with increased protection on E329 (Figure 6.7B). As 
GLUT1 adopts the inward-facing conformation, initiated by cytochalasin B binding, the salt-
bridge interactions on the intracellular side are disrupted, E329 becomes more solvent accessible, 
and it undergoes increased modification (Figure 6.7B). Meanwhile, the inward-facing 
conformation is stabilized by salt bridging on the extracellular side formed by K38 (TM1) from 
N-domain and E299 (TM7) from the C-domain (Figure 6.7E). Thus, the changes in modification 
of E299 on the extracellular side are opposite to those of E329 on the other side of the transporter 
(Figure 6.7D), verifying the alternating accessing motion of the membrane transporter.   
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Figure 6.7. Salt bridge interactions in hGLUT1. (A) Chemical structures of the ligands for 
GLUT1. (B) GEE modification extents of E329, and (C) the associated salt bridge interactions 
on the intracellular side. (D) GEE modification extents of E299, and (F) the associated salt 
bridge interactions on the extracellular side. In (C) and (E), the structure of hGLUT1 in the 
inward- and outward-facing conformation is shown in pink and blue, respectively. (F) Effect of 
substitution of E299 or E329 to alanine on the glucose-uptake ability of hGLUT1.  
0%
5%
10%
15%
20%
E329
F
ra
c
ti
o
n
 m
o
d
if
ie
d
hGLUT1_control
+ Glucose
+ Maltose
+ Cytochalasin B
0%
5%
10%
15%
20%
25%
E299
F
ra
c
ti
o
n
 m
o
d
if
ie
d
hGLUT1_control
+ Glucose
+ Maltose
+ Cytochalasin B
Intracellular
TM1K38
TM7
Extracellular 
E299
B
D
F
C
E
A
D-glucose maltose cytochalasin B
173 
 
 
Figure 6.8. Asp/Glu residues in hGLUT1 showing no significant change in the level of GEE 
modification. 
 
Examining the functional significance of the identified salt-bridge interactions (Figure 6.7F). we 
found that substitution of E329 to alanine almost inactivate the uptake of D-glucose. However, 
substitution of E299 slightly increases the uptake of D-glucose, all in comparison to WT. Thus, 
disruption of the intracellular salt bridge (with E329) weakens the interactions between the N- 
and C- domains and significantly impedes the transport cycle by disfavoring the outward-facing 
conformation for substrate binding. Conversely, disruption of the extracellular salt bridge (with 
E299) results in hyperactivity in substrate translocation, suggesting that during the transport 
cycle the inward-facing conformation needs to be maintained transient.  
The intracellular salt bridge with E329 is seen by X-ray crystallography10, as disruption of the 
salt bridge by substituting E329 with Gln arrests GLUT1 in an inward-facing conformation and 
hence facilitates crystallography. Actually, it was believed that GLUT1 lacks conserved salt 
bridge on the extracellular side. Nevertheless, we found a salt bridge with E299 on the 
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extracellular side of GLUT1 by probing the in-cell dynamic structure of the transporter using 
MS-based footprinting. 
6.4.5  Apo GLUT1 contains outward- and inward-facing conformations in 
equilibrium 
It was previously hypothesized that apo GLUT1 prefers an outward-facing conformation because 
of the extensive interactions between the TM and ICH domain.30 Our live-cell footprinting 
results, however, show the modification extents of E299 and E329 in the ligand-free state 
(control) fall into a medium level between those of the outward- and inward-facing states. This 
suggests that apo GLUT1 in its the native cellular state contains both outward- and inward-facing 
conformations in equilibrium.   
6.4.6  Intracellular salt bridges stabilize GLUT5 in the outward-facing 
conformation 
GLUT5 is the only GLUT family member identified so far to translocate specifically fructose 
(Figure 6.9A). We applied the live-cell protein footprinting to study the ligand-free hGLUT5 and 
and its conformations in presence of glucose, fructose, and cytochalasin B. The GEE 
modification extents of hGLUT5 upon addition of glucose or cytochalasin B are nearly identical 
to that of the ligand-free protein. This suggests GLUT5, a fructose-specific transporter, interacts 
weakly if at all with glucose or cytochalasin B (Figure 6.9B, D and Figure 6.10).   
By contrast, two acidic residues, D64 and E337, in the fructose-bound GLUT5 are modified 
differentially compared to those in the ligand-free protein. Similar to the effect of glucose or 
maltose on GLUT1, excess fructose favors the outward-facing conformation of GLUT5. X-ray 
crystal structures of GLUT5 are available for both outward- and inward-facing conformations of 
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rat (rGLUT5) and bovine (bGLUT5), respectively9. rGLUT5 and bGLUT5 share ~81% sequence 
identity to hGLUT5. On the basis of the rGLUT5 structure, we can conclude that for the 
outward-facing conformation of rGLUT5, E336 (TM8) forms salt bridges with both R158 (TM5) 
and R340 (TM9) on the intracellular side. Extrapolating to hGLUT5, we expect equivalent salt 
bridges to form between the conserved residues E337, R159 and R341. To facilitate structural 
analysis, we will use the hGLUT5 residue numbers to annotate the conserved residues in 
rGLUT5 (Figure 6.9C, left). The above hypothesis with hGLUT5 is further supported by a 
bioactivity assay of hGLUT5 mutants. Compared to the WT protein, single alanine substitutions 
of R159, E337 and E401 in hGLUT5 strongly reduce the uptake of fructose by ~ 70%, and 
mutation of R341 reduces the uptake by ~ 60%, indicating that salt bridging on the intracellular 
side of GLUT5 is essential for stabilizing the outward-facing conformation. In contrast, as the 
structure of GLUT5 rearranges to the inward-facing conformation (using bGLUT5 for 
demonstration), the N- and C-domains move apart to release substrate, leading to disruption of 
the interdomain R159-E401 and the E337-R341 salt bridge formed in the C-domain of GLUT5 
(Figure 6.9C, right).  
176 
 
 
Figure 6.9. Salt bridge interactions in hGLUT5. (A) Structure of fructose. (B) GEE-
modification extents of E337 in hGLUT5. (C) Salt bridge interactions associated with E337 
mapped onto the structure of rGLUT5 in the outward open conformation (cyan, PDB 4YBQ) and 
bGLUT5 in the inward-facing conformation (violet, PDB 4YB9). To facilitate structural 
comparison, rGLUT5 and bGLUT5, residues are labelled with hGLUT5 numbering. Views are 
from the intracellular side, and ICHs are omitted for clarity. (D) GEE modification extents of 
D64 in hGLUT5. (E) Orientation of E56 in hGLUT3 (equivalent to D64 in hGLUT5) in the 
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outward-open (cyan, PDB 4ZWC) and outward-occluded (pink, PDB 4ZW9) conformations. 
Views are from the extracellular side. (F) Effect of substitution of D64 or E337 to alanine on the 
fructose-uptake ability of hGLUT5.  
 
 
Figure 6.10. Asp/Glu residues in hGLUT5 showing no significant change in the level of 
GEE modification. 
 
On the extracellular side, D64 undergoes increased GEE modification in the fructose-bound 
hGLUT5 that presumably favors the outward-facing conformation (Figure 6.9D). The structure 
of GLUT5 in the outward-open conformation obtained for rGLUT5, however, lacks resolution in 
the region containing the residue equivalent to D64 in hGLUT5. As a result, we based our 
analysis on the structures of hGLUT3 that has E56 equivalent to D64 in hGLUT5. Only 
structures of the outward-facing hGLUT3 are available, including the outward-open and 
outward-occluded conformations.24 For inward-facing hGLUT3, E56 (TM3) can salt bridge in 
the N-domain with both K36 (TM2) and K39 (TM2) on the extracellular side. Figure 6.9E shows 
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those putative salt bridge residues mapped onto the outward-open and outward-occluded 
conformations of hGLUT3, in which the distance between the acidic and basic residues are > 9 Å 
and > 4Å, respectively. These distances indicate salt bridging on the extracellular side is 
abolished or severely weakened in GLUT3 in the outward-facing conformation. Assuming a 
similar set of interactions with the conserved residues in hGLUT5 as in hGLUT3, the salt bridge 
is between D64 (TM3) and K47 (TM2) in the N-domain of hGLUT5. Our protein footprinting 
result shows that interaction of D64 is weakened in the outward-facing conformation, as 
evidence by its increased GEE modification for fructose-bound GLUT5 (Figure 6.9D). 
Comparing the structure of GLUT3 in the outward-open and outward-occluded conformations 
shows a difference in the side-chain orientation of E56, equivalent to D64 in hGLUT5; the side 
chain points inward to the translocation pore in the outward-open conformation (Figure 6.9E, 
left), and rearranges to point to the extracellular side in the outward-occluded conformation 
(Figure 6.9E, right), indicating that E56 in GLUT3 structurally rearranges in the translocation 
cycle (we lack its structure in the inward-facing conformation for a direct comparison). 
Substitution of D64 slightly increases the substrate uptake activity of hGLUT5 (Figure 6.9F), 
suggesting the role of  D64, similar to that of E299 in hGLUT1, on the extracellular side in 
maintaining a transient inward-facing conformation. 
 
6.5  Conclusions 
We implemented a novel live-cell protein footprinting approach, combining suspension cell 
expression, GFP tagging, isotope-encoded labeling, improved in-gel digestion and mass 
spectrometry to identify key salt bridges that controls the alternating access motion of MFS 
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transporters. As a probe of changes in protein solvent accessibility in live cells, MS-based 
footprinting offers direct evidence for the alternate access model of the membrane transporters, 
which is consistent with the X-ray structures and site-directed alkylation, tryptophan 
fluorescence and Förster resonance energy transfer. Our results also provide a confirmation that 
in the cell, the salt bridges are as predicted from X-ray. 
The use of suspension cells provides sufficient amount of a membrane protein that has a low 
expression level for protein footprinting. Incorporation of isotope-encoding facilitates the 
detectivity of the modified peptides and allows unambiguous identification of the modification in 
a complex mixture of peptides. Optimization of the downstream proteomics workflow 
overcomes the problem of under-representation of peptides from hydrophobic regions by 
affording high coverage across a membrane protein with multiple TM domains.  The outcome is 
a detailed view of the local structure of the membrane proteins. Using the method, we studied 
structures of the MFS transporters, exemplified by GLUTs, in their native cellular environment 
by chemical “footprints”, and identified the key salt bridges that act as molecular switches for the 
conformational changes required for substrate translocation. 
MFS transporters specifically, and membrane proteins in general, are heterogenous in term of 
conformation and post translational modification. Advantageously, the applicability of the live-
cell protein footprinting method is minimally affected by this limitation. Furthermore, structure 
information obtained from the membrane protein in live cell can also be used to facilitate 
interpretation of X-ray crystallography for an atomic-level characterization of the membrane 
protein. In addition, adapting chemical probes with different specificities and reactivities with 
amino-acid residues, we envision continued expansion of the approach to study other function-
related structural features of membrane proteins and their interactions with ligands and drugs that 
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regulate/affect the biological activity. Although the focus of this study is the translocation 
mechanism of MFS, we suggest that ligand-induced conformational changes, aggregation, and 
effects of modification of other membrane receptors are now in reach. 
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Chapter 7: Conclusion and Outlook 
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MS-based protein footprinting is a valuable tool for characterizing protein and protein 
complexes. The method probes in-solution structure and provide information complementary to 
that from X-ray crystallography or nuclear magnetic spectroscopy (NMR). The primary interest 
in Gross lab is focused on the development and application of MS-based structural proteomics to 
study protein biophysics. The six chapters in this dissertation reflect the method development 
and application of MS-based protein footprinting to study protein aggregation, protein-ligand 
interaction and higher order structure of membrane proteins.  
 
7.1  FPOP and MS for monitor amyloid formation 
In Chapter 2, we described the application of FPOP to characterize the oligomerization and 
fibrillation of Aβ by monitoring its solvent accessibility changes that accompany these processes. 
Compared to a traditional thioflavin T (ThT) fluorescence assay and an HDX approach, the level 
of FPOP modification sensitively responds to the solvent accessibility of various Aβ species. 
Therefore, we were able to identify different oligomeric species based on their characteristic 
modification levels and to resolve a more detailed picture of the transition stages in Aβ 
aggregation. Furthermore, the irreversible labeling by FPOP permits characterization of 
aggregation behaviors of Aβ sub-regions and even some amino-acid residues.  
We later extended the platform to evaluate the effect of a polyphenol amyloid inhibitor in 
remodeling Aβ aggregation (Chapter 3) and found that binding of the inhibitor results in different 
structural effects on Aβ sub-regions. The interaction leads to stabilization of small Aβ oligomers 
and a significant extension in the lag phase and may provide hints for slowing aggregation in 
vivo.   
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For the future, in addition to small molecule inhibitors, other forms of inhibitors, including 
peptides and antibodies can also be investigated by using the platform. Furthermore, the 
approach should be useful for the study of Aβ mutant.  Other investigations have shown that 
some mutants (e.g., Tottori (D7N), Flemish (A21G), and Arctic (E22G)) and N-terminal 
truncated Aβ species (e.g., pyroglutamate-modified Aβ) exhibit different early oligomer 
distributions and accelerated rates of aggregation. The platform can be readily expanded to study 
those Aβ species.  
Another immediate interest in this field is the interaction of Aβ with lipid membranes. It is 
known that there is a complex interplay between lipids and the generation, clearance, and 
deposition of Aβ. Membrane surfaces can serve as catalytic sites and promote formation of toxic 
Aβ aggregates. Compared to HDX, FPOP is advantageous for studying Aβ in a lipid 
environment, because the irreversible modifications it imparts allow more flexibility in the post-
labeling sample clean-up (e.g., acetone precipitation, chromatography or buffer exchange) to 
remove lipids that are incompatible with MS analysis. Furthermore, FPOP can be applied to 
study the interaction of Aβ with apolipoprotein E (Apo E), which binds to Aβ and significantly 
influences the receptor-mediated Aβ uptake by neurons that ultimately leads to slow Aβ 
clearance. Last but not the least, the FPOP platform can be applied to study aggregation and 
misfolding of other amyloidogenic proteins such as α-synuclein and Tau protein.     
 
7.2  FPOP for Protein-Ligand Interaction 
In Chapter 4-5, we demonstrated the capabilities of three different protein footprinting 
techniques, including HDX, FPOP and carboxyl-group footprinting in deciphering protein-ligand 
188 
 
interaction and protein higher order structures. In the case of bromodomain-containing protein 
interacting with a benzodiazepine inhibitor (Chapter 5), FPOP clearly points to a critical binding 
region, whereas HDX is not sufficiently sensitive in mapping the binding interface in the protein 
hydrophobic cavity. This study serves as an example for using FPOP to map directly the binding 
interface of a protein for a small-molecule ligand that does not induce significant conformational 
change on protein conformation. In this study, we incorporated a peptide reporter into the FPOP 
experiment to provide a measure of the hydroxyl radical lifetime. Interestingly, we find the 
modification on Met residues saturates as the hydroxyl radical lifetime increases (achieved 
through decreasing the scavenger concentration). This phenomenon is specifically observed for 
Met and is worth further investigation to help understand the modification mechanism of Met in 
FPOP.  
 
7.3 Live-cell footprinting for membrane protein 
characterization 
In Chapter 6, we applied protein footprinting, specifically carboxyl group footprinting, to label 
proteins in a live cell and capture the structure of membrane transport proteins (i.e., hGLUT5 and 
hGLUT5). We demonstrated a live-cell footprinting methodology combining suspension cell 
expression, GFP tagging, improved in-gel digestion, and mass spectrometry to study structures 
of MFS transporters in a native cellular environment. This proof of concept study is a template 
for using chemical footprinting, a method normally performed on purified protein in buffer 
solution, to interrogate a complicated, biologically relevant system such as the cell. 
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Although this example is focused on using glycine ethyl ester to label specifically acidic residues 
(Asp/Glu) and identify potential key salt bridges controlling the alternating access motion of 
membrane transport proteins, the method should be readily expandable by adapting other 
footprinting reagents into the established workflow to study many other biological activities of 
interest for membrane proteins. For example, development of a hydrophobic precursor that can 
enter the lipid bilayers will permit footprinting of residues in transmembrane regions. Moreover, 
the methodology can be applied to characterize dynamic biological processes that happen in the 
cell. For example, ferroportin, an iron-regulated transporter, undergoes ubiquitination followed 
by internalization upon binding of its endogenous hormone inhibitor hepcidin. By footprinting 
ferroportin in the cell at different times after its exposure to hepcidin, we should be able to 
characterize the ligand-induced conformational change and ubiquitination sites of ferroportin 
during degradation.  
 
 
  
 
 
 
